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I.1 The liver 
The liver is the largest internal organ of the human body and one of the most important 
organs for the maintenance of the metabolic homeostasis in our body. The liver performs 
vital functions including the synthesis, metabolism, storage and redistribution of 
nutrients. In addition, due to its localization, the liver is exposed to a variety of toxic 
compounds, the detoxification and neutralization of these toxins is one of the vital 
functions that the liver performs (1, 2). 
 
I.1.1 Anatomy 
The liver is arranged in hexagonal subunits named hepatic lobules (Figure I.1). The 
hepatic lobule is organized around a central vein and is structured by the confluence of 
the hepatic sinusoids. The hepatic sinusoids drain the blood from one branch of the portal 
vein and from another branch of the hepatic artery. Between the hepatic sinusoids are 
located the hepatocytes, these cells are arranged radially forming rows around the central 
vein. In the vertex of the hepatic lobules is located the portal triad, which is formed of 
connective tissue and contains a branch of the hepatic artery, a branch of the portal vein 
and a bile duct. To the latter reaches the bile produced by hepatocytes through a network 
of canaliculi (1, 2) (Figure I.1). 
  
 




Figure I.1. Structure of the liver and the hepatic lobule. The liver is structured in hexagonal 
hepatic lobules which are arranged around a central vein. (Adapted from Mescher et al, 2013). 
 
The perisinusoidal space or space of Disse is located between the hepatic sinusoids and 
the hepatocytes and contains a network of reticular fibers and blood plasma. In the 
perisinusoidal space takes place the metabolic exchange between the hepatocyte and the 
plasma (1, 2). 
 
I.1.2 Microscopic anatomy of the liver 
The liver consists of two types of epithelial cells, hepatocytes and cholangiocytes. About 
70-80% of the liver volume is occupied by parenchymal hepatocytes which are large 
cuboidal or polyhedral epithelial cells that are often binucleated. These cells are 
responsible of performing the majority of the metabolic functions of the liver (1, 2).  
The non-parenchymal liver cells of the liver include populations of cholangiocytes, 
liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), Kupffer cells 
(KCs) and intrahepatic lymphocytes. Cholangiocytes are the epithelial cells that line-up 
the biliary duct, they only represent the 3-5% of the liver cells but they carry out important 
functions in bile modification and transport (3-5). HSCs are present in the space of Disse, 
these cells store vitamin A, produce extracellular matrix (ECM) and are the main pro-
fibrogenic cells (6). The liver sinusoids are lined with two types of cells, sinusoidal 
endothelial cells and phagocytic KCs. KCs are the resident macrophages in the liver, they 
have cytokine-producing phagocytic activity and together with lymphocytes form part of 
the immune system in the liver (7). In addition, LSECs perform an important function in 
filtering metabolites. For that, these cells have small fenestrations that allow the free 
diffusion of many substances between the blood and the hepatocytes (8) (Figure I.1).  
 
I.1.3 Physiological functions of the liver 
The liver is responsible for multiple functions and plays a central role in metabolism. For 
that, hepatocytes contain thousands of enzymes that are able to perform key metabolic 
functions such as the oxidative energy metabolism, carbohydrate metabolism, lipid 
metabolism, amino acid and nitrogen metabolism, bile formation and secretion and the 
metabolism of xenobiotics. In addition, the liver also serves as a reservoir of glucose, 
lipids, iron and vitamin A (in HSCs) and other vitamins. Among other functions that the 




liver carries out are also the synthesis and secretion of albumins, apolipoproteins, 
transferrins, fibrinogen and other plasma proteins to the blood (2). 
 
I.2 Liver injury 
The liver plays an important role in the detoxification of drugs, xenobiotics and toxic 
metabolites and thus, due to its constant exposure to harmful agents is susceptible to 
damage and the development of liver disease. Etiologic factors include the chronic 
infection with hepatitis B virus or hepatitis C virus (HBV or HCV), chronic alcohol 
intoxication, poisoning, obesity and metabolic-syndrome associated non-alcoholic 
steatohepatitis (NASH), genetic alterations such as hemochromatosis and α1-antitrypsin 
deficiency or immune-type damage (9-19). The maintenance of the hepatic function is of 
paramount importance at a systemic level; if liver function is lost it causes a great impact 
on the body and may result in the death of the organism (20). 
 
I.2.1 Acute liver failure 
Acute liver failure (ALF) is a life-threating disease with an increasing incidence in the 
developing world (20). ALF often occurs without a pre-existing liver disease as 
commonly arises in healthy adults and may be caused by drug overdose, such as 
acetaminophen, alcohol overdose, viral hepatitis (especially A, B or E), acute fatty liver 
of pregnancy or poisoning by Amanita phalloides and other amatoxin-producing fungus 
among others. Clinically, ALF manifests hepatic dysfunction with alterations in the 
biochemical values of the liver and coagulopathy. It may also cause encephalopathy and 
organ failure, ultimately leading to death in about 50% of ALFs (Figure I.2) (13, 20). 
In the developing world ALFs are mostly related to hepatitis viral infection, whereas 
in the USA and Western Europe viral infection-mediated ALFs are decreasing and drug-
induced liver injury (DILI) is now the most common cause of ALFs (Figure I.2) (21). 





Figure I.2. Acute liver failure cases worldwide. HAV; hepatitis A virus, HBV; hepatitis B virus, 




DILI is the most common ALF in the developed world with an estimation incidence of 
10-15 cases per 100000 inhabitants (13). However, due to the difficulties in the diagnosis, 
DILI cases may be largely under-estimated (13). Of note, one of the main reasons for the 
discontinuation of developing and already approved drugs is DILI (22). Acetaminophen 
(APAP) overdose is the most common DILI and it may represent more than half of all 
ALFs in some countries of the developed world, up to 70% of the APAP intoxications 
being reported as suicidal intents (Figure I.2) (20).  
APAP hepatotoxicity is well established and is caused by N-acetyl-p-benzoquinone 
imine (NAPQI), which is a highly reactive intermediate metabolite (13). At therapeutic 
dosage, acetaminophen is mainly metabolized by sulfation and glucuronidation in the 
liver, while a small part is metabolized by CYP2E1 and CYP3A4 isoenzymes that form 
NAPQI that is conjugated by glutathione. However, when APAP intoxication occurs, 




sulfation and glucuronidation mechanisms are overwhelmed and acetaminophen is 
oxidized by CYP2E1 and CYP3A4 isoenzymes forming high amounts of NAPQI that 
cannot be detoxified as the glutathione pool is diminished. NAPQI generates reactive 
oxygen species (ROS), causes distortions in the nuclear and mitochondrial function, 
covalently binds to intracellular proteins and may lead to apoptosis and necrosis (13). 
Importantly, alcohol abuse and obesity have been reported to be risk factors of 
acetaminophen-mediated ALF (23, 24).  
As mentioned earlier, half of ALFs result in death. However, the liver has an 
extraordinary capacity of regeneration and therefore, if the injury is not fatal, liver 
regeneration will be triggered in order to recover the lost liver mass and function (25, 26). 
 
I.3 Mechanisms of liver regeneration 
After a liver injury, the architecture and function of the liver are compromised and as a 
consequence, liver regeneration is triggered. A central event in this scenario is the death 
of the hepatocyte. The death of this parenchymal liver cell triggers a powerful 
inflammatory and regenerative response that tries to restore the lost liver tissue (27, 28). 
Liver regeneration involves several molecular and cellular mediators, such as cytokines, 
chemokines and growth factors and the involvement of different cell-types including 
resident macrophages. Liver regeneration is triggered immediately after the injury and is 
fundamental for the activation of the proliferation of viable hepatocytes and therefore, for 
the recovery of the liver mass and its function (25, 29).  
For the study of liver regeneration animal models such as partial hepatectomy (PHx) 
in rodents are widely used (30). These animal models have helped us to gain knowledge 
about the early responses that trigger the regenerative process after a liver resection (29, 
30). The immune system plays a very important role in the normal liver regeneration. In 
this sense, interleukin 6 (IL6) is a cytokine that orchestrates the early phases or priming 
phase of liver regeneration, as it seems to regulate almost 40% of all the genes that are 
deregulated immediately after PHx (31, 32). IL6 binds to its receptor in hepatocytes 
activating the extracellular signal-related kinase 1 and 2 (ERK1/2) and signal transducer 
and activator of transcription 3 (STAT3) pathways. Another important cytokine is tumor 
necrosis factor (TNF) which is rapidly upregulated after PHx, and binds to TNF receptor 
1 primarily in Kupffer cells, leading to nuclear factor kappa B (NF-κB) activation and 
IL6 production. In addition, components of the innate immunity such as 




lipopolysaccharide (LPS), C3a and C5a also bind to their receptors in Kupffer cells and 
promote liver regeneration (26, 32, 33) (Figure I.3). 
After the priming phase orchestrated by cytokines, growth factors are upregulated 
during the proliferative phase. Among these growth factors, hepatocyte growth factor 
(HGF) seems to play a key role; HGF is paracrinally secreted from HSCs to induce 
hepatocyte proliferation. Besides HGF, other growth factors are also implicated in liver 
regeneration, such as the epidermal growth factor (EGF), vascular-endothelial growth 
factor (VEGF) and transforming growth factor (TGF). All these growth factors contribute 
to the normal regeneration of the liver after PHx (Figure I.3) (32, 33). 
To restore the lost parenchymal structure, the participation of ECM producing cells 
is also essential. These fibrogenic cells are activated by inflammatory mediators and have 
their origin primarily from the activation of periportal fibroblasts and HSCs (6). At the 
beginning of liver regeneration the ECM is degraded in order to help the proliferation of 
hepatocytes. However, about 3-4 days after PHx HSCs produce ECM and the normal 
liver architecture is reconstructed, by properly reconnecting hepatocytes and the 
sinusoidal epithelium (Figure I.3) (26, 34). 
However, in a chronic injury the regenerative capacity of the liver is severely 
impaired due to the excessive inflammation and fibrosis (25, 29). 
 
 




Figure I.3. Liver regeneration after PHx. Liver regeneration is divided in 3 different phases; 
the priming phase, in which inflammatory cytokines are induced right after the surgery and ECM 
is degraded, the proliferative phase, in which growth factors are upregulated and hepatocytes 
proliferate and the growth termination phase, in which proliferation ends and the ECM is 
synthesized. ECM, extracellular matrix; EGF, epidermal growth factor; EGFR, epidermal growth 
factor receptor; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; HGF, 
hepatocyte growth factor; IGFBP1, insulin like growth factor binding protein 1; IL1β, interleukin 
1 β; IL1βR, interleukin 1 β receptor; IL6, interleukin 6; IL6R, interleukin 6 receptor; NF-κB, 
nuclear factor kappa B; PH, partial hepatectomy; TGF, transforming growth factor β; TGFβR, 
transforming growth factor β receptor; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor 




I.4 Chronic liver injury and progression of the disease 
As mentioned earlier, liver injury occurs as a result of the exposure to different potentially 
harmful agents and when liver injury persists on time it becomes chronic. Interestingly, 
the progression of liver injury shares virtually common features regardless of the 
underlying cause (Figure I.4) (18).  
As aforementioned, in a context of an acute liver damage the death of liver 
parenchymal cells after an injury triggers an inflammatory and regenerative process to 
restore the lost liver tissue, following a normal regenerative process of controlled healing 
(25, 26, 29). However, when the liver injury persists and becomes chronic, the 
inflammatory response is perpetuated and a chronic hepatitis is developed. Moreover, the 




liver parenchyma will be progressively replaced by fibrotic tissue, developing liver 
fibrosis. If the injury is severe and persists on time, the hepatocellular parenchyma is 
progressively lost, the normal architecture of the liver is replaced by regenerative 
hepatocytes surrounded by fibrous septa, the function of the liver is compromised and 
liver cirrhosis is developed. In the cirrhotic liver complications such as ascites and hepatic 
encephalopathy may appear, and ultimately, renal failure, liver failure and the 
development of hepatocellular carcinoma (HCC) (Figure I.4) (35-38).  
All these evidences support the idea that the progression of the liver injury includes 
the development of fibrosis and its evolution to cirrhosis and that this progression results 
largely from the chronic and uncontrolled activation of physiological mechanisms of 
tissue repair and regeneration. 
 
 
Figure I.4. Progression of liver injury. Chronic liver injury regardless of its aetiology produces 
inflammatory damage, matrix deposition, cell death and angiogenesis leading to liver fibrosis 
which is reversible. However, if the injury persist the liver losses its architecture and function and 
becomes cirrhotic, that may regress but not resolve. At this point, HCC and other complications 
may appear. HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis. (Adapted 
from Pellicoro et al, 2014).  
 
 I.4.1 Liver fibrosis 
Liver fibrosis results from a process of scarring of the liver which is characterized by an 
excessive accumulation of ECM proteins that occurs in a chronic liver damage (18). The 




ECM production and accumulation is termed liver fibrogenesis, which is characterized 
by several key features: i) chronic persistent damage to parenchymal liver cells; ii) 
chronic inflammation; iii) activation of ECM producing cells and iv) qualitative and 
quantitative changes in the composition of the ECM (39). 
After a hepatic injury the hepatocyte damage provokes the recruitment and 
stimulation of inflammatory cells, including the activation of the macrophages resident 
in the liver (i.e KCs) (40, 41). These inflammatory cells, together with the damaged and 
regenerative hepatocytes secrete inflammatory mediators and growth factors that promote 
the activation of HSCs, the main fibrogenic cells that transdifferentiate into 
myofibroblasts (42, 43). Myofibroblasts secrete and deposit collagen and other ECM 
proteins, ECM accumulates in the space of Disse and causes several changes in different 
cell types; hepatocytes lose their microvilli and endothelial cells lose their fenestrations 
(44-46). All these, dramatically affects the normal function of the liver (Figure I.5) (18).  
 
Figure I.5. Changes occurring in the hepatic sinusoid in liver fibrosis. During fibrosis 
activated HSCs secrete ECM in the space of Disse, as a consequence, hepatocytes lose their 
microvilli and endothelial cells lose their fenestrations compromising the normal function of the 
liver. ECM, extracellular matrix; HSC, hepatic stellate cell. (Adapted from Friedman SL et al., 
2005). 
I.4.1.1 HSCs: Main pro-fibrogenic cells 
HSCs are the main pro-fibrogenic cells as they are the main producers of ECM during 
liver fibrosis (43). HSCs reside in the space of Disse and are responsible of the storage of 
vitamin A in the normal liver. However, after a liver damage, HSCs activate or 




transdifferentiate into myofibroblasts constituting one of the most important events 
during fibrogenesis. Myofibroblasts then migrate and accumulate in tissue repair sites 
secreting large amounts of ECM and regulating ECM degradation (47). For that, the 
activated HSCs or myofibroblasts acquire proinflammatory, proliferative, fibrogenic and 
contractile properties (47, 48) Apart from collagen, HSCs also secrete matrix 
metalloproteinases (MMPs) that serve to degrade the ECM. Besudes, HSCs also secrete 
the tissue inhibitors of metalloproteinases (TIMPs), the inhibitors of MMPs (49). 
The discovery of the activation of HSCs was a milestone in the research of liver 
fibrosis, gaining key knowledge for the bases of liver fibrogenesis (6, 50). However, 
myofibroblasts are a complex cell population and HSCs are not the only cells contributing 
to myofibroblast population, Moreover, activation pathways and the overall contribution 
of fibrogenic cells to myofibroblasts during liver damage may be very different (42, 51). 
Depending on the aetiology of liver disease, myofibroblasts not only derive from resident 
HSCs, but may also be derived from portal fibroblasts, from circulating fibrocytes and 
from bone marrow derived cells (42, 51). In addition, cell-fate studies showed that neither 
hepatocytes nor cholangiocytes contribute to the myofibroblast population (Figure I.6) 









Figure I.6. Contribution of HSCs and other cells to liver myofibroblasts. Different cell types 
may transdifferentiate into myofibroblasts and promote fibrosis, HSCs being the main 
contributors to myofibroblast population. HSC, hepatic stellate cell. (Adapted from Elpek GO et 
al., 2014). 
 
The activation of HSCs is a complex but highly programmed event. The initiation or pre-
inflammatory stage is associated with a rapid gene induction, resulting from paracrine 
stimulation of inflammatory cells and hepatocytes or cholangiocytes, and early changes 
in the composition of the ECM (42). Oxidative stress is one of the early determinants of 
HSC activation. The main intermediates of ROS are hydrogen peroxide, superoxide 
anion, hydroxyl radicals and also 4-hydroxy-2,3-nonenal and 4-hydroxy-2,3-alkenal, the 
main end products of lipid peroxidation and can be derived from hepatocytes, 
macrophages, HSCs and other inflammatory cells (6, 56). In addition to oxidative stress, 
early changes in ECM composition, such as the production of fibronectin by endothelial 
cells, can stimulate the activation of HSCs (57). Besides, Wnt/β-catenin pathway is 
activated during HSC activation and Wnt3A ligand activates HSCs in culture and 
promotes their survival (58). In addition, Wnt4, Wnt5a and Wnt6 ligands are expressed 
in rat HSCs, modulating HSC activation and survival through non-canonical Wnt/β-
catenin (59, 60). 
The classic stimulus of inflammation and fibrogenesis is necrosis. However, 
apoptosis is now viewed as a pro-fibrogenic response for HSCs (27). These cells are able 
to phagocytose apoptotic bodies making HSC more activated and pro-fibrogenic (61-63). 
In the last decade, the role of innate immunity in HSC activation has gained attention. In 
this regard, HSCs express different Toll-like receptors (TLRs) that may respond to 
components of bacteria translocated from the gut, the so called gut-liver-axis. In this line, 
LPS has been shown to increase the fibrogenic activity in HSCs through TLR4. TLR4 
activation upregulates cytokines and chemokines and also the levels of TGFβ by 
downregualting the expression of BMP and activin membrane bound inhibitor (BAMBI) 
(64). 
Activated HSCs may be maintained an amplified due to a mechanism of 
perpetuation. This implies autocrine and paracrine stimulation of growth factors, as well 
as the accelerated remodeling of the ECM. In this scenario, HSCs acquire new functions 
such as proliferation, fibrogenesis, chemotaxis, contractility and the production of various 
enzymes, growth factors and receptors. One of the main features of HSC activation is the 




de novo expression of alpha smooth muscle actin (αSMA). HSCs are the main source of 
ECM production and are key players in the development of fibrosis (47).  
The resolution of hepatic fibrosis has been demonstrated in animal models and in 
humans and can be therefore considered a potentially bidirectional and reversible process. 
In this sense, the remodeling of the ECM and the regression of fibrosis are always 
associated with the interruption of the chronic damage. In addition, one of the most 
relevant characteristics of the hepatic fibrosis resolution process is the decrease of the 
myofibroblast pull. For that, myofibroblast may reverse to quiescent HSCs, entering into 
senescence or apoptosis (65, 66). During a chronic liver damage, apoptosis of activated 
HSCs is impeded, however, when the deleterious stimulus is removed, the loss of survival 
factors leads to the apoptosis of the activated HSCs, which facilitates the process of 
remodeling the matrix by eliminating the main source of collagen and TIMPs (67, 68). 
Nevertheless, the loss of activated HSCs is not sufficient to allow the remodeling of the 
collagen excess. The degradation of this collagen must also occur, and for that the 
increase in the activity of collagen degrading MMPs is necessary. In this regard, 
macrophages play an important role in fibrosis resolution; they produce different MMPs, 
such as MMP12 and MMP13. Both MMPs being key players in the degradation of the 
excessive ECM (65, 69, 70).  
 
 I.4.2 Liver cirrhosis 
Liver fibrosis and its final stage, cirrhosis, represent the final common consequence of 
almost all chronic liver diseases. They are a serious global health problem; the incidence 
of death in patients with cirrhosis is high and is also the optimal physiopathological 
context for the development of HCC. Therefore, a better understanding of the 
mechanisms responsible of this pathology and its evolution towards HCC and other 
complications is necessary in order to develop novel therapeutic strategies against liver 
fibrosis and cirrhosis (35, 71-73). 
Cirrhosis is a pathology characterized by the massive synthesis of ECM by 
myofibroblasts, which occupies the parenchymal space and gives the liver a scar-like 
appearance. This process is accompanied by a decrease in the functional capacity of 
hepatocytes, which lose the expression of key genes in the maintenance of the 
hepatocellular phenotype, causing their de-differentiation (35, 71).  




Thus, progressively, liver architecture and functionality is lost and due to the 
massive accumulation of ECM hepatic blood vessels are obstructed causing portal 
hypertension, which is the underlying cause of most complications of cirrhosis and the 
subsequent mortality in cirrhotic patients. In the same way, the lobular organization of 
the liver is replaced by regeneration nodules surrounded by fibrotic tissue, with zones 
composed of proliferating hepatocytes (74). These nodules may contain phenotypically 
altered hepatocytes that can lead to neoplastic nodules. Moreover, within the regenerating 
hepatocytes, new monoclonal cell populations can arise that derive from cells that could 
have accumulated genetic alterations, with an increase in proliferation and a proportional 
decrease in apoptosis, which is associated with an increased risk of developing HCC (35, 
49, 75). 
 
 I.4.3 HCC 
HCC is the sixth most common cancer worldwide, the third leading cause of cancer 
mortality and accounts for more than 80% of malignant primary liver tumours (76). Risk 
factors are well established in HCC as up to 80% of all HCCs develop in a background 
of cirrhotic liver (76). Chronic liver disease, caused by viral infections by HBV or HCV, 
alcohol consumption, obesity, or a combination of the above are the most common trigger 
factors of HCC (77, 78).  
The distribution of HCC in the world population is not homogeneous, its prevalence 
is increasing and is especially high in areas of East Asia and Sub-Saharan Africa; In East 
Asia the main causative agent is viral infection by HBV, whereas in Africa HBV infection 
and food intoxication with aflatoxin B1 are the main causatives of HCC. In contrast, in 
industrialized regions such as Europe, North America and Japan HCC incidence is mainly 
caused by chronic HCV infection (Figure I.7). Other risk factors associated with the 
development of HCC include chronic genetic conditions such as hereditary 
hemochromatosis, α1-antitrypsin deficiency and non-alcoholic fatty liver disease 
(NAFLD) and NASH, the latter being especially relevant in countries with increasing 
rates of obesity such as in the USA and Europe (76, 79, 80). 
 





Figure I.7. HCC rates worldwide. HCC rates are high in East Asia and Africa. The HCC 
causatives are different, HBV being high in China, HCV in Egypt, and both HCB and HCV and 
also alcohol consumption in Mongolia, having the world’s highest HCC incidence. In the USA 
and other developed countries HCC associated to NASH and metabolic syndrome is increasing 
whereas in African countries such as Sudan poisoning with aflatoxin B1 is an important co-factor 
in the development of HCC. HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis. (Adapted 
from Llovet JM et al, 2016). 
 
HCC shows a very poor prognosis, with almost similar number of new cases of HCC 
diagnosed and deaths. This is in part due to the high resistance of HCC to chemotherapy, 
the deleterious state of the liver in which most of the HCC develop and the lack of reliable 
diagnostic markers. Because of this, intense research efforts are being made to understand 
the cellular and molecular mechanisms of HCC development to uncover novel therapeutic 
strategies to tackle this disease (81). 
 
 I.4.3.1 Mechanisms involved in the development of HCC 
HCC is a clear example of inflammation-related cancer, as HCC is a type of tumour that 
slowly unfolds on a background of chronic inflammation, mainly triggered by exposure 
to infectious agents or toxic compounds (82). HCC development is a multistep process, 
characterized by chronic inflammation, fibrogenesis and hepatocyte death and 
regeneration (79). HCC develops in a cirrhotic background and the risk of developing 




HCC increases while liver function is impaired. Like other tumours, HCC is developed 
as a consequence of somatic mutations. Genetically, HCCs exhibit a high heterogeneity, 
with numerous mutations in diverse genes. However, some genes appear to be frequently 
mutated in HCC, such as telomerase reverse transcriptase (TERT) (60%), TP53 (25-
30%), CTNNB1 (18%), AXIN1 (8%), CDKN2A (2-12%), CCND1 (7%), RB1 (3-8%) and 
ARID2 (3-18%) (79, 83, 84). 
Mutations in the promoter of TERT are very common in HCC but TERT is not 
usually expressed in hepatocytes, however, during HCC development its expression in 
becomes re-activated. Telomerase activation happens in up to 90% of HCCs, whereas in 
precancerous nodules telomerase activation occurs in 6-20% of cases. Therefore, 
telomerase activation is important for the transformation and for the promotion of 
uncontrolled proliferation of hepatocytes (84, 85). Wnt/β-catenin pathway is an 
embryogenic pathway that is also commonly re-activated in HCC (20-35%) and a 
significant proportion of HCCs have mutations in key genes of this pathway, such as 
CTNNB1 and AXIN1 (86, 87). As a consequence, β-catenin stabilizes in the cytoplasm 
and translocates to the nucleus promoting the transcription of genes associated to an 
increased proliferation, migration and metastasis, such c-Myc and cyclin D1 (87, 88). 
Inactivation of p53 and cell-cycle related alterations are a common feature in various 
cancers and also in HCC, especially in HCCs related to HBV infection or to aflatoxin B1 
poisoning. Other key pathways altered during HCC are the ras/raf/MEK/ERK pathway, 
PI3K/Akt/mTOR, NF-κB and JAK/STAT pathways. In addition, chromatin remodelling 
complexes and epigenetic regulators and oxidative stress are other key processes altered 
in HCC (75, 79, 89-94). 
Apart from these common mechanisms, according to the different aetiological 
agents the hepatocarcinogenic process may have relevant differences. In the case of the 
deoxyribonucleic acid (DNA) virus HBV, the integration of viral DNA into the host cell 
genome may cause genomic instability. Commonly, HBV viral genome inserts in TERT 
promoter and other oncogenes, In addition, both HBV and HCV viral proteins may also 
promote HCC: HBV protein HBx and HCV proteins NS3, NS5A and NS5B have been 
shown to be oncogenic and are associated to tumour promotion (95-97). In alcohol-
mediated HCC two main factors co-exist. One of the factors includes the direct damage 
produced in hepatocytes due to oxidative stress and lipid peroxidation produced when 
ethanol is metabolized by the enzyme Cyp2E1. In addition, when ethanol is metabolized, 
the carcinogenic primary metabolite acetaldehyde is produced. Acetaldehyde promotes 




adduct formation, that causes DNA damage, alters the function of key proteins and as a 
consequence may provoke mutagenesis and HCC. On the other hand, these two factors, 
combined with the inflammatory and fibrotic environment in alcohol consumption-
mediated cirrhotic liver ultimately cause the development and promotion of HCC (98).  
In addition to the direct oncogenic activity of hepatitis B and C viruses and the 
chronic consumption of alcohol, these agents can also cause liver tumours through an 
indirect action. This involves the accumulation and fixation of mutations in the 
hepatocyte genome during the compensatory proliferation that is triggered by the loss of 
parenchymal cells and the chronic inflammation that occurs during fibrogenesis and 
cirrhosis (99-101). This scenario of chronic inflammation and regeneration appears to be 
essential for the complete development of the neoplastic phenotype, facilitating the 
accumulation of genetic alterations in a large population of progenitor cells (102, 103). 
This hyper-proliferative state found in the chronically affected liver is in part due to over-
expression of mitogenic factors for hepatocytes, such as HGF. What initially is part of the 
endogenous defence of the damaged liver for a proper regeneration in response to the loss 
of parenchymal cells of the liver, its perpetuation in a chronic setting of liver damage may 
enhance the hepatocarcinogenic process establishing autocrine mechanisms for self-
sustained cell growth (99-101). 
Therefore, despite the molecular and aetiological heterogeneity of HCCs, there are 
common features that characterize the early stages of liver cancer development. Including 
the alteration of the normal expression of specific genes of the liver and the persistence 
of an inflammatory and regenerative environment guided by a complex interaction of 
cytokines and growth factors (75, 100).  
 
I.4.3.2 Current therapies for HCC 
HCC staging is very important for the correct management of HCC patients, in this 
regard, several staging systems have been proposed, including the tumour, node, 
metastasis (TNM) staging, which is used in most cancers and the Barcelona clinic liver 
cancer (BCLC) staging, that has been extensively validated and is the most widely used 
for HCC (76). The BCLC algorithm does not only take into account the tumour stage, but 
also incorporates other factors such as the liver function impairment with the Child-Pugh 
classification and the existence of cancer-related symptoms with the ECOG Performance 
Status, which are strongly associated to the prognosis of HCC. Importantly, the BCLC 




staging system is classified in 5 different HCC stages which are paired with the best 
therapeutic option (76).  
Current therapies are divided in three main categories: surgical treatments, 
locoregional therapies and systemic therapies. Surgical treatments are considered at very 
early or early BCLC stages and are based on the resection of the tumour tissue or in liver 
transplantation. Yet after tumour resection recurrence is common as the underlying 
cirrhosis is still present and liver transplantation in selected patients remains the best 
therapy for HCC. However, this approach is limited as there is a low availability and 
compatibility of organs to transplant. Regarding locoregional treatments, tumour ablation 
is indicated in early HCC stages when tumour resection and liver transplant are not 
possible. Other locoregional treatments such as transarterial chemoembolization and 
radioembolization are indicated in intermediate BCLC stages, for asymptomatic patients 
with multinodular tumours and a preserved liver function (76). 
Regarding systemic therapies, HCC is a tumour that is highly resistant to 
conventional treatments based on nonspecific cytotoxic drugs and so far, there is no 
convincing evidence that systemic chemotherapy improves the overall survival of patients 
with HCC (76, 104). Even though major progress has been made during the last decade, 
due to the complex scenario in which HCC develops with the underlying liver cirrhosis, 
to date, there is no effective therapy to treat and cure this cancer. Thus, the development 
of novel therapeutic strategies is an urgent need (76, 104-106). Targeted therapies aiming 
to treat HCC have been shown modest beneficial effects (104) (107, 108). In this regard, 
sorafenib, a multikinase inhibitor drug, was the first food and drug administration (FDA) 
approved first-line treatment for HCC showing improved progression-free survival and 
overall survival (109, 110). Recently, Lenvatinib, another multikinase inhibitor was also 
approved as first-line and also as a second-line treatment for HCC after showing non-
inferior to sorafenib overall survival improvement (111). In addition, regorafenib, another 
multikinase inhibitor drug, has been approved as a second-line treatment after sorafenib 
(112). In addition, a number of drugs are currently in Phase III trial and it is expected to 
enter in the clinics soon (107, 108). However, many phase II and III clinical trials result 
in the discontinuation of drugs because they are clinically unsuccessful (104).  
Immunotherapy has emerged as a promising therapeutic approach for cancer 
treatment (113). Immunotherapy consists on the modulation of the immune system to 
tackle cancer, and may be achieved through different strategies, such as the use of 
monoclonal antibodies to modulate proteins of the immune system, treatment vaccines 




and adoptive cell transfer among others. However, this field is still in its infancy and 
efforts should be made in order to learn how cancer cells evade the immune system 
surveillance (113). Currently there is only one FDA approved immunotherapy based drug 
for HCC as a second-line treatment; nivolumab, a programmed death receptor-1 (PD-1) 
blocking antibody. PD-1 is expressed in T cells and suppresses T cell inflammatory 
response promoting their apoptosis. PD-1 blockade by nivolumab is able to reverse the 
suppression of T cells, activating and helping them fight cancer cells (108, 114, 115). 
However, nivolumab has not yet been approved by the European medicines agency 
(EMA). 
In view of these, the development of new therapeutic approaches to treat HCC is of 
paramount importance, and for that, a better understanding of the molecular mechanisms 
in the progression of liver diseases and HCC is necessary.  
 
I.5 Innate immune system in the liver 
The innate immune system plays a key role in liver homeostasis and disease. The liver is 
continually exposed to pathogens from the blood and acts as a barrier being the first line 
defence against pathogens derived from the gut. In this sense, the liver is able to detect 
and respond to pathogens due to its anatomical location and to the immune cells 
population (7, 116). The immune resident cells are located in the sinusoidal lumen and in 
the space of Disse and comprise a cell network of immune sentinels and effector cells (7, 
116). The interaction of the resident immune cells with the pathogens is facilitated by the 
low pressure of the blood and the endothelial cells’ fenestrae. This way, immune cells 
directly detect and destroy circulating pathogens (8). 
In the liver, different adaptive and innate immune cells are present, including the 
antigen presenting cells (APC), lymphoid cells and myeloid cells (7, 116). These resident 
immune cells play important roles in the maintenance of the liver homeostasis and also 
during liver disease. Interestingly, the liver contains the greatest densities of natural killer 
cells (NK) and natural killer T cells (NKT) and the largest macrophages population 








I.5.1 The role of KCs in innate immunity 
As above mentioned KCs are the resident macrophages of the liver and comprise the 
largest population of resident macrophages in the organism (7). Although resident KCs 
have a prenatal origin and are generated from the yolk sac and/or fetal liver, during liver 
injury, circulating Ly6C+ monocytes are recruited to the injured liver in a Monocyte 
chemoattractant protein 1 / chemokine (C-C motif) receptor 2 (MCP1/CCR2) dependent 
manner, where they can contribute to injury (117-119). KCs are key players in the innate 
immune response in the liver, for that, they localize strategically in the hepatic sinusoids 
allowing them to phagocytise pathogens, especially the ones entering from the gut 
through the portal vein. Therefore, KCs act as components of the gut barrier by serving 
as a first line of defence in the liver for gut derived immunoreactive material. Thus, due 
to their phagocytic and inflammatory activity, KCs play a major role clearing the blood 
entering from the gut from pathogens, and preventing them from travelling past the 
hepatic sinusoid (120). In addition, KCs are specialized in phagocytising apoptotic bodies 
from the hepatic parenchyma, as well as dying erythrocytes from the systemic circulation 
(121-123). The phagocytic activity of KCs can be mediated by phagocytic pseudopodia, 
pinocytosis vesicles, vacuoles, and invaginations (124). Particles can be detected and 
phagocytised by specific receptors such as Fc and C3 receptors (124). In addition, 
opsonizing agents such as plasma fibronectin also facilitates the phagocytic activity of 
KCs. These cells also express CD14, a co-receptor that forms a complex with TLR4 and 
MD-2 to recognize bacterial-derived LPS (125, 126). 
KCs also play a role in the metabolism of lipoproteins. Specifically, KCs are 
responsible of the metabolism of oxidized low density lipoproteins (LDL), which are 
metabolized in the liver also by endothelial cells (127, 128). For that, KCs express 
scavenger receptors such as CD36 and SR-A which are able to phagocytise and destroy 
the circulating oxidized LDLs (129, 130). This is particularly important in NASH, where 
the uptake of circulating oxidize LDLs triggers activation of KC promoting inflammation 
in the liver (130, 131). 
 
 
I.5.1.1 Activation of KCs 
KCs are activated by binding different molecules such as LPS, complement factor C5a, 
growth factors, TNF or interferon γ (IFNγ). Besides, KCs can also be activated by 
phagocytised particles such as apoptotic bodies, LDLs or pathogens (120, 124). Once 




activated KCs secrete a number of inflammatory mediators such as cytokines, TGFβ, 
IFNs, growth factors and ROS among others (122). These inflammatory mediators are 
secreted in an autocrine-paracrine manner, affecting them and nearby cells in the hepatic 
sinusoid. In addition the phagocytic capacity of activated KCs increases and also these 
cells become more proliferative (122). Moreover, KCs show an important plasticity, as 
other macrophages, they are able to polarize into different inflammatory-state cells 
termed M1 or M2, M1 being the classic pro-inflammatory macrophages, involved in 
inflammatory processes, while M2 being anti-inflammatory macrophages, involved in the 
resolution of injury and wound healing and also related to tumorigenic processes. In 
addition, there are also different states termed as M2-like phenotypes which are involved 
in immunoregulation and can also promote tumorigenesis (120, 132).  
KCs play an important protective role in the liver as they are important mediators of 
liver injury and repair (122). After liver injury KCs activate and help in the resolution of 
the liver damage (133). However, KCs may also play a deleterious role in the liver, as a 
change in the functional activity of these cells is associated with a number of liver 
diseases. Besides, deregulation of KCs may promote chronic inflammation which 
contributes to a number of diseases such as NASH, alcoholic liver disease (ALD) and 
insulin resistance and is also associated with the progression of liver injury and HCC 
(120, 134).  
 
  
I.5.2 The gut-liver axis 
As aforementioned, the liver due to its anatomical location is the first organ that 
encounters portal venous blood from the gut, an organ consisting of vast numbers of 
micro-flora. Blood from the portal vein mixes with oxygenized blood from the hepatic 
artery and drains through the sinusoids, allowing a rapid exchange of nutrients with 
hepatocytes and the elimination of immunoreactive molecules. Thus, the liver is capable 
of tolerating these immunogenic agents and at the same time responds efficiently to 
pathogens and infections (116). 
The primary aim of the innate immune response is the rapid elimination of 
pathogens before they multiply, spread systemically and invade tissue. This prevents 
excessive inflammation that can result in immuno-pathology and organ failure. A variety 
of pattern recognition receptors (PRRs), including those of the TLR family are expressed 
by innate immune effector cells including KCs and dendritic cells. PRRs recognize 




pathogen associated molecular patterns (PAMPs), conserved in microbes and trigger 
innate immune responses which shape adaptive immunity. PRRs also recognise damage 
associated molecular patterns (DAMPS) which recognize biomolecules that are exposed 
by damaged endogenous cells (120, 135, 136). 
Recently, the role of bacterial flora and TLRs in the pathogenesis of fibrosis has 
been demonstrated. The gut-liver axis plays a significant role in liver injury and in the 
diseased state; the normal tolerogenic liver is exposed to bacteria and bacterial products 
including LPS, which is recognized by TLR4 (137). Moreover, polymorphisms in TLRs 
are associated with complications in cirrhosis (138). TLRs including TLR4 are expressed 
on KCs and also on hepatocytes (albeit at a low level) and on HSCs and as 
aforementioned, HSCs are extremely important in the synthesis of ECM, collagen and 
consequently the development of fibrosis (139, 140) (Figure I.9).  
There is increasing evidence showing that TLRs play an important role in hepatic 
injury and liver disease. Mechanistically, gut microbiota are believed to be one of the 
main players, with the current idea being that liver injury causes altered intestinal 
permeability that ultimately results in induction of inflammatory responses which impact 
on the disease process (135, 141). Thus, it seems logical that the liver similar to the 
intestine would require mechanisms to control the intensity and duration of TLR driven 
cytokine production, which can contribute to the pathogenic process in various types of 
chronic and acute liver disease (142-144). By using genetic and molecular approaches it 
has been shown that LPS through TLR4 is able to increase the fibrogenic activity of TGFβ 
in HSCs (64). By the same means, TLR4 has been shown to promote the development of 
HCC (145). In line with this dogma, treatment of mice with antibiotics or probiotics 
attenuates various forms of liver injury including; carbon tetrachloride (CCl4), bile duct 
ligation (BDL), NASH and HCC development (64, 145-148). Indeed, Tlr4 deficient mice 
are protected from the aforementioned insults to the liver (145, 147, 148) (Figure I.8).  
 





Figure I.8. Gut-liver axis and chronic liver disease progression. During chronic liver damage 
the gut epithelia is also damaged; the intestinal barrier disintegrates, and the intestinal 
permeability increases. In this scenario, bacterial products derived from the gut microbiota 
translocate to the liver promoting TLR signaling in KCs and HSCs and, eventually, promoting 
inflammation, fibrosis and chronic liver disease progression. BAMBI, BMP and activin 
membrane bound inhibitor; CCR, chemokine (C-C motif) receptor; COL1A1, collagen type 1 
alpha 1; MAPK, mitogen-activated protein kinases; MCP1, monocyte chemoattractant protein 1; 
Mip-1β (CCL4), C-C motif chemokine ligand 4; Myd88, myeloid differentiation primary 
response gene 88; NF-κB, nuclear factor kappa B; LPS, lipopolysaccharide; RANTES (CCL5), 
C-C motif chemokine ligand 5; TGFβ, transforming growth factor β 1; TGFβR, transforming 
growth factor β receptor; TLR, toll-like receptor. (Adapted from Seki E et al, 2012).  
I.6 Triggering receptor expressed on myeloid cells (TREM) family 
The TREM family of genes are encoded on human chromosome 6p21.1 and are composed 
by TREM1 and TREM2, the TREM-like genes TREML1, TREML2 and TREML4 and also 
the pseudogenes TREML3P and TREML5P. In mice, this family is encoded in 
chromosome 17C and are composed by Trem1, Trem2, Trem3, Treml1, Treml2 and 
Treml4 (Gene database from the NCBI, https://www.ncbi.nlm.nih.gov/gene) (Figure 
I.9). These genes encode a single V-type extracellular immunoglobulin-like domain, a 
trans-membrane domain and a short cytoplasmic tail. However, human and mouse 
TREM1 and TREM2 and mouse TREM3 lack any signalling motif. For that, they couple 
to the immunoreceptor tyrosine-based activation motif (ITAM) of DNAX-activation 
protein-12 (DAP-12) which becomes tyrosine phosphorylated and modulate cells 




involved in immune innate responses (149). Regarding TREM-like genes, they also 
encode a V-type single variable type immunoglobulin domain and a transmembrane 
domain, but in the case of human TREML1 and mouse Treml1, Treml2 and Treml4 they 
also have a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) domain 
and in the case of human TREML2 a SH3 binding domain for their signalling (150). 
Interestingly, soluble forms of TREM receptors exist, either by alternative splicing or by 
cleavage soluble forms of TREM1, TREM2, TREML1 and TREML2 (sTREM1, 
sTREM2, sTREML1 and sTREML2) exist and although their role is still not clear they 
seem to negatively regulate their signalling by competing with the full form of the 
receptors (149).  
TREM receptors are expressed on myeloid cells and also in other cells such as 
platelets and endothelial cells (149). TREM1 receptor was first described as a pro-
inflammatory receptor whereas TREM2 has been described as an anti-inflammatory 
receptor (149). However, this may be cell-type specific and ligand-dependent (151, 152). 
By contrast, TREM-like proteins function is less clear and they may be involved in the 






Figure I.9. The TREM family of genes. (A) The TREM family of genes is a gene cluster encoded 
on human chromosome 6 and composed by TREM1, TREM2, TREML1, TREML2, TREML4 genes 
and TREML3P and TREML5P pseudogenes. (B) In mouse, they are encoded on chromosome 17 
TREML1TREM2TREML2TREML3PTREML5P TREML4TREM1
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and are composed by Trem1, Trem2, Trem3, Treml1, Treml2 and Treml4. TREM, triggering 
receptor expressed on myeloid cells; TREML, triggering receptor expressed on myeloid cells like. 




I.6.1 TREM1 and TREML members 
TREM1 was the first TREM family member being described (153). TREM1 is a pro-
inflammatory receptor that acts as an enhancer of TLR mediated inflammation (153). 
TREM1 has been implicated in a number of diseases, including sepsis atherosclerosis, 
inflammatory bowel disease and many cancers such as intestinal, lung and liver cancer 
(154-165). Regarding the liver, TREM1 has been shown to be expressed in LSECs, KCs, 
HSCs and also in HCC cells (163-165). TREM1 promotes liver injury and HCC 
progression in mice; Trem1-/- mice are protected from diethylnitrosamine (DEN)-
mediated tumourigenesis and Trem1-/- KCs have diminished activation with less 
activation of p38, ERK1/2, c-Jun N-terminal kinase (JNK), mitogen activated protein 
kinase (MAPK) and NF-κB pathways and a decreased expression of inflammatory 
markers (163). Moreover, TREM1 is associated with lower survival and faster time to 
recurrence in human HCC (164, 165). In addition, another study reported that activated 
HSCs show augmented levels of sTREM1 when cultured with HCC cells. Importantly, 
TREM1 was associated with migratory effects in HCC cells (165). 
Considering the other members of the TREM family, TREML1 is expressed in 
megakaryocytes and platelets (166), contains an ITIM signalling motif and has been 
reported to regulate Ca+2 influx (167). TREML1 and its soluble form sTREML1 induce 
platelet aggregation interacting with fibrinogen (168-170). Interestingly, sTREML1 show 
high homology with TREM1 and is able to block TREM1-mediated inflammation (171). 
In this regard, sTREML1 has been reported to dampen TREM1-mediated leukocyte 
activation during sepsis by competing with TREM1 ligands (168). Moreover, serum 
levels of sTREML1 during sepsis are increased and could be used to differentially 
diagnose sepsis from non-infectious systemic inflammatory response syndrome (SIRS) 
(172). Of note, a TREML1 transcript variant is able to inhibit TREM2-mediated 
osteoclastogenesis (173).  
Regarding TREML2, it has been reported to be expressed in macrophages, 
neutrophils and in B and T lymphocytes (174). TREML2 expression was shown to 
promote T cell activation, which was mediated by direct interaction with B7-H3 (175). 
Moreover, B7-H3 was shown to augment the function of tumor infiltrating CD8+ T 




expressing TREML2 cells (176). However, two more studies did not found any 
association between TREML2 and B7-H3 and the role of both TREML2 and B7-H3 in T 
cell activation remains controversial (177, 178). In addition, TREML2 promotes 




TREM2 is a TREM family member expressed in dendritic cells, alveolar, liver and 
intestinal macrophages and endothelial cells among others (151). This receptor is a type 
1 membrane glycoprotein, and as previously mentioned can be cleaved forming the 
soluble protein sTREM2. Cleavage is mediated by α-secretases ADAM10 and ADAM17, 
then γ-secretase cleaves the remaining C-terminal amino acids (181, 182).  
TREM2 was first described as performing opposite functions to TREM1 being an 
anti-inflammatory receptor that negatively regulates TLR mediated inflammatory 
responses while TREM1 acts to augment TLR induced inflammation (154). In this sense, 
similar to IRAK-M and A20 null macrophages, Trem2-/- macrophages exhibit augmented 
cytokine responses to TLR ligands (183, 184). In this regard, TREM2 signals via the 
ITAM motif of the adaptor protein DAP-12, which becomes tyrosine phosphorylated 
leading to increases in intracellular calcium and ERK1/2 phosphorylation (185) (Figure 
I.10). However, TREM2 signalling is cell-type specific and may be ligand specific too, 
as it may exert pro-inflammatory effects under certain circumstances (151, 152, 186).  
 
 




I.10. TLR-mediated signaling of TREM1 and TREM2. TREM1 and TREM2 both 
lack any signaling motif and therefore signal through ITAM motifs of DAP-12. TREM1 
induces TLR signal amplification promoting the transcription of inflammatory genes. 
By contrast, TREM2 inhibits TLR-derived signaling reducing the transcription of 
inflammatory genes. These signals are further enhanced by non-TLR signalling. DAP-
12, DNAX-activation protein 12; IKK, IκB kinase; ITAM, immunoreceptor tyrosine-
based activation motif; MAPK, mitogen-activated protein kinases; Myd88, myeloid 
differentiation primary response gene 88; TLR, toll-like receptor; TREM, triggering 
receptor expressed on myeloid cells. 
 
 
Importantly, TREM2 was described as a phagocytic receptor. In this regard, TREM2 has 
been shown to promote phagocytosis of apoptotic bodies by microglia (187, 188). 
However, a recent study showed that TREM2 was not involved in phagocytosis of 
apoptotic cells in the 5XFAD Alzheimer’s disease (AD) model (189). In addition, 
TREM2 has been shown to promote bacterial clearance by peritoneal macrophages, bone 
marrow-derived macrophages (BMDM) and neutrophils (190, 191). However, 
surprisingly, Trem2 deficient alveolar macrophages showed an increased phagocytosis of 




bacteria (192), therefore, showing that TREM2-mediated phagocytosis may be cell-type 
specific. 
TREM2 was first linked to a degenerative disease termed Nasu–Hakola, also known 
as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL) (193). PLOSL is a rare disease that is associated with bone cysts and fractures 
and dementia. Importantly, PLOSL patients have loss of function mutations in TYROBP 
(encoding DAP-12) or TREM2 (194). TREM2 was also associated to osteoclast 
differentiation from myeloid cells as osteoclast differentiation is impeded in patients-
derived myeloid cells with mutations in TREM2 (195). 
More recently, TREM2 has attracted considerable interest due to its potential role 
in AD and other neurodegenerative diseases. In 2013, the TREM2 variant R47H 
(rs75932628) substitution was strongly associated to an increased predisposition to AD 
(196, 197). Since then, the role of TREM2 especially in microglia, the resident immune 
cells of the brain, has been extensively investigated (198), showing that TREM2 
modulates the metabolism of microglia, via mTOR regulating the function of these cells 
(199). Moreover, TREM2 was shown to act as a sensor of lipids in microglia, such as 
phosphatidylcholine and sphingomyelin while the TREM2 variant R47H impaired the 
recognition of these lipids which was associated with β-amyloid accumulation and 
neuronal loss (189). Interestingly, human TREM2 transgene is able to restore the 
amyloid-β-induced microgliosis and microglial activation in the 5XFAD AD mice model 
(200). In addition, a missense variant of TREML2 was associated with protection to AD 
(201) and a recent study demonstrated that TREM2 and TREML2 have opposing roles in 
microglia activation (202). 
The function of TREM2 has also newly been described in the gut, where it drives 
epithelial proliferation and stem cell replacement in crypts via the regulation of cytokine 
expression profile (203). Moreover, TREM2 levels are increased during inflammatory 
bowel disease (IBD) and TREM2 promotes mucosal inflammation during experimental 
colitis in mice (186). In addition, TREM2 is also expressed in alveolar macrophages, 
where it regulates opsonin secretion and bacterial phagocytosis (192). Besides, the 
expression of TREM2 has been found upregulated in lung cancer, gastric cancer, glioma, 
and renal cell carcinoma (204-207). 
By contrast, the role of TREM2 in liver disease progression is largely unknown. 
TREM family expression in KCs and LSECs was analysed and TREM2 expression is 
suggested to be inhibited following LPS in both cell types (208). In addition, TREM2 




expression in KCs was demonstrated to limit malaria parasite expansion in hepatocytes 
and Trem2-/- KCs showed an M2-like phenotype compared to WT KCs (209). Moreover, 
given that TREM2 attenuates TLR4-mediated inflammation and has previously been 
shown to be important in injury responses in the colon (203) and brain (188), we proposed 

































































As TREM2 plays a role in various forms of injury our interest is centered on the analysis 
of the possible role of this receptor in the liver. Therefore, this dissertation aims to explore 
the potential implication of this receptor in different forms of liver disease, including 
acute and chronic liver injury and the development of HCC. Thus, we propose the 
following objectives to evaluate:  
 
1. Role of TREM2 in liver injury. 
1.1. Gene expression analysis of TREM2 in samples from healthy patients and from 
cirrhotic human tissue samples and in mouse models of liver injury. 
1.2. Analysis of TREM2 expression in liver cells. 
1.3. Determination of the role of this receptor in chronic liver injury. 
1.4. Characterization of the role of this receptor in acute liver injury. 
1.5. TREM2-mediated molecular mechanisms in liver injury. 
 
2. Role of TREM2 in liver regeneration. 
2.1. Characterization of the potential role of TREM2 in the hepatic regenerative 
process and in hepatocyte proliferation. 
 
3. Role of TREM2 in HCC. 
3.1. Gene expression analysis of TREM2 in samples from healthy patients and from 
HCC human tissue samples and correlation with inflammation and fibrosis. 
3.2. Study of the role of the TREM2 receptor in the hepatocarcinogenic process. 

































































M.1 Human liver tissue samples 
 
M.1.1 San Sebastian cohort of patients 
To carry out gene expression analysis at mRNA level, liver tissue from control individuals 
and patients with liver cirrhosis and HCC of different aetiology was obtained. Patient 
characteristics and liver-injury related serology are described in Table M.1 and Table 
M.2. To perform TREM2 expression analysis by immunohistochemistry (IHC) 1 control 
sample and 5 cirrhotic liver samples were also used (Table M.3). Control liver tissue 
samples were obtained from non-neoplastic liver tissue resected specimens for colorectal 
metastasis and selected sections were located furthest away from tumour mass lesions. 
Samples for this study were provided by the Basque Biobank and were processed 
according to standard procedures approved by the Clinical Research Ethics Committees 
of the Basque Country and the Donostia University Hospital. An informed consent was 
obtained from all subjects.  
 
 
Table M.1. Patient characteristics and parameters of liver-injury related serology of cirrhotic 
samples. 
Parameters Controls* Cirrhotic 
Cases, n  21 23 
Sex, n 
Male 16 22 
Female 5 1 
Age, n (±SD)  65.5 (±7.1) 60.8 (±8.7) 
Aetiology, n 
Alcoholic - 9 
HCV - 7 
HBV - 2 
HCV, HBV - 2 
HCV, HBV, HIV - 1 
HCV, Alcoholic - 1 
Idiopathic - 1 
Serum ALT, IU/L  20.85 (±7.10) 54.60 (±36.82) 
Serum ALT, IU/L  23.52 (±5,85) 47.04 (±24.67) 
Data are shown as median ± SD.  
ALT, alanine aminotransferase; AST, aspartate transaminase; HBV, hepatitis B virus; HCV, 
hepatitis C virus; HIV, human immunodeficiency virus; IU, international units; SD, standard 
deviation. 
* Background normal liver from resection specimens of colorectal liver metastasis. 
 
 




Table M.2. Patient characteristics and parameters of liver-injury related serology of HCC 
samples. 
Parameters Controls* HCC 
Cases, n  21 35 
Sex, n Male 16 33 
 Female 5 2 
Age, n (±SD)  65.38 (±7.28) 62.80 (±9.13) 
Aetiology, n    
 Alcoholic - 10 
 HCV - 10 
 HBV - 2 
 HCV, HBV - 3 
 HCV, HBV, HIV - 1 
 HCV, Alcoholic - 1 
 Hemochromatosis - 1 
 Idiopathic - 7 
Serum ALT, IU/L  21.19 (±7.32) 44.74 (±32.62) 
Serum ALT, IU/L  23.19 (±6.19) 40.54 (±23.21) 
Data are shown as median ± SD.  
ALT, alanine aminotransferase; AST, aspartate transaminase; HBV, hepatitis B virus; HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IU, 
international units; SD, standard deviation. 
* Background normal liver from resection specimens of colorectal liver metastasis. 
 
 
Table M.3. Patient characteristics and parameters of liver-injury related serology used for 
histological analysis. 
Parameters Control* Cirrhotic 
Cases, n  1 5 
Sex, n Male - 4 
 Female 1 1 
Age, n (±SD)  49 58.6 (±10.6) 
Aetiology, n    
 HCV - 1 
 HBV - 1 
 HCV, HIV - 1 
 HCV, Alcoholic - 1 
 Fatty liver disease - 1 
Serum ALT, IU/L  33 87.8 (±51.20) 
Serum ALT, IU/L  32 97.66 (±56.36) 
Data are shown as median ± SD.  
ALT, alanine aminotransferase; AST, aspartate transaminase; HBV, hepatitis B virus; HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IU, 
international units; SD, standard deviation. 
* Background normal liver from resection specimens of colorectal liver metastasis. 
 




M.1.2 The cancer genome atlas (TCGA) cohort of patients 
TREM2 expression in 366 HCC and 49 surrounding normal tissue samples was also 
analysed in the obtainable RNAseq data of the TCGA. TREM2 expression was also 
correlated to tumour stage.  
 
M.1.3 Human samples for hepatic myofibroblast isolation 
Isolation of human hepatic myofibroblasts was performed from livers of adult male 
patients after surgical resection with the approval of the Newcastle and North Tyneside 
Local Research Ethics Committee, subject to patient consent (10/H0906/41).  
 
M.2 Experimental mouse models of liver injury and carcinogenesis 
Animal experiments were performed in age-matched male C57BL/6 [wild type (WT)] 
and Trem2 knockout (Trem2-/-) mice bred at Biodonostia Research Institute or Medical 
University of Vienna. Trem2-/- mice backcrossed onto a >98% C57BL/6 background were 
obtained from Marco Colonna (Washington University) (184). 
All procedures were approved by the Animal Experimentation Ethics Committee 
(CEEA) of the Biodonostia Research Institute as well as the Animal Care and Use 
Committee of the Medical University of Vienna and the Austrian Ministry of Sciences. 
After the indicated treatments mice were sacrificed by cardiac puncture under 
general anaesthesia, body weight was recorded and blood was collected. Liver was 
extracted, weighted and processed as follows: 3 liver pieces (~50 mg) of different lobules 
from each mouse were fixed in paraformaldehyde 4% (Merck) for histological analysis. 
2 liver pieces (~25 mg each, for mRNA and protein extraction) were collected from all 
mice and stored at -80ºC for further processing. The rest of the liver was also stored at -
80ºC. Serum was extracted by centrifugation at 1500 g for 20 minutes at 4ºC. Alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) levels in serum were 
measured at the Donostia University Hospital in a Cobas 8000 c702 (Roche) analyser.  
 
 
M.2.1 CCl4-induced acute liver injury model 
2 µl/g body weight CCl4 (Sigma-Aldrich) was mixed 1:1 vol:vol with olive oil (Sigma-
Aldrich) and intraperitoneally injected to 8-10 week old male WT mice. Mice were 




sacrificed 24, 48 and 72 hours after for the analysis of Trem2 expression. Similarly, the 
same model was carried out in 8 week old male WT and Trem2-/- mice, which were 
injected with CCl4 and sacrificed after 6, 12 and 24 hours. Controls were injected with 
olive oil. 
 
M.2.2 Acute CCl4 treatment and gut sterilization with antibiotics (Abx) 
6 week old WT and Trem2-/- male mice were treated for 4 weeks with a combination of 
antibiotics: 1 g/l ampicillin (Sigma-Aldrich), 1 g/l neomycin (Gibco), 1 g/l metronidazole 
(Acros Organics) and 500 mg/l vancomycin (Pfizer) in drinking water. After the antibiotic 
treatment, mice were intraperitoneally injected with CCl4 at 2 μl/g body weight 
(CCl4:olive oil at 1:1 [vol:vol]) and sacrificed after 12 hours. To determine intestinal 
permeability, all animals were gavaged with 4 kDa fluorescein isothiocyanate (FITC)-
dextran (Sigma-Aldrich; 800 mg/kg body weight) four hours before the sacrifice. FITC-
dextran was measured in 100 μl of mice serum by fluorimetry with an excitation 
wavelength of 485 nm and an emission wavelength of 535 nm using the Fluoroskan 
Ascent® fluorometer (Labsystems).  
 
M.2.3 CCl4-induced chronic liver injury model 
8 week old WT male mice were intraperitoneally injected with CCl4 at 2 µl/g body weight 
mixing it with olive oil 1:3 (vol:vol). Mice were injected twice per week during 12 weeks 
and sacrificed after 1, 3, 7 and 10 days for the analysis of Trem2 mRNA expression as 
described (210). In the same way, a similar model was performed in 8 week old male WT 
and Trem2-/- mice, which were injected with CCl4 twice per week during 8 weeks and 
sacrificed after 1 and 5 days. Controls were injected with olive oil. 
 
M.2.4 Bone marrow (BM) transplantation  
To perform BM transplantation Trem2-/- mice were crossed on a C57BL/6 background 
mice that ubiquitously express green fluorescent protein (GFP) (WT/GFP+) to generate 
Trem2-/-/Ub-GFP+ mice. BM was isolated from Trem2-/-/Ub-GFP+ or WT-GFP+ 
expressing mice, while 8-10 week-old male WT and Trem2-/- mice were irradiated 
administrating γ irradiation (9 Gy). Mice were immediately reconstituted by intravenous 
injection of 2x106 isolated BM cells to generate WT mice (WT/WT), Trem2-/- mice 
(Trem2-/-/Trem2-/-) or chimeric mice (WT/Trem2-/-) and (Trem2-/-/WT) mice (recipient 




mouse and donor mouse, respectively). To control the efficiency of irradiation, 1 mouse 
of each genotype was left without reconstitution. Mice were kept under sterile conditions 
for 8 weeks after which repetitive CCl4 injury was performed. BM reconstitution was 
confirmed by flow cytometry for GFP+ blood leukocytes. 
 
M.2.5 BDL-induced cholestasis liver injury model 
WT male mice were surgically bile duct ligated and were sacrificed after 14 or 21 days. 
In short, mice were anesthetized, the abdomen was opened and bile duct was exposed. 
Afterwards, two surgical knots were performed on the bile duct using 5-0 non-absorbable 
sutures (Figure M.1). Finally, the peritoneum was sewed with 5-0 sutures and the skin 
with a 3-0 suture. Controls were sham operated.  
 
M.2.6 APAP-induced acute liver injury model 
APAP model was performed in 8-10 week old WT and Trem2-/- male mice (25-30 g). 
Mice were overnight starved, intraperitoneally injected with 300 mg/Kg or 500 mg/kg 
APAP (Sigma-Aldrich) dissolved in saline (Braun) and sacrificed 24 hours after. Controls 
were injected with saline. 
 
M.2.7 APAP-induced ALF 
For survival studies WT and Trem2-/- mice were injected with a lethal dose (750 mg/kg) 
of APAP and survival was monitored every hour during the first 30 hours and after that, 
it was monitored every day for the following days. 
 
M.2.8 DEN-induced liver carcinogenesis 
For studies of liver tumour development, 15 day-old WT and Trem2-/- mice were 
intraperitoneally injected with a single dose of DEN (Sigma-Aldrich) diluted in saline at 
a dose of 30 mg/kg body weight. Mice were sacrificed 30 or 40 weeks after DEN 
administration and tumours were manually counted and size was recorded. Control mice 
were injected with saline. 
 




M.2.9 DEN-induced liver carcinogenesis and treatment with the anti-oxidant diet 
butylated hydroxyanisole (BHA) 
Another group of WT and Trem2-/- mice were DEN treated in the same way and 15 weeks 
post-DEN injection were fed a diet supplemented with the antioxidant BHA (0,7% w/w) 
(Sigma-Aldrich). Mice were fed this diet for another 15 weeks and were sacrificed 30 
weeks after DEN injection. 
 
M.2.10 DEN-induced acute liver injury model 
For short-term studies to asses DEN-induced hepatic injury and inflammatory response, 
experiments were performed in 8-10 week old male WT and Trem2-/- mice. Mice were 
intraperitoneally injected with a DEN dose of 100 mg/kg to induce liver DNA damage 
and mice were sacrificed 6, 24 and 72 hours after DEN administration. Control mice were 
injected with saline. 
 
M.2.11 PHx model of liver regeneration 
PHx was performed according to the method of Higgins and Anderson surgically 
removing ~70% of the liver (211). Adult male WT mice were used for the analysis of 
Trem2 expression and animals were sacrificed 2, 4, 24, 48 and 72 hours after PHx. 
Similarly, PHx was performed in WT and Trem2-/- mice and these were sacrificed 6, 36, 
72 hours and 5 days after the operation. In addition, Mice were injected intraperitoneally 
with 150 mg per kg of body weight of 5’-bromo-2’-deoxyuridine (BrdU; Sigma-Aldrich) 
two hours before culling to analyse proliferating hepatocytes.  
 
M.3 Primary liver cell isolation, culture and treatments 
M.3.1 In situ mouse liver perfusion for primary cell isolation 
Liver perfusion was performed to digest the liver. In short, mice were anesthetized with 
5% isoflurane (abbvie) in inhaling oxygen, then the abdomen was opened and the internal 
organs were exposed. Afterwards, the portal vein was cannulated with a 22G cannula (BD 
Insyte), the infusion tubing of the perfusion pump (Bio-Rad) was connected to the 
catheter and the inferior vena cava (IVC) was cut below the liver, which allows solutions 
to perfuse the liver and exit the IVC. Meanwhile, the liver was flushed with a perfusion 
buffer [10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (hepes), 2.7 mM 




KCl, 135 mM NaCl and 250 μM HNa2PO4 (all from Sigma-Aldrich)] to wash the liver at 
a flow of 5-7 ml/minute. After, 150 μl of liberase (Roche), which is a collagenase mixture, 
at 7 mg/ml and 10 mM CaCl2 was added to the perfusion buffer and the liver was flushed 
at 3 ml/minute to achieve digestion of the liver. During this step, the IVC was clamped 
above the diaphragm in order to direct the solutions through the liver and to prevent the 
perfusion of other organs. To isolate HSCs and KCs, an additional intermediate digestion 
step with a solution containing Pronase was carried out, before the collagenase digestion. 
In this case, 100 μl of pronase (Roche) at 200 mg/ml were added to 50 ml of F-12 media 
(Gibco) and the liver was flushed at 3 ml/minute. Finally, the liver was carefully removed. 
For HSC isolation a minimum of 3 mouse livers are necessary to yield enough cells and 
in this case, livers were kept in ice until all the livers were perfused. 
 
M.3.2 Isolation of mouse hepatocytes  
After liver perfusion, livers were homogenized, filtered through a 70 µM cell strainer 
(Falcon) to eliminate undigested tissue remnants. Liver cell suspension was washed three 
times with William’s medium E (Sigma-Aldrich) supplemented with 10% heat-
inactivated foetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin (Gibco) and 
1% MEM Non-essential amino acids (NEAA) (Gibco), by centrifugation at 800 g for 6 
minutes at 4ºC. Hepatocytes were then resuspended in 25 ml of supplemented William’s 
medium E. Next, a Percoll (Sigma-Aldrich) containing density gradient solution was 
prepared by adding 2.4 ml of phosphate buffered saline (PBS) 10X to 21.6 ml Percoll and 
adding the cells on top of this solution. Then, the gradient was centrifuged for 10 minutes 
at 1500 g at 4ºC without brake. Isolated hepatocytes were cultured in William’s medium 
E supplemented with 10% FBS, 1% penicillin-streptomycin and 1% NEAA. 
 
M.3.2.1 Hepatocyte cell viability assay 
Hepatocytes isolated from WT and Trem2-/- mice were plated for 3 hours at 104 
cells/well in opaque 96-well plates (Thermo fisher scientific). Afterwards, media was 
changed to William´s E Medium with 0.5% FBS, 1% penicillin-streptomycin and 1% 
NEAA. Hepatocytes were treated with 5 mM or 10 mM APAP for 24 hours after which 
the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used to measure 
cell viability according to the manufacturer´s instructions. Briefly, the CellTiter-Glo® 
substrate was resuspended with the CellTiter-Glo® buffer and incubated for 30 minutes 




at room temperature. Meanwhile, cells were also incubated for 30 minutes at room 
temperature. After the incubation, 100 μl of the resuspended mix was added to each well 
and the plate was incubated for two minutes shaking at room temperature. Finally, the 
plate was incubated for another 10 minutes at room temperature and luminometry was 
measured in a PHERAstar luminometer (BMG Labtech). 
 
M.3.3 Isolation of rodent non-parenchymal liver cells: KCs and HSCs  
After the in situ liver digestion, livers were further digested in vitro for 30 minutes at 
37ºC in F-12 media supplemented with 10 μl pronase at 200 mg/ml and 50 μl DNase 
(Roche) at 2 mg/ml. Livers were homogenized, filtered through a 70 µM cell strainer and 
washed twice by centrifugation at 800 g for 6 minutes at room temperature. Subsequently, 
liver cell suspensions were subjected to density gradient centrifugation with Nycodenz 
(Sigma-Aldrich) (11% over 16.5%) at 1500 g at RT for 22 minutes without brake. KCs 
are collected in the 16.5% layer while HSCs are present in the 11% layer. KCs were plated 
at 106 cells/ml in 6 well dishes (Corning) in roswell park memorial institute medium 1640 
(RPMI) (Gibco) supplemented with 10% FBS and 1% penicillin-streptomycin, and HSCs 
in Dulbecco's modified eagle medium (DMEM) (Gibco) supplemented with 10% FBS 
and 1% penicillin-streptomycin. KCs were plated for 20 minutes to allow them to adhere, 
and plates were then washed thoroughly to remove the contaminating endothelial cells. 
Purity of KCs was established by measuring liver cell type specific markers and all the 
experiments were carried out one or two days after the isolation. Purity of HSCs was 
assessed by autoflorescence one day after the isolation and was always higher than 95%. 
Experiments in activated HSC were carried out by culturing these cells on tissue culture 
plastic for 7 days at 37ºC and 5% of CO2. Both KCs and HSCs were stimulated with 
2x107 cells/ml heat-killed Escherichia coli (E. coli) (O18:K1), 100 ng/ml LPS (Sigma-
Aldrich), 10 ng/ml IL1β (Peprotech) or 10 ng/ml TNFα (Peprotech) for various time-
points. Following treatment, cells were processed for RNA extraction or immunoblotting 
and stored at -80ºC, or supernatant was harvested and stored at -20ºC for cytokine 
measurements. 
Activated HSCs from rat livers injured by BDL for 10 days or chronically injured 
with CCl4 for 3 weeks were isolated as described (212). 




Human hepatic myofibroblasts were isolated as described (213), were cultured in 
DMEM supplemented with 2 mM L-glutamine (Gibco), 16% FBS and 1% penicillin-
streptomycin and were maintained at 37°C and at 5% CO2. 
 
M.3.4 Isolation of liver cells for flow cytometry  
Liver mononuclear cells were isolated from chronic CCl4-injured mice. Livers were first 
perfused with Hanks' Balanced Salt solution (HBSS) (Gibco) and then homogenised and 
digested for 1 hour at 37ºC in RPMI supplemented with 0.05% collagenase and dispase 
and 0.01% trypsin inhibitor (Gibco). The digested liver was then filtered through a 40 µM 
cell strainer (Falcon), centrifuged at 800 g for 10 minutes at 4ºC and resuspended with 10 
ml RPMI media. A Percoll gradient was done by overlaying the resulting cell suspension 
in 15 ml of 33% (vol/vol) Percoll solution and centrifuging it for 30 minutes at room 
temperature without brake. Erythrocytes were lysed by adding 2 ml of red blood lysis 
buffer for 4 minutes to the cells. Cells were washed twice with RPMI and finally 
resuspended in PBS 1X with 2% of FCS. Total cell number per liver was counted using 
a hemocytometer and death cells were stained using fixable viability dye eFluor 780 
(eBioscience). Fc receptors were blocked with CD16/CD32, clone 93 antibody 
(eBiosceince) and mononuclear cells were incubated with antibodies (Table M.4). Cells 
were washed, resuspended in PBS 1X and analysed by flow cytometry (BD LSR 
Fortessa). Neutrophils were identified as CD45+CD11b+Ly6C+Ly6G+F4/80- cells, 
whereas macrophages were identified as CD45+CD11b+Ly6C+Ly6G-F4/80+ cells. Cell 
number was normalized with the total cell count and the liver weight. Blood staining was 
performed by the addition of antibodies for 30 minutes to 50 µl of sample. Cell lysis was 
performed by the addition of 140 µl of ADG lysis buffer (Andergrub Bioresearch) for 10 
minutes and 3.5 ml of H2O was added for another 7 minutes. Cells were washed, 
resuspended in PBS 1X and analysed by flow cytometry.  
On the other hand, hepatocytes, KCs and HSCs were isolated as previously 
mentioned (M.3.2 and M.3.3) and were analysed by flow cytometry following standard 
procedures. Cells were stained with APC-conjugated anti-mouse TREM2 antibody or an 








Table M.4. Antibodies used for flow cytometry. 
Antibody Company Reference 
Monoclonal rat anti-CD16/CD32, clone 93 eBioscience 14-0161-81 
V500 monoclonal rat Anti-Mouse CD45, clone 30-F11 BD Horizon 561487 
PE monoclonal rat anti-Ly-6G, clone 1A8 BioLegend 127607 
PE/Cy7 monoclonal rat anti-Ly-6C, clone HK1.4 BioLegend 128017 
PerCP/Cy5.5 monoclonal rat anti-F4/80, clone BM8 Invitrogen 45-4801-80 
Alexa Fluor/700 monoclonal rat anti-CD11b, clone M1/70 Invitrogen 56-0112-82 
Monoclonal rat anti-mouse TREM2 APC-conjugated R&D FAB17291A 
Monoclonal rat IgG2B APC-conjugated R&D IC013A 
IgG2B, Ig gamma 2b chain; PerCP, peridinin chlorophyll protein complex; TREM2, triggering 
receptor expressed on myeloid cells 2. 
 
M.4 Isolation of BMDMs  
BMDMs were isolated by flushing the femurs and tibias of mice with RPMI following a 
protocol previously described (214). BMDMs were differentiated in RPMI supplemented 
with 1% penicillin-streptomycin, 10% foetal calf serum (FCS) (Gibco) and 10% L-929 
conditioned media for 7 days.  
 
M.5 TREM2 overexpression in human hepatic stellate LX-2 cells 
3x105 LX-2 cells were plated in 6 well plates in DMEM/F-12 supplemented with 2% of 
FBS and 1% penicillin-streptomycin. Cells were transfected using 1 μg of human TREM2 
expression plasmid (Sino Biological Inc, HG11084-UT) or untagged negative control 
vector (Sino Biological Inc, CV011) with Fugene HD (Promega). In short, a mix with 1 
μg of control or TREM2 plasmid per well was mixed with 100 μl of DMEM 
supplemented with 10 mM of hepes per well. Next, 6 μl of Fugene HD per well was added 
to the transfection mix and was incubated for 15 minutes at room temperature. Meanwhile 
media was changed and 875 μl of fresh DMEM/F-12 media supplemented with 2% of 
FBS and 1% penicillin-streptomycin was added to the cells. After 15 minutes of 
incubation, 100 μl of transfection mix was added to each well in a drop-wise manner. 
Transfection media was removed 8 hours after and replaced by DMEM/F-12 
supplemented with 2% of FBS and 1% penicillin-streptomycin. 24 hours after, cells were 
treated for 3 hours with 100 ng/ml LPS and RNA was extracted for quantitative real-time 
polymerase chain reaction (qRT-PCR). In the same manner, LX-2 transfected cells and 
media were collected at different time-points post-transfection for qRT-PCR analysis and 
enzyme-linked immunosorbent assay (ELISA) respectively. 





M.6 Culture of HCC spheroids with conditional media from HSCs 
TREM2 was experimentally overexpressed in HSCs as previously mentioned. Twenty-
four hours post-transfection, the cell culture supernatant was collected and incubated with 
the HCC spheroids. To generate the HCC spheroids, a total of 3000 Hep3B or PLC/PRF 
human HCC cells were seeded in a droplet of 20 μl of 10% FBS containing DMEM/F-12 
media hanging in the lid of a petri dish for 7 days. Then, HCC spheroids were transferred 
to droplets of 20 μl of LX-2-conditioned media (i.e., media of LX-2 cells transfected with 
control plasmid or overexpressing TREM2) and were incubated hanging in the lid of a 
petri dish. Pictures of the HCC spheroids were taken at baseline (0 hours) and after 72 h 
using a Nikon eclipse TS100 microscope, and the spheroid size was measured with the 
Image J software. In addition, LX-2 cells or Hep3B spheroids were treated with 0.1 µM 
of the Wnt ligand secretion inhibitor IWP-2 (Sigma-Aldrich) and Hep3B spheroids were 
treated with the 5 µM of the Wnt/β-catenin inhibitor IWR-1 (Sigma-Aldrich). 
 
M.7 Liver histology and staining  
Tissue samples were collected and fixed in 4% paraformaldehyde for 24 hours, tissues 
were processed using the MTM tissue processor (Slee Medical GmbH), embedded in 
paraffin (Thermo fisher scientific) and cut using the HM355S microtome (Thermo fisher 
scientific) in sections at a thickness of 4-5 µm. 
 
M.7.1 Haematoxylin and eosin (H&E) staining  
H&E staining was performed to analyse tissue morphology as previously described (213). 
Human and mouse paraffin-embedded tissue samples were cut and then de-paraffined by 
incubating at room temperature in xylene (VWR) two times for 5 minutes. Slides were 
hydrated with solutions of decreasing alcohol concentration [100%, 96%, 70% and 50% 
ethanol (VWR)] for 2 minutes and finally with PBS 1X. Slides were incubated in Harris 
Haematoxylin (Merck) for 5 minutes. Then samples were washed with tap water and were 
incubated with eosin (Merck) for 5 minutes at room temperature. Next, samples were 
washed again with tap water and dehydrated with increasing grade alcohol solutions 
(50%, 70% and 100% ethanol). Finally, slides were incubated with xylene for 5 minutes 
at room temperature two times and were mounted with Pertex (Sigma-Aldrich). 





M.7.2 Sirius red staining  
Sirius red staining was performed for the determination of collagen deposition in liver 
tissue. Samples were de-parafinned and hydrated as previously described. Next, slides 
were stained for 2 minutes using 0.2% phosphomolybdic acid (Sigma-Aldrich). After 
that, samples were washed with distilled H2O and incubated with 0.1% Sirius Red F3BA 
(Gibco) for 3 hours. Finally, slides were incubated with 0.01 N HCl (Merck) for 2 minutes 
and slides were dehydrated and mounted as previously mentioned. 
 
M.7.3 Liver histology and scoring 
Liver tissue samples were formalin-fixed, embedded in paraffin, cut in 5 μm thick 
sections and stained with H&E or Sirius red as previously described. All sections were 
blindly assessed by an experienced hepatopathologist. 
Inflammation severity (scored 0-3, 0=none, 1=mild, 2=moderate, 3=severe), extent 
of necrosis (score 0-3, 0=none, 1=focal, 2=moderate, 3=extensive), acinar topography, 
type of inflammatory cells involved, and type of necrosis (zone 3, central-central bridging 
necrosis) were recorded. Hepatocyte injury, in the form of ballooned hepatocytes and 
apoptotic (oxyphilic) bodies, was also semi-quantitatively evaluated (score 0-3, 0=none, 
1=few, 2=several, 3=many), and acinar involvement (zone 3 or both zones 3 and 2) was 
recorded. The presence, type and topography of hepatocyte steatosis were also recorded. 
Fibrosis was evaluated based on the characteristic topography of fibrosis in chronic 
CCl4-related liver damage (0=no significant fibrosis, 1=mild zone 3 sinusoidal fibrosis 
(Z3SF), 2=prominent Z3SF, 3=Z3SF plus central-central (C-C) fibrous septa, 
4=advanced bridging fibrosis with C-C and few central-portal fibrous septa, 5=as per 4 
plus occasional fully circumscribed nodules, 6=cirrhosis). 
Damaged area in the acute DEN model was measured calculating the mean damaged 
area per field in 15 10X fields in each slide using NIS-Elements software (Nikon) in an 
Eclipse 80i (Nikon) microscope. 
 
M.7.4 IHC and image analysis 
IHC was performed in formalin-fixed and paraffin embedded mouse and human liver 
tissue sections. Mouse and human liver tissue sections were de-paraffinized in xylene and 
rehydrated in graded ethanol as previously described followed by 3% H2O2 (Sigma-




Aldrich) in methanol (Applichem Panreac) treatment for 15 minutes to block endogenous 
peroxidases. Thereafter, sections were subjected to antigen-retrieval and slides were 
blocked using the Avidin/Biotin Blocking Kit (Vector laboratories) after which slides 
were blocked with appropriate blocking buffers. Primary antibodies (Table M.5) were 
incubated at 4ºC overnight and the next day antibodies were washed with PBS 1X and 
slides were incubated with appropriate biotinylated secondary antibodies (Table M.5). 
Vectastain ABC Reagent (Vector laboratories) followed by 3,3-diaminobenzidine (DAB) 
peroxidase substrate Kit (Vector laboratories) was used for antigen visualization. Slides 
were counterstained with Mayer’s haematoxylin (Sigma-Aldrich), dehydrated and 
mounted as previously described. Immunostained cells were manually counted in 15 high 
power fields (20X) of each slide and the mean number of positive cells was calculated. 
On the other hand, image analysis of 15 fields (20X) per slide was performed using NIS-
Elements software for F4/80. Pictures were taken with NIS-Elements. Representative 
pictures were taken in an Eclipse 80i (Nikon) microscope using the Digital sight DS-U2 
camera controller (Nikon). 
An experienced hepatopathologist evaluated the IHC for human TREM2 by 
recording the type and topography of immunostained cells and evaluated the intensity of 
TREM2 specific cytoplasmic immunostaining as mild, moderate or severe compared to 
the immunostaining intensity of neutrophils in control liver sections.  
For BrdU staining, IHC was performed in a similar way. Briefly, slides were de-
waxed in xylene and hydrated in decreasing methanol concentration (100% and 70% 
methanol). Endogenous peroxidases were blocked; antigen retrieval was performed and 
primary antibody was incubated overnight at 4ºC. The next day slides were washed and 
incubated with a FITC-conjugated secondary antibody for 2 hours wrapped in foil. Next, 
slides were washed and incubated with a tertiary anti-FITC horseradish peroxidase (HRP) 
conjugated antibody. Antigen visualization, haematoxylin counterstaining, dehydration 
and mounting were performed as previously mentioned. 
 
 
Table M.5. Antibodies used for IHC. 
Antibody Company Reference Dilution Antigen retrieval 
Rabbit polyclonal anti-
4-HNE 




Serotec MCA1477 1/100 1 mM pH8.0 EDTA 
(Sigma-Aldrich) 

















551459 1/70 citrate buffer pH6.0 
Rat monoclonal anti-
NIMP.R14 
Abcam ab2557 1/100 citrate buffer pH6.0 














347580 1/10 citrate buffer pH6.0 
Rabbit polyclonal anti-
FITC conjugate 
Inverness  F0313 1/100 - 
Polyclonal Rabbit anti-
FITC HRP conjugate 
Dako  P5100 1/200 - 
Swine anti-rabbit IgG 
biotinylated secondary 
antibody 
Dako E0353 1/200 - 
Goat anti-rat IgG 
biotinylated secondary 
antibody 
Serotec STAR80B 1/200 - 
4-HNE, 4-hydroxynonenal; BrdU, 5’-bromo-2’-deoxyuridine; BSA, bovine serum albumin; 
EDTA, ethylenediaminetetraacetic acid; FITC, fluorescein isothiocyanate; γH2AX, phospho-
histone H2A.X; HRP, horseradish peroxidase; IgG, immunoglobulin G; IHC, 
immunohistochemistry; PCNA, proliferating cell nuclear antigen; TREM, triggering receptor 








M.8 Label free proteomic analysis 
 
M.8.1 In solution digestion 
Protein from DEN-induced WT and Trem2-/- tumour tissue was extracted using 7 M urea, 
2 M thiourea, 4% CHAPS. Samples were incubated for 30 minutes under agitation at 




room temperature and digested following the filter-aided FASP protocol as described 
(215). Trypsin was added to a ratio of 1:10 (trypsin:protein) and the mixture was 
incubated at 37oC overnight, dried out in a RVC2 25 speedvac concentrator (Christ), and 
resuspended in 0.1% FA. 
 
M.8.2 Mass spectrometry (MS) analysis 
500 ng of each sample was submitted to liquid chromatography - mass spectrometry (LC-
MS) label free analysis. Peptide separation was performed on a nanoACQUITY ultra 
performance liquid chromatography (UPLC) System (Waters) connected to an LTQ 
Orbitrap XL mass spectrometer (Thermo Electron). An aliquot of each sample was loaded 
onto a Symmetry 300 C18 UPLC Trap column (180 µm x 20 mm, 5 µm (Waters)). The 
precolumn was connected to a BEH130 C18 column (75 μm x 200 mm, 1.7 μm; Waters), 
and equilibrated in 3% acetonitrile and 0.1% FA. Peptides were eluted directly into an 
LTQ Orbitrap XL mass spectrometer (Thermo Finnigan) through a nanoelectrospray 
capillary source (Proxeon Biosystems), at 300 nl/minutes and using a 120 minutes linear 
gradient of 3-50% acetonitrile. The mass spectrometer automatically switched between 
MS and MS/MS acquisition in data-dependent acquisition mode. Full MS scan survey 
spectra (m/z 400-2000) were acquired in the orbitrap with mass resolution of 30000 at 
m/z 400. After each survey scan, the six most intense ions above 1000 counts were 
sequentially subjected to collision-induced dissociation (CID) in the linear ion trap. 
Precursors with charge states of 2 and 3 were specifically selected for CID. Peptides were 




M.8.3 Progenesis LC-MS software analysis 
Progenesis LC-MS (version 2.0.5556.29015, Nonlinear Dynamics) was used for the label 
free differential protein expression analysis. One of the runs was used as the reference to 
which the precursor masses in all other samples were aligned to. Only features comprising 
charges of 2+ and 3+ were selected. The raw abundances of each feature were 
automatically normalised and logarithmised against the reference run. Samples were 
grouped in accordance to the comparison being performed, and an ANOVA analysis was 
performed. A peak list containing the information of all the features was generated and 




exported to the Mascot search engine (Matrix Science Ltd.). This file was searched 
against a Uniprot/Swissprot database restricted to Mus musculus entries, and the list of 
identified peptides was imported back to Progenesis LC-MS. Protein quantitation was 
performed based on the three most intense non-conflicting peptides (peptides occurring 
in only one protein), except for proteins with only two non-conflicting peptides. The 
significance of expression changes was tested at protein level, and proteins with a p-value 
≤0.05 were selected for further analyses. Protein abundances were loaded onto Perseus 
software (216) and log2 transformed for the generation of the heatmaps. 
 
M.8.4 Functional analysis 
Gene ontology (GO) enrichment analysis of the differentially expressed proteins was 
carried out using the database for annotation, visualization and integrated discovery 
(DAVID) online tool (http://david.abcc.ncifcrf.gov/summary.jsp) (217). DAVID is a GO 
Term annotation and enrichment analysis tool used to highlight the most relevant GO 
terms associated with a given gene list. A Fisher Exact test was used in order to determine 
whether the proportion of genes considered into certain GO term or categories differ 
significantly between the dataset and the background. Biological Process, Molecular 
Function and Cellular Component categories were assessed, and only GO Terms enriched 




M.9 Determination of protein expression by immunoblot 
 
M.9.1 Protein extraction from liver tissue 
Liver tissue (~20 mg) was homogenised in 400 μl of radio-immunoprecipitation assay 
(RIPA) lysis buffer which contains: 50 mM Tris pH 7.5 (Applichem Panreac), 150 mM 
NaCl (Sigma-Aldrich), 1% triton X100 (Sigma-Aldrich), 0.1% Sodium dodecyl sulfate 
(SDS) (Applichem Panreac), 0.5% sodium deoxycholate (Sigma-Aldrich), phosphatase 
inhibitors [1 mM sodium orthovanadate (Sigma-Aldrich), 10 mM NaF (Sigma Aldrich), 
100 mM β-glycerophosphate (Sigma-Aldrich)] and protease inhibitors [Complete 
(Roche)]. Homogenised tissue was placed in a rotator (Stuart) for 30 minutes at 4ºC. Next, 
samples were sonicated (JP Selecta) two times for 15 seconds and centrifuged for 15 




minutes at 18000 g at 4ºC. Supernatant was placed in a new tube for cell debris removal 
and total protein was quantified. 
 
M.9.2 Protein extraction from culture cells 
~2-3x105 cells were plated in 6-well plates and cultured in their corresponding media. 
Cells were washed with PBS 1X and 80 μl of RIPA was added to the plates. After 
scrapping, cells were collected and centrifuged for 15 minutes at 18000 g at 4ºC. 
Supernatant was placed in a new tube for cell debris removal and total protein was 
quantified. 
 
M.9.3 Determination of protein concentration 
Pierce Bicinchoninic acid (Thermo fisher Scientific) was used to measure total protein 
concentration in both tissue and cells. An aliquot of each sample was diluted 1/5 for cells 
or 1/40 for tissue, with distilled H2O and placed in a 96-well plate (Corning). A standard 
curve was also prepared using bovine serum albumin (BSA). A and B reagents were 
mixed in a proportion 1:50 and 200 µl of the mixture was added to each sample. The plate 
was incubated 30 minutes at 37ºC in darkness and protein concentration was measured at 
570 nm in a Multiskan Ascent® spectrophotometer (Thermo fisher Scientific) 
 
M.9.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting 
To perform the SDS-PAGE, 30-60 μg of total protein was fractioned by 12.5% SDS-
PAGE and then transferred onto nitrocellulose membranes (Bio-Rad). Blots were blocked 
in Tris-buffered saline with 0.1% Tween-20 (T-TBS) containing 5% BSA or 5% skim 
milk powder (all from Sigma-Aldrich) for 1 hour. Primary antibodies (Table M.6) were 
incubated overnight at 4ºC diluted in 5% BSA or 5% milk at 1:1000 dilution. The next 
day membranes were washed 3 times with T-TBS and incubated for 1 hour with 
appropriate HRP-conjugated secondary antibodies at 1:5000 dilution (Table M.6). Blots 
were washed and antigen was detected by ECL HRP Chemiluminiscent Substrate 
Reagent Kit (Invitrogen). β-actin was used as a protein loading control. 
 
 
Table M.6. Antibodies used for immunoblot. 
Antibody Company Reference Dilution 




Polyclonal rabbit anti-phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
Cell signalling 9101 1/1000 
Polyclonal rabbit anti-p44/42 MAPK (Erk1/2) Cell signalling 9102 1/1000 
Polyclonal rabbit anti-phospho-p38 MAPK 
(Thr180/Tyr182) 
Cell signalling 9211 1/1000 
Polyclonal rabbit anti-p38 MAPK Cell signalling 9212 1/1000 
Polyclonal rabbit anti-phospho-SAPK/JNK 
(Thr183/Tyr185) 
Cell signalling 9251 1/1000 
Polyclonal rabbit anti-SAPK/JNK Cell signalling 9252 1/1000 
Monoclonal rabbit anti-phospho-NFκB p65 
(Ser536) 
Cell signalling 3033 1/1000 
Monoclonal mouse anti-NF-κB p65 Santa cruz sc-8008 1/1000 
Polyclonal rabbit anti-IκB-α (C-21) Santa cruz sc-371 1/1000 
Polyclonal rabbit anti-PCNA Abcam ab2426 1/1000 
Polyclonal rabbit anti-GAPDH Abcam Ab22555 1/1000 
Monoclonal mouse anti-TREM2 (B-3) Santa Cruz Sc373828 1/100 
Monoclonal mouse anti-β-Actin Sigma-Aldrich A5316 1/1000 
Anti-rabbit IgG HRP-linked Antibody Cell signalling 7074 1/5000 
Anti-mouse IgG HRP-linked Antibody Sigma-Aldrich A4416 1/5000 
Erk1/2, extracellular signal-regulated kinases 1/2; HRP, horseradish peroxidase; JNK , c-
Jun N-terminal kinase; MAPK, mitogen-activated protein kinases; NF-κB, nuclear factor 
kappa B; PCNA, proliferating cell nuclear antigen; SAPK, stress-activated protein kinases; 
 
 
M.10 ROS Measurement  
M.10.1 ROS measurement in liver tissue 
ROS levels were analysed in mouse liver tissue homogenising 20 mg of liver tissue in 
500 μl PBS 1X. The lysate was sonicated and centrifuged for 10 minutes at 3200 g at 4ºC. 
The supernatant was transferred to a new tube and 50 μl of supernatant was incubated 
with 50 μl of 2′,7′-dichlorodihydrofluorescein diacetate (DCF) (Thermo fisher scientific) 
in opaque 96-well plates at a final concentration of 10 μM for 30 minutes at room 
temperature in darkness. Fluorescence was measured at excitation and emission 
wavelengths of 492 nm and 535nm respectively, in a Fluoroskan Ascent® 
spectophotometer. 
 
M.10.2 ROS measurement in cells 
Intracellular ROS was measured using the dye dihydrorhodamine 123 (DHR123) 
(Invitrogen). 106 cells/ml of WT and Trem2-/- BMDMs or KCs were plated in 24 well 
plates (Corning), treated for 3 hours with 100 ng/ml LPS and incubated 10 minutes with 




the dye. Cells were washed with PBS 1X and ROS levels were analysed by flow 
cytometry. 
 
M.11 Oxygen consumption assay 
Oxygen consumption was analysed in KCs and BMDM plated in XF 24-well plates 
(Seahorse Bioscience). Cells were treated with 100 ng/ml LPS for 3 hours, media was 
replaced with 600 μl of buffer free Assay Medium (Seahorse Bioscience) and cells were 
incubated in a CO2 free incubator at 37°C for 1 hour. Cells were transferred to XF24 Flux 
Analyzer (Seahorse Bioscience) and oxygen consumption was measured following the 
protocol. Briefly, 1 μM oligomycin was added to inhibit adenosine triphosphate (ATP) 
synthase, 3 μM trifluoromethoxyphenylhydrazone (FCCP) was used for mitochondrial 
uncoupling and 1 μM rotenone/antimycin was added to shut down the electron transport. 
 
M.12 ELISA  
M.12.1 Cytokine and chemokine detection by ELISA 
The supernatant of isolated WT and Trem2-/- KCs and HSCs treated with E. coli or LPS 
was analysed by ELISA. C-X-C motif chemokine ligand 1 (CXCL1), MCP1 and IL6 were 
analysed with specific ELISAs following the manufacturer’s instructions (R&D 
Systems).  
Supernatant of LX-2 transfected cells was collected and ELISA of MCP1 and TNF 
was performed according to the manufacturer’s instructions (Peprotech). 
 
M.12.2 Quantification of 4-hydroxynonenal (4-HNE) levels in liver tissue by ELISA 
OxiSelectTM HNE Adduct Competitive ELISA (Cell Biolabs) was used to measure 4-
HNE protein adducts in liver tissues of WT and Trem2-/- mice following manufacturer´s 
instructions. Briefly, wells were coated with HNE conjugate by adding 100 μl of 1X 
conjugate diluent and 1 μg/ml HNE conjugate mixed at 1:1 ratio and incubated overnight 
at 4ºC. The next day, liquid was removed from the wells, 200 μl of assay diluent was 
added and incubated for 1 hour at room temperature, after which they were kept at 4ºC 
prior its use. Next, a standard curve of HNE-BSA was prepared ranging from 0 to 200 
μg/ml. Then, the assay diluent was removed and 50 μl of sample or HNE-BSA standard 
curve was added to the wells and they were incubated for 10 minutes in an orbital shaker. 




After that, 50 μl of anti-HNE antibody was added to each well and they were incubated 
for 1 hour at room temperature in an orbital shaker. Wells were washed 3 times and 100 
μl of secondary antibody HRP conjugated was added for 1 hour at room temperature in 
an orbital shaker. After 3 washes, wells were incubated with 100 μl of substrate solution 
for ~5-10 minutes at room temperature in an orbital shaker. Finally, once the colour of 
the wells changed, 100 μl of stop solution was added and absorbance was measured at 
450 nm in a Multiskan Ascent® spectrophotometer. 
 
M.13 RNA isolation and qRT-PCR analysis 
M.13.1 Total RNA isolation 
RNA was isolated by homogenising small tissue samples (~20 mg) or cells in culture in 
1 ml Tri-Reagent® (Sigma-Aldrich). 200 µl of chloroform (Merck) was added to the tubes 
and after vortexing, tubes were incubated at room temperature for 15 minutes and then 
centrifuged for another 15 minutes at 18000 g at 4ºC. The upper phase was transferred to 
a new tube and 500 µl of 2-propanol (AppliChem Panreac) was added. Tubes were mixed 
by inverting them several times, incubated 10 minutes at room temperature and 
centrifuged for 15 minutes at 18000 g at 4ºC. Supernatant was discarded and 1 ml of 75% 
ethanol was added. After a brief vortex tubes were again centrifuged for 15 minutes at 
18000 g at 4ºC, the supernatant was discarded and the pellet was left to dry. Finally, 
pellets were resuspended in UltrapureTM DNase/RNase-free distilled water (Gibco). RNA 
was quantified with NanoDrop® ND-1000 apparatus (Thermo fisher Scientific). 
 
M.13.2 Reverse transcription (RT) of RNA from human tissue samples 
The SuperScript® VILO™ cDNA Synthesis Kit (Life technologies) was used for human 
tissue RNA RT following manufacturer´s instructions. 2 μl of 10X SuperScript® Enzyme 
Mix, 4 μl of 5X VILOTM Reaction Mix and DNase/RNase-free distilled water to a total 
volume of 20 µl was added to 500 ng of total RNA of each sample. 
RT was performed in a Verity 96 well thermal cycler (Applied biosystems) using a 
three step protocol: i) 10 minutes at 25ºC, ii) 1 hour at 42ºC, and iii) 5 minutes at 85ºC. 
DNase/RNase-free distilled water was added to the newly synthetized complementary 
deoxyribonucleic acid (cDNA) for a 12.5 ng/µl final concentration. 
 




M.13.3 RT of RNA from cell culture 
1 µg of extracted RNA was subjected to DNase treatment to remove genomic DNA by 
adding 1 µl of DNase I Amplification Grade (Invitrogen) and 1 µl of 10X DNase I 
Reaction Buffer (Invitrogen) and incubating for 20 minute at 37°C to enable the reaction. 
Next, 1 µl of 25 mM ethylenediaminetetraacetic acid (EDTA) (Invitrogen) was added and 
samples were incubated 10 minutes at 65°C, 1 minute at 90°C and kept at 4°C to chelate 
magnesium and stop DNase I reaction. Afterwards, to synthetize the cDNA, 30 µl of RT 
Mix (8 µl Buffer 5X, 4 µl Random primers 100 ng/µl, 4 µl Deoxy-nucleotide-triphosphate 
mix (dNTPs), 2 µl DTT, 1.2 µl RNase OUT, 1.2 µl M-MLVRT (all from Invitrogen) and 
9.6 µl DNase/RNase-free distilled water) were added to the samples and reaction was 
performed by incubating the tubes 37°C for 60 minutes, 95°C for 1 minute and cooled at 
4°C. Finally, obtained cDNA was diluted to a concentration of 12.5 ng/µl with 
DNase/RNase-free distilled water.  
 
M.13.4 Gene expression analysis by qRT-PCR 
For gene expression analysis, a mix was prepared with 10 μl of iQ™ SYBR® Green 
Supermix (Bio-Rad) 0.6 μl of 10 μM forward and reverse primers (Table M.7) and 
DNase/RNase-free distilled water to a final volume of 17 µl per sample and were added 
to Hard-Shell PCR plates 96-well (Bio-Rad). Afterwards 3 µl of each cDNA sample at 
12.5 ng/µl were added and CFX96 apparatus (Bio-Rad) was used to detect DNA 
amplification using a iQ™ SYBR® Green Supermix standard protocol: i) cDNA 
denaturation and enzyme activation were performed by heating for 10 minutes at 95°C, 
ii) for DNA amplification 40 cycles of 3 steps consisting in 95°C for 15 seconds, 60°C 
for 30 seconds (primer binding) and 72°C for 45 seconds (extension) were carried out, 
iii) an incubation of 15 seconds at 95°C and iv) a dissociation curve was obtained by 
gradually increasing the temperature from 60°C to 93ºC. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) expression was used as a housekeeping control. Gene 
expression was determined using the ΔCT calculation and mRNA levels are expressed as 






















Table M.7. Primer sequences used for qRT-PCR. 
Gene (human) Forward primer (5’  3’) Reverse primer (3’  5’) 
ACTA2 CGGGACTAAGACGGGAATCCT GTCACCCACGTAGCTGTCTT 
COL1A1 GATGGCTGCACGAGTCACAC AACGTCGAAGCCGAATTCCT 
GAPDH CCAAGGTCATCCATGACAAC TGTCATACCAGGAAATGAGC 
IL1B AGCTACGAATCTCCGACCAC CGTTATCCCATGTGTCGAAGAA 
IL6 AAAGAGGCACTGGCAGAAAA AGCTCTGGCTTGTTCCTCAC 
IL8 GTGCAGTTTTGCCAAGGAGT ACTTGTCCACAACCCTCTGC 
MCP1 CAGCCAGATGCAATCAATGCC TGGAATCCTGAACCCACTTCT 
TNF CCTGCTGCACTTTGGAGTGA CAGCTTGAGGGTTTGCTACA 
TREM2 1 ACGAGATCTTGCACAAGGCA GGTAGAGACCCGCATCATGG 
TREM2 2 CAAGATTCTAGCAGCCAGCG CTCAGCCCTGGCAGAGTTTG 
WNT3 ACAGCCTGGCCATCTTTGG TATGATGCGAGTCACAGCCG 
WNT7A GCCCGGACTCTCATGAACTT AAACTGTGGCAGTGTGGTCC 
WNT8A GCATTCAGTGCCTCTGCCT ACTGGAACTTGCACTCCTCG 
Gene (mouse) Forward primer (5’  3’) Reverse primer (3’  5’) 
Acta2 TCAGCGCCTCCAGTTCCT AAAAAAAACCACGAGTAACAAATCAA 
Bax TGAAGACAGGGGCCTTTTTG AATTCGCCGGAGACACTCG 
Bcl2 GTCGCTACCGTCGTGACTTC CAGACATGCACCTACCCAGC 
Bcl2l1 GACAAGGAGATGCAGGTATTGG TCCCGTAGAGATCCACAAAAGT 
Col1a1 TTCACCTACAGCACGCTTGTG GATGACTGTCTTGCCCCAAGTT 
Cxcl1 CTGGGATTCACCTCAAGAACATC CAGGGTCAAGGCAAGCCTC 
Cybb TGTGGTTGGGGCTGAATGTC CTGAGAAAGGAGAGCAGATTTCG 
Gapdh GCACAGTCAAGGCCGAGAAT GCCTTCTCCATGGTGGTGAA 
Hgf ATGTGGGGGACCAAACTTCTG GGATGGCGACATGAAGCAG 
Hmox1 AAGCCGAGAATGCTGAGTTCA GCCGTGTAGATATGGTACAAGGA 
Hspa1b GAGATCGACTCTCTGTTCGAGG GCCCGTTGAAGAAGTCCTG 
Il1b GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
Il6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 




Mcp1 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
Mmp13 CTTCTTCTTGTTGAGCTGGACTC CTGTGGAGGTCACTGTAGACT 
Nos2 GTTCTCAGCCCAACAATACAAGA GTGGACGGGTCGATGTCAC 
Tgfb1 CTCCCGTGGCTTCTAGTGC GCCTTAGTTTGGACAGGATCTG 
Tnf CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
Trem2 TTGCTGGAACCGTCACCATC CACTTGGGCACCCTCGAAAC 
Gene (rat) Forward primer (5’  3’) Reverse primer (3’  5’) 
Gapdh TGTGAACGGATTTGGCCGTA ATGAAGGGGTCGTTGATGGC 
Trem2 AAGATGCTGGAGACCTCTGG GGATGCTGGCTGTAAGAAGC 
Acta2, actin alpha 2, smooth muscle; Bax, B-cell lymphoma 2 associated X, Bcl2, B-cell 
lymphoma 2; Bcl2l1, B-cell lymphoma 2-like 1; COL1A1, collagen type 1 alpha 1; Cybb, 
cytochrome b-245 beta; Cxcl1, C-X-C motif ligand 1; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; HGF, hepatocyte growth factor; Hmox1, heme oxygenase 1; Hspa1b, heat-shock 
family member 1b; IL, interleukin; MCP1, monocyte chemoattractant protein 1; MMP13, matrix 
metalloprotease 13, Nos2, nitric oxide synthase 2; tgfb1, transforming growth factor beta-1; TNF, 
tumor necrosis factor; TREM2, triggering receptor expressed on myeloid cells 2; WNT3, Wnt 
family member 3; WNT7A, Wnt family member 7A; WNT8A, Wnt family member 8A. 
M.14 Statistical analysis 
GraphPad Prism 6.00 (GraphPad Software) was used to perform the statistical analysis. 
Data following a normal distribution were compared using a Student’s T test and data not 
following a normal distribution were compared using Mann Whitney Test. When more 
than two groups were compared one-way analysis of variance with Tukey’s post hoc test 
or Kruskal-Wallis test followed by Dunn’s multiple comparison test for individual 
subgroup comparison were used. For correlation analysis non-parametric Spearman’s 
correlation test was used. Data are expressed as mean ± standard error of the mean (SEM). 
Statistically significant data is represented in figures where *, **, ***, **** denote a P value 

















































R.1 Role of TREM2 in liver injury 
R.1.1 TREM2 expression is upregulated during chronic liver injury in humans  
First, the mRNA levels of TREM2 in human liver tissue were analysed in a cohort of 21 
control liver samples and 23 cirrhotic samples of different aetiologies, including HBV 
and/or HCV virus infection, HBV/HCV/HIV virus co-infection and alcoholics (Table 
M.1). Interestingly, we could observe upregulated TREM2 transcript levels in diseased 
versus healthy liver (Figure R.1A). Moreover, TREM2 mRNA levels correlated with 
liver injury markers ALT and AST, the inflammation markers IL6 and IL8 and collagen 





Figure R.1. TREM2 mRNA expression in human liver disease. (A) TREM2 mRNA expression 
analysis in 21 control livers and 23 cirrhotic tissue samples. (B-D) Correlation between TREM2 
expression and markers of liver injury and expression of inflammatory (IL6 and IL8) and fibrotic 
markers (COL1A1). (A) Non-parametric Mann Whitney test was used. (B-D) Non-parametric 
Spearman’s correlation test was used. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; AU, arbitrary units; COL1A1, collagen type 1 alpha 1; IL, interleukin; IU, 
international units; TREM2, triggering receptor expressed on myeloid cells 2. 
 




Next, TREM2 expression was analysed by IHC in an independent cohort consisting of 
control liver and cirrhotic liver tissue samples of different aetiology (Table M.2 and 
Figure R.2). The analysis of TREM2 immunostaining confirmed that TREM2 expression 
was more prominent in cirrhotic compared to control livers. In the control liver, mild 
cytoplasmic staining in monocytes and KCs was observed whereas no expression was 
detected in endothelial cells or lymphocytes. However, in cirrhotic samples TREM2 
staining was observed in neutrophils, monocytes and macrophages in the fibrous septa, 
within sinusoids and in parenchymal inflammatory foci. Sirius red staining was also 
performed and collagen deposition was confirmed in fibrous septa (Figure R.2).  
 
 
Figure R.2. TREM2 protein expression in human liver disease. TREM2 IHC staining and sirius 
red staining in a control liver tissue sample and 5 cirrhotic tissue samples of different aetiologies. HBV, 
hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; TREM2, triggering 
receptor expressed on myeloid cells 2. 




Altogether, these data demonstrate that TREM2 expression increases during liver injury 
in humans and suggest that it could serve to dampen hepatic inflammation and injury. 
 
R.1.2 Trem2 expression is upregulated during acute and chronic liver injury in mice  
As in humans, Trem2 expression was also upregulated during liver injury in mice (Figure 
R.3). Trem2 was induced during both CCl4 mediated acute and chronic liver injury 
compared to olive oil treated controls (Figure R.3A-B). Of note, after cessation of liver 
injury in the chronic CCl4 model, levels of Trem2 gradually descended but after 10 days 
of recovery remained slightly higher than olive oil injected mice (Figure R.3B). 
Similarly, Trem2 was upregulated during chronic cholestatic liver injury after BDL 
compared to sham operated mice (Figure R.3C).  
We conclude that during liver injury and recovery in mice Trem2 expression is 








Figure R.3. Expression of Trem2 during liver injury in mice. (A) Trem2 mRNA expression was 
analysed in mice liver tissue after 24, 48 and 72 hours of CCl4 administration (n=3). (B) CCl4 was 
administered for 12 weeks and Trem2 mRNA expression was measured 1, 3, 7 and 10 days after 
the last CCl4 injection (n=3-5). (A-B) Olive oil was administered as control. (C) BDL surgery was 
performed and Trem2 expression was measured after 14 and 21 days (n=4-5). Mice were sham 
operated as controls. One-way analysis of variance, followed by Tukey’s posthoc test was used, 
data represent mean ± SEM and ** and *** denote a P value of ˂0.01 and ˂0.001, respectively 
versus O.Oil or sham mice. AU, arbitrary units; BDL, bile duct ligation; CCl4, carbon tetrachloride; 
O.Oil, olive oil; Trem2, triggering receptor expressed on myeloid cells 2. 




R.1.3 TREM2 is expressed on non-parenchymal liver cells and its expression is induced 
during HSC activation  
The expression of TREM2 was analysed by flow cytometry in different mouse liver cell 
populations, demonstrating its expression in KCs and quiescent HSCs while no 
expression in hepatocytes was observed (Figure R.4A). These results were also 
confirmed by qRT-PCR (Figure R.4B), demonstrating that TREM2 is expressed in non-
parenchymal liver cells. Next, TREM2 expression during HSC activation was analysed 
by culturing freshly isolated quiescent HSCs in plastic for 7 days. TREM2 was found 
strongly induced not only in mouse but also in rat and human activated HSCs compared 
to quiescent HSCs, showing a conserved upregulation during HSC trans-differentiation 
in vitro (Figure R.4C). We next compared the activation status of mouse HSCs in both 
genotypes, for that WT and Trem2-/- HSCs were isolated and the markers of HSC 
activation αSMA and α1(I)procollagen which are encoded by Acta1 and Col1a1 
respectively were examined. However, no differences were observed in Acta1 and Col1a1 
(Figure R.4D), suggesting that TREM2 does not affect the activation status of HSCs. We 
then focussed on HSC activation in vivo and for that, we isolated activated HSCs from 
chronic CCl4 injured or BDL operated rats. Similarly, Trem2 expression was significantly 
induced in HSCs isolated from chronic injured rat livers (Figure R.4E).  
In conclusion, we demonstrated that TREM2 is expressed on non-parenchymal liver 






















Figure R.4. TREM2 expression in liver cells and in activated HSCs during liver injury. (A) 
TREM2 expression in primary mouse liver cells (hepatocytes, KCs and qHSCs) detected by flow 
cytometry. Red line depicts the isotype and blue line depicts TREM2 antibodies. (B) Trem2 
mRNA expression in mouse hepatocytes, KCs and qHSCs (n=4-10). (C) Trem2 mRNA 
expression in quiescent and activated mouse, rat and human HSCs (n=3). (D) mRNA levels of 
Acta2 and Col1a1 in WT and Trem2-/- mice isolated HSCs (n=3). (E) Trem2 expression of 
activated HSCs isolated from rats treated with CCl4 or BDL. Controls were treated with olive oil 
or sham operated (n=4-5). Parametric unpaired Student’s t-test was used, data represent mean ± 
SEM and *, ** and *** denote a P value of ˂ 0.05, ˂ 0.01 and ˂ 0.001, respectively versus quiescent 
HSCs or O.Oil or sham mice. Acta2, Actin alpha 2, smooth muscle; AU, arbitrary units; BDL, 
bile duct ligation; CCl4, carbon tetrachloride; Col1a1, collagen type 1 alpha 1; HSCs, hepatic 
stellate cells; KCs, Kupffer cells; O.Oil, olive oil; qHSC, quiescent HSC; Trem2, triggering 
receptor expressed on myeloid cells 2; WT, wild type. 




The fact that TREM2 expression was induced in a conserved manner during the activation 
of HSCs, suggested that TREM2 expression could play a role during chronic liver injury, 
a process where HSCs are key fibrogenic effectors as well as mediators of the cross-talk 
with other cell types, including liver resident and infiltrating cells, during hepatocellular 
injury. 
 
R.1.4 TREM2 halts chronic liver injury and inflammation 
We thus decided to study the role of TREM2 during chronic liver injury. For that purpose, 
we used WT mice and Trem2-/- mice and performed a model of chronic liver injury based 
on the administration of CCl4 during 8 weeks. Mice were sacrificed 1 day (peak injury) 
or 5 days (recovery) after CCl4 administration and serum transaminases were checked 
and histology as well as qRT-PCR analysis in the liver of these mice were performed.  
We first analysed serum transaminase levels in these mice and found that they were 
significantly augmented during peak injury in Trem2-/- mice compared to WT mice 
(Figure R.5A) suggesting an increase in hepatocyte damage and death in Trem2-/- mice. 
In line with this, histologic analysis revealed increased apoptosis and necrosis in Trem2-
/- livers and a non-significant tendency towards an increase in liver fibrosis in Trem2-/- 
mice (Figure R.5B-C). 
We then analysed the mRNA expression of key inflammatory and fibrogenic 
mediators. The mRNA levels of monocyte chemoattractant protein 1 (Mcp1) and matrix 
metalloproteinase 13 (Mmp13) were induced 1 day after the last administration of CCl4 
in WT and Trem2-/- mice and recovered to almost basal levels after 5 days (Figure R.6A). 
Interestingly, Trem2-/- mice showed significantly elevated levels of Mcp1 and Mmp13 at 
peak injury compared to WT mice while no differences were recorded at recovery phase 
(Figure R.6A). In addition, mRNA expression of genes related to cellular stress and 
apoptosis were analysed and the stress marker heat-shock family member 1B (Hspa1b) 
and the anti-apoptotic marker B-cell lymphoma 2-like 1 (Bcl2l1) were found upregulated 
at peak injury in Trem2-/- mice compared to WT mice (Figure R.6B).  
We conclude that TREM2 is able to protect the liver from excessive injury in the 
context of iterative hepatotoxic damage. 
 





Figure R.5. TREM2 has a marked effect in chronic CCl4-induced liver injury. WT and 
Trem2-/- mice were injected chronically for 8 weeks with CCl4 and mice were sacrificed 1 and 5 
days after the last injection (n=4-8). Controls were treated with olive oil (n=3). (A) ALT and AST 
levels were determined. (B) Histology was analysed for necrosis, apoptosis and fibrosis and (C) 
representative H&E (10X) from day 1 are shown. Non-parametric Mann Whitney test was used, 
data represent mean ± SEM and * and ** denote a P value of ˂ 0.05 and ˂ 0.01, respectively versus 
WT mice. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl4, carbon 
tetrachloride; H&E, haematoxylin and eosin; IU, international units; O.Oil, olive oil; Trem2, 
triggering receptor expressed on myeloid cells 2; WT, wild type.  














Figure R.6. mRNA expression analysis of key inflammatory, fibrogenic and injury mediators in 
the liver of WT and Trem2-/- mice after chronic CCl4 administration. WT and Trem2-/- mice were 
injected chronically for 8 weeks with CCl4 and mice were sacrificed 1 and 5 days after the last injection 
(n=4-8). Controls were treated with olive oil (n=3). (A) mRNA expression analysis of liver Mcp1 and 
Mmp13 and (B) stress and apoptosis-related genes was performed. Non-parametric Mann Whitney test 
was used, data represent mean ± SEM and * denotes a P value of ˂0.05. AU, arbitrary units; Bax, B-cell 
lymphoma 2 associated-X protein; Bcl2, B-cell lymphoma 2; Bcl2l1, B-cell lymphoma 2-like 1; CCl4, 
carbon tetrachloride; Cybb, cytochrome b245 heavy chain; Hmox1, heme oxygenase 1; Hspa1b, heat-
shock family member 1B; Mcp1, monocyte chemoattractant protein 1; Mmp13, matrix metalloproteinase 
13; Nos2, nitric oxide synthase 2; O.Oil, olive oil; Trem2, triggering receptor expressed on myeloid cells 
2; WT, wild type.  
 




Intriguingly, when we checked the mRNA expression of other markers of inflammation, 
such as Il6 and Il1b, Tnf and transforming growth factor beta-1 (Tgfb1) no differences 
were observed between genotypes (Figure R.7A-B). In addition, although there was a 
tendency, towards having more Acta2 and Col1a1 mRNA levels in the livers Trem2-/- 
mice, Sirius red staining confirmed minor effects of TREM2 in liver fibrosis at peak 
injury (Figure R.7C-D). 
 
Figure R.7. No differences in inflammation and fibrosis in the liver of WT and Trem2-/- mice 
after chronic CCl4 administration. Mice were treated as in Figure R.4 and mRNA levels of (A) 
Il1b, Il6 and Tnf cytokines and (B) Tgfb1 and (C) Acta2 and Col1a1 were determined. (D) 
Representative sirius red stained image and quantifications are shown (4X) (n=3-8). Non-
parametric Mann Whitney test was used, data represent mean ± SEM. AU, arbitrary units; CCl4, 
carbon tetrachloride; Il, interleukin; O.Oil, olive oil; Tgfb1, transforming growth factor beta-1; 
Tnf, tumour necrosis factor; Trem2, triggering receptor expressed on myeloid cells 2; WT, wild 
type. 




R.1.5 Combined effect of resident liver cells and infiltrating immune cells is required for 
TREM2 to dampen chronic liver injury 
In order to elucidate which cells are contributing to TREM2-mediated dampening of 
chronic liver injury, we developed a BM transplantation model. For that WT and Trem2-
/- mice were lethally irradiated and reconstituted with WT and Trem2-/- BM cells that 
ubiquitously express green fluorescent protein (GFP), generating 4 different groups of 
mice: WT/WT, Trem2-/-/Trem2-/-, WT/Trem2-/- and Trem2-/-/WT (recipient and donor, 
respectively). Interestingly, corroborating previous results, the transaminase levels were 
found increased in Trem2-/-/Trem2-/-, compared to the other genotypes. Of note, a 
significant damage was only observed when both infiltrating and resident cells were null 
for Trem2 (Figure R.8A-B).  
 
Figure R.8. TREM2 expression within liver resident and infiltrating immune cells is 
necessary for the reduction of CCl4 mediated chronic liver injury. WT and Trem2
-/- mice were 
lethally irradiated and reconstituted with WT-GFP+ BM (WT-WT) or Trem2-/--GFP+ BM (Trem2-
/--Trem2-/-), respectively. In addition, chimeric mice (WT-Trem2-/- and Trem2-/--WT) were also 
developed. These mice were treated for 8 weeks with CCl4 and sacrificed 1 day after the last CCl4 
injection (n=3-5). Controls were treated with olive oil (n=3). (A) Serum ALT and AST levels 
were determined and (B) representative images of H&E staining are shown. One-way analysis of 
variance, followed by Tukey’s posthoc test was used, data represent mean ± SEM and **, *** 
and **** denote a P value of ˂0.01, ˂0.001 and <0.0001 respectively. ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; CCl4, carbon tetrachloride; GFP, green 
fluorescent protein; H&E, haematoxylin and eosin; IU, international units; O.Oil, olive oil; 
Trem2, triggering receptor expressed on myeloid cells 2; WT, wild type. 




Thus, we conclude that TREM2 protects from immune-mediated hepatocellular damage 
via its combined functions in liver resident and infiltrating immune cells.  
Next, immune cell populations of the BM transplant model were analysed by flow 
cytometry (Figure R.9).  
 
Figure R.9. Gating strategy used to determine liver neutrophil and macrophage numbers 
following BM transplantation and CCl4 treatment. BM transplantation and CCl4 treatment was 
performed as in Figure R.8 and livers were isolated and analysed by flow cytometry. (A) Viable 
cells were gated for CD45 positivity, the non-lymphocyte (CD19-CD3-) fraction was selected and 
gated for Ly6C+ and Cd11b+. Infiltrating neutrophils were identified as 
CD45+CD11b+Ly6C+Ly6G+F4/80-GFP+ cells whereas monocyte derived macrophages were 
identified as CD45+CD11b+Ly6C+Ly6G-F4/80+GFP+ cells. CCl4, carbon tetrachloride; GFP, 
green fluorescent protein; LCs, Leukocytes.  
 
Importantly, successful reconstitution was obtained in all groups as shown by a nearly 
100% of GFP positive blood leukocytes (Figure R.10A). When we monitored hepatic 
immune cell infiltration, recruited neutrophil numbers were not altered between the 
different groups of mice (Figure R.10B). However, there was an increase in the recruited 
monocyte derived macrophages in Trem2-/-/Trem2-/- compared to the rest of the groups, 
correlating with the mRNA levels of the chemokine Mcp1 (Figure R.10C-D).  




These data demonstrates that TREM2 expression in both resident and infiltrating 




Figure R.10. Liver neutrophil and macrophage numbers following BM transplantation and 
CCl4 treatment. BM transplantation and CCl4 treatment was performed as in Figure R.8 and 
livers were isolated and analysed by flow cytometry. (A) Blood was isolated and flow cytometry 
conducted for CD45 and GFP. Depicted is the % CD45+ cells that are GFP + within each group 
and represent mean ± SEM. n = 3 per genotype (olive oil) and 3-5 per genotype (CCl4). (B-C) 
Livers were isolated and (B) hepatic neutrophil numbers were determined by gating on 
CD45+CD11b+Ly6C+Ly6G+F4/80-GFP+ cells and (C) monocyte derived macrophages were 
identified as CD45+CD11b+Ly6C+Ly6G-F4/80+GFP+ cells. Total number of (B) neutrophils and 
(C) macrophages normalised to liver weight are indicated. (D) Mcp1 mRNA levels were analysed 
in the liver tissue of these animals. One-way analysis of variance, followed by Tukey’s posthoc, 
data represent mean ± SEM and * and ** denote a P value of ˂0.05 and ˂0.01 respectively. AU, 
arbitrary units; CCl4, carbon tetrachloride; GFP, green fluorescent protein; Mcp1, monocyte 
chemoattractant protein 1; O.Oil, olive oil; Trem2, triggering receptor expressed on myeloid cells 
2; WT, wild type.  




R.1.6 TLR4-mediated inflammation is decreased by TREM2 in non-parenchymal liver 
cells 
As gut bacteria dysbiosis plays an important role in CCl4-induced liver injury and 
inflammation (218, 219), we decided to uncover the role of TREM2 in non-parenchymal 
liver cells following TLR activation by LPS or E. coli stimulation. For that, we first 
analysed the inflammatory properties of WT and Trem2-/- KCs upon LPS or E. coli 
stimulation.  
As shown in Figure R.11, LPS stimulated Trem2-/- KCs exhibited increased 
induction of the mRNA levels Cxcl1, Il6, Tnf and Il1b compared to WT KCs, as early as 
1h post LPS treatment (Figure R.11A).  
This was further confirmed when KCs were treated with the intestinal bacterium E. 
coli that also resulted in increased mRNA levels of pro-inflammatory cytokines in Trem2-
/- KCs compared to WT (Figure R.12A). Moreover, these results were also confirmed at 
protein level by ELISA, and Trem2-/- KCs showed increased mRNA levels of Cxcl1 and 
Il6 compared to WT KCs after LPS or E. coli stimulation (Figure R.11B and Figure 
12B). However, we could not observe any difference in LPS-induced Mcp1 transcript 



























Figure R.11. Cytokine responses in WT and Trem2-/- KCs after TLR4 stimulation. (A) WT 
and Trem2-/- KCs were treated with LPS (100 ng/ml) for 1, 3 or 6 hours and levels of Cxcl1, Il6, 
Tnf and Il1b were determined by qRT-PCR (n=4-5). (B) WT and Trem2-/- KCs were treated with 
LPS (100 ng/ml) for 3 hours and protein levels of CXCL1 and IL6 were evaluated in the 
supernatant by ELISA (n=4-5). (C) WT and Trem2-/- KCs were treated with LPS (100 ng/mL) 
and mRNA levels of Mcp1 were determined (n=4). One-way analysis of variance, followed by 
Tukey’s posthoc test was used, data represent mean ± SEM and *, **, *** and **** denote a P 
value of ˂0.05, ˂0.01, ˂0.001 and <0.0001, respectively versus WT KCs. AU, arbitrary units; 
Cxcl1, C-X-C motif chemokine ligand 1; Il, interleukin; KCs, Kupffer cells; LPS, 
lipopolysaccharide; Mcp1, monocyte chemoattractant protein 1; Tnf, tumour necrosis factor; 
Trem2, triggering receptor expressed on myeloid cells 2; WT, wild type.  
 











Figure R.12. Cytokine responses in WT and Trem2-/- KCs upon heat-killed E.coli treatment. 
(A) WT and Trem2-/- KCs were treated with heat-killed E. coli (2×107 CFU/ml) for 1, 3 or 6 hours 
and levels of Cxcl1, Il6, Tnf and Il1b were determined by qRT-PCR (n=4-5). (B) WT and Trem2-
/- KCs were treated with heat-killed E. coli (2×107 CFU/ml) for 3 hours and protein levels of 
CXCL1 and IL6 were evaluated in the supernatant by ELISA (n=4-5). One-way analysis of 
variance, followed by Tukey’s posthoc test was used, data represent mean ± SEM and *, **, *** 
and **** denote a P value of ˂0.05, ˂0.01, ˂0.001 and <0.0001, respectively versus WT KCs. 
AU, arbitrary units; CFU, colony-forming unit; Cxcl1, C-X-C motif chemokine ligand 1; E. coli, 
Escherichia coli; Il, interleukin; KCs, Kupffer cells; Tnf, tumour necrosis factor; Trem2, 
triggering receptor expressed on myeloid cells 2; WT, wild type.  




As we had reported an increased mRNA expression of Mcp1 during chronic liver injury 
in vivo (Figure R.6A and Figure R.10D) and that KCs were not the source of the increase 
in Mcp1 levels (Figure R.11) we speculated about other possible cellular sources of these 
chemokine. In this sense, HSCs could be a source of Mcp1 in vivo. Indeed when we 
treated WT and Trem2-/- HSCs with LPS or E. coli, we found increased levels of the Cxcl1 
and MCP1 chemokines in Trem2-/- HSCs compared to WT HSCs (Figure R.13A-B).  
To corroborate this, we performed gain of function experiments on human LX-2 
HSCs. Thus, LX-2 cells were transfected with a control plasmid or a TREM2 plasmid 
and were treated with LPS. As expected, TREM2 overexpression in LX-2 cells dampened 






























Figure R.13. Cytokine responses in WT and Trem2-/- HSCs upon LPS and heat-killed E.coli 
treatment. Cxcl1 mRNA levels and MCP1 protein levels in WT and Trem2-/- activated mouse 
HSCs treated with 100 ng/ml LPS or (A) 2×107 CFU/ml heat-killed E. coli (B) (n=3-4). (C) 
Human HSC LX-2 cells were transfected with a control or TREM2 overexpressing plasmid, 
36 hours post-transfection were stimulated with 100 ng/ml LPS for 3 hours and levels of TREM2, 
IL6 and MCP1 were determined by qRT-PCR (n=4). One-way analysis of variance, followed by 
Tukey’s posthoc test was used, data represent mean ± SEM and *, ** and *** denote a P value 
of ˂0.05, ˂0.01 and ˂0.001, respectively versus WT HSCs or control plasmid LX-2 cells. AU, 
arbitrary units; CFU, colony-forming unit; Cxcl1, C-X-C motif chemokine ligand 1; E. coli, 
Escherichia coli; HSCs, hepatic stellate cells; IL6, interleukin 6; LPS, lipopolysaccharide; MCP1, 
Monocyte chemoattractant protein 1; TREM2, triggering receptor expressed on myeloid cells 2; 
WT, wild type. 




We also tested whether TREM2-mediated effects in inflammation were only specific for 
TLR dependent signalling or if other signalling pathways could also be involved. With 
that purpose, we treated isolated mouse WT and Trem2-/- KCs and HSCs with LPS, TNFα 
or IL1β. Trem2-/- KCs displayed increased pro-inflammatory gene expression compared 
to WT KCs only when cells were treated with LPS but not with TNFα or IL1β (Figure 
R.14A). Similarly, Trem2-/- HSCs showed increased levels of inflammation after LPS 
treatment, but not after IL1β treatment (Figure R.14B). These data further suggest that 
TREM2 receptor does not directly have an effect on TNFα or IL1β signalling pathways 
in non-parenchymal cells and ratifies the specificity for TLR4-mediated signalling.  
We therefore conclude that TREM2 attenuates TLR4-mediated inflammatory 
responses in both KC and HSC. 
 
Figure R.14. Only LPS but not IL1β or TNFα treatment results in augmented inflammatory 
response in Trem2-/- KCs and HSCs. (A) WT and Trem2-/- KCs were treated with LPS (100 
ng/ml), IL1β (10 ng/ml) and TNFα (10 ng/ml) for 3 hours and mRNA levels of Il1b, Il6 and Tnf 
were evaluated (n=3-4). (B) WT and Trem2-/- HSCs were treated with LPS (100 ng/ml) and IL1β 
(10 ng/ml) for 3 hours and mRNA levels of Cxcl1 and Il6 were determined (n=4-5). One-way 
analysis of variance, followed by Tukey’s post hoc test was used, data represent mean ± SEM and 
*, ** and **** denote a P value of ˂0.05, ˂0.01 and <0.0001 respectively versus WT KCs and 
HSCs. AU, arbitrary units; Cxcl1, C-X-C motif chemokine ligand 1; HSCs, hepatic stellate cells; 
Il, interleukin; KCs, Kupffer cell; LPS, lipopolysaccharide; Tnf, tumor necrosis factor alpha; 
Trem2, triggering receptor expressed on myeloid cells 2; WT, wild type. 
Mechanistically, TREM2 has been reported to modulate the activation of MAPK 
signalling, including ERK, p38 and JNK phosphorylation, which are early and critical 




signal transduction events in TLR4-induced cytokine production (185, 188, 220). We 
decided to check TREM2 effects on TLR4-mediated MAPK activation. Phosphorylation 
of p38 was potentiated in Trem2-/- KCs after E. coli treatment as well as ERK 
phosphorylation after both E. coli and LPS treatment. In addition, JNK phosphorylation 
after LPS and E.coli treatment was less pronounced in Trem2-/- KCs compared to WT 
KCs (Figure R.15). However, no differential effects were observed on TLR4-mediated 
NF-κB activation in WT and Trem2-/- KCs (Figure R.15).  
We conclude that TREM2 dampening of TLR4-driven inflammation is associated 
with an early attenuation of MAPK phosphorylation, particularly ERK activation within 
KCs. 
 
Figure R.15. TLR4-mediated MAPK signalling responses in WT and Trem2-/- KCs. WT and 
Trem2-/- KCs were treated with (A) LPS (100 ng/ml) or (B) 2×107 CFU/ml heat-killed E. coli for 
15, 30, 60 and 180 minutes. Phosphorylation of ERK1/2, p38, JNK, p65 and IκB-α degradation 
was determined by immunoblot. CFU, colony-forming unit; ERK, extracellular regulated kinase; 
JNK, C-Jun N-terminal kinase; LPS, lipopolysaccharide; Trem2, triggering receptor expressed on 
myeloid cells 2; WT, wild type. 
R.1.7 TREM2 blunts CCl4 and acetaminophen-induced liver injury and inflammation  
Given that TREM2 in non-parenchymal liver cells plays a key role in inflammation we 
wondered if this receptor could influence the response to acute liver injury. To answer 




this question, we performed two acute liver injury models consisting in a single 
administration of CCl4 or APAP.  
Twelve hours after acute CCl4 injury Trem2
-/- mice displayed elevated ALT and AST 
levels compared to WT (Figure R.16A-B). This was associated with increased mRNA 
levels of the neutrophil chemoattractant Cxcl1 and accompanied with increased liver 
neutrophil recruitment 24h post injury as determined by IHC (Figure R.16C-D). In 
accordance, we isolated inflammatory cells from the livers of WT and Trem2-/- mice 24h 
after CCl4 injury and observed a strong tendency (p=0.06) for increased liver neutrophil 
numbers in Trem2-/- mice compared to WT controls by flow cytometry (Figure R.16E).  
Thus, these data demonstrate that TREM2 is important for dampening CCl4-

























Figure R.16. CCl4-mediated liver injury and inflammation is enhanced in Trem2
-/- mice. (A) Serum 
ALT and AST levels, (B) representative H&E stains of liver tissue and (C) mRNA levels of liver Cxcl1 
6 and 12 hours after CCl4 treatment in WT and Trem2
-/- mice (n=5) Scale bar in (B) indicates 200 µm. (D) 
Representative images of liver sections of WT and Trem2-/- mice 24 hours after acute CCl4 treatment 
immunostained for neutrophils (NIMP.R14). Manual counts for NIMP-positive cells (n=6-10). Arrows 
denote positively stained cells. (E) Representative flow cytometry plot of hepatic neutrophils of WT and 
Trem2-/- mice 24 hours after CCl4 treatment. Total number of neutrophils normalised to liver weight are 
shown (n=6-10). Parametric unpaired Student’s t-test was used and data represent mean ± SEM and * and 
** denote a P value of ˂0.05 and ˂0.01, respectively versus WT mice.. ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; AU, arbitrary units; CCl4, carbon tetrachloride; Cxcl1, C-X-C motif 
chemokine ligand 1; H&E, haematoxylin and eosin; IU, international units; Trem2, triggering receptor 
expressed on myeloid cells 2; WT, wild type. 




Similarly, following sub-lethal APAP intoxication, Trem2-/- mice displayed augmented 
transaminase levels, more necrosis and increased neutrophil content compared to WT 
(Figure R.17A-C). In addition, in this model, Trem2-/- mice also exhibited increased 
macrophage content, which was also associated with elevated levels of Mcp1 (Figure 
R.17C-D). All these data suggested that the driver for the increased liver damage could 
be an enhanced PAMP-driven inflammation from non-parenchymal liver cells in Trem2-
/- mice. Therefore, to exclude a toxic effect of APAP on hepatocytes, we isolated WT and 
Trem2-/- hepatocytes, treated them with APAP and evaluated cell viability. APAP dose 
dependently killed hepatocytes; however, cell death was not elevated in Trem2-/- 
hepatocytes. In fact, there was a small although statistically significant tendency that 
viability was increased in Trem2-/- hepatocytes (Figure R.17E). As APAP overdose is a 
common cause of human acute liver failure that is associated with mitochondrial 
dysfunction, stress, lipid peroxidation and liver necrosis (221), we decided to administer 
a lethal dose of APAP (750 mg/kg) to WT and Trem2-/- mice and monitor survival. 
Strikingly, all Trem2-/- mice died within 25 hours, while as previously described, ~70% 
of WT mice survived 72h post APAP overdose (222, 223) (Figure R.17F).  
We conclude that TREM2 is important for dampening acute liver damage and the 
associated inflammatory reaction, this immune receptor therefore being essential for 




















Figure R.17. TREM2 dampens APAP-induced liver injury. (A-C) 300 mg/kg APAP were 
injected in WT and Trem2-/- mice and (A) representative H&E, F4/80 and Ly6G stains from WT 
and Trem2-/- mice are depicted. Arrows denote positively stained cells (n=5). (B) ALT and AST 
levels 24 hours after APAP were determined (n=5). (C) Manual counts for F4/80 and Ly6G 
positive cells in WT and Trem2-/- mice livers after APAP injection (n=5). (D) 500 mg/kg APAP 
were injected in WT and Trem2-/- and mRNA levels of liver Mcp1 were determined. (E) WT and 
Trem2-/- hepatocytes were treated with 0, 5 or 10 mM of APAP for 24 hours and cellular viability 
was evaluated (n=6). (F) 750 mg/kg APAP were injected and survival was monitored in WT and 
Trem2-/- mice (n=9-11). (A-E) Parametric unpaired Student’s t-test and (F) Log-rank (Mantel-
Cox) test were used and data represent mean ± SEM and *, ** and *** denote a P value of ˂0.05, 
˂0.01 and ˂0.001, respectively versus WT mice. Scale bar in (B) indicates 50 µm (left panel) or 
200 µm (right panel). ALT, alanine aminotransferase; AST, aspartate aminotransferase; APAP, 
acetaminophen; AU, arbitrary units; H&E, haematoxylin and eosin; IU, international units; Mcp1, 
monocyte chemoattractant protein 1; Trem2, triggering receptor expressed on myeloid cells 2; 
WT, wild type. 




R.1.8 Trem2-/- mice exhibit increased injury-induced hepatic lipid peroxidation 
TREM2 is able to modulate PPAR and nuclear receptor activities that regulate lipid-
associated pathways (192). In addition, CCl4 and APAP intoxication-mediated 
inflammation is associated with enhanced lipid peroxidation, which can result in 
hepatocyte death (224-226). Therefore, in search for a unified mechanism for the elevated 
liver injury of Trem2-/- mice following chronic CCl4 and acute APAP intoxication, we 
decided to monitor the levels of 4-hydroxynonenal (4-HNE), representative of lipid 
peroxidation (226). After chronic CCl4 treatment and APAP intoxication, elevated 4-HNE 
levels were observed in the livers of Trem2-/- mice (Figure R.18A-C). To confirm these 
data in an independent experiment, we also measured 4-HNE levels by ELISA in the 
livers of WT and Trem2-/- mice 24 hours post APAP treatment. Indeed, with this approach 
we could also observe significantly elevated levels of 4-HNE in Trem2-/- mice (Figure 
R.18D).  
Interestingly, examining 4-HNE staining revealed that lipid peroxidation was most 
intense around hepatic venules, where inflammatory cells reside. These data suggest that 
resident or infiltrating immune cells could be responsible for the elevated lipid 
peroxidation through enhanced ROS levels (Figure R.18A-C). Supporting this idea, 
elevated lipid peroxidation after chronic CCl4 treatment was only observed when both 





























Figure R.18. TREM2 impacts hepatic lipid peroxidation. (A) Representative liver 4-HNE stain 
from WT mice reconstituted with WT-GFP+BM (WT-WT), Trem2-/- mice reconstituted with 
Trem2-/--GFP+BM (Trem2-/--Trem2-/-) or chimeric mice (WT-Trem2-/-) and (Trem2-/--WT) that 
were treated with CCl4 chronically for 8 weeks and sacrificed 1 day after the last CCl4 injection 
(n=3-5). Scale bar in 5X indicates 200 µm and in 20X indicates 50 µm. (B) Representative liver 
4-HNE stain from WT and Trem2-/- mice that were chronically treated with CCl4 for 8 weeks and 
sacrificed 1 day after the last CCl4 injection (n=4-8 CCl4, and n=3 O.Oil). (C) Representative liver 
4-HNE stain from WT and Trem2-/- mice injected with 300 mg/kg APAP and sacrificed 24 hours 
after (n=5). Scale bar in (B-C) indicates 200 µm (D) 4-HNE content was determined by ELISA 
in livers of mice injected with 300 mg/kg APAP for 24 hours (n=5-7). Parametric unpaired 
Student’s t-test was used and data represent mean ± SEM and * denote a P value of < 0.05 versus 
WT. 4-HNE, 4-hydroxynonenal; APAP, acetaminophen; CCl4, carbon tetrachloride; TREM2, 
triggering receptor expressed on myeloid cells 2; WT, wild type. 




As previously shown in the bone-marrow transplantation experiment, the ability of 
TREM2 to dampen liver damage after chronic CCl4 treatment depended on TREM2 
expression in both resident and infiltrating cells (Figure R.8), these data further linked 
elevated lipid peroxidation to injury and also suggested that this effect could be associated 
with enhanced ROS levels within Trem2-/- resident and/or liver infiltrating immune cells.  
However, ROS levels in WT and Trem2-/- KCs revealed similar levels in both basal 
as well as in LPS-driven ROS (Figure R.19A). Considering that increased lipid 
peroxidation in Trem2-/- mice was associated with elevated MCP1 and newly recruited 
monocyte derived hepatic macrophage levels, we wondered if increased liver damage in 
Trem2-/- mice could be due to the differential ROS levels within injury-associated 
inflammatory monocytes that repopulate the liver. For that, we isolated BMDM and 
strikingly, Trem2-/- BMDM exhibited higher baseline and LPS-induced ROS levels 
(Figure R.19B). The production of ROS is mediated by oxidative phosphorylation as 
well as the nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase complex in 
the mitochondria. Therefore, we determined the source for the elevated ROS in Trem2-/- 
macrophages. Interestingly, we observed that Trem2-/- BMDM exhibited higher baseline 
oxidative phosphorylation and maximal respiration, suggesting that this metabolic 
signature could be responsible for the enhanced ROS (Figure R.19C).  
We conclude that TREM2 affects lipid peroxidation and subsequent damage of 
hepatocytes by skewing metabolic pathways and ROS generation within newly recruited 





















Figure R.19. TREM2 impacts ROS levels in BMDMs. WT and Trem2-/- (A) KCs or (B) BMDM 
were treated with 100 ng/ml LPS for 3 hour and total cellular ROS levels were determined using 
flow cytometry with dihydrorhodamine 123 and a representative histogram is shown (n=3-4). (C) 
Oxygen consumption rate and maximal respiration of naive and LPS-treated BMDM was 
evaluated (n=4-5). Parametric unpaired Student’s t-test was used and data represent mean ± 
SEM and **** denotes a P value of <0.0001 versus WT. BMDM, bone marrow derived 
macrophages; DHR123, dihydrorhodamine 123; KCs, Kupffer cells; LPS, lipopolysaccharide; 
OCR, oxygen consumption rate; ROS, reactive oxygen species; Trem2, triggering receptor 
expressed on myeloid cells 2; WT, wild type. 




R.1.9 PAMPs are upstream of TREM2 during liver injury 
After showing the importance of TREM2 in dampening liver injury and inflammation we 
tried to elucidate whether the upstream driver of TREM2 were PAMPs associated to 
TLR4 signalling downstream of gut microbiota. With this aim, we administered WT and 
Trem2-/- mice antibiotics for 4 weeks, acute injured with CCl4 and evaluated liver injury 
and inflammation compared to animals that did not receive antibiotics. We also evaluated 
intestinal permeability administering FITC-Dextran 4 hours before culling and sacrificed 
all animals 12 hours after CCl4 administration. Serum FITC levels were unaltered in WT 
and Trem2-/- mice with or without antibiotics after CCl4 treatment, showing no differences 
in intestinal permeability (Figure R.20A). Interestingly, Trem2-/- mice exhibited 
increased ALT and AST serum levels compared to WT after acute CCl4 treatment, as 
previously observed (Figure R.20B), however, antibiotic treatment abolished these 
differences (Figure R.20B). In addition, antibiotic treatment also reverted the augmented 
liver inflammation levels of Trem2-/- mice compared to WT mRNA levels, as demonstrate 
the mRNA levels of Il1b and Il6 (Figure R.20C).  
Altogether, these data show that after acute liver injury, differences in altered 
intestinal permeability of Trem2-/- mice do not contribute to the enhanced liver damage 
and further support the concept that TREM2 dampens PAMP-derived signals from gut 























Figure R.20. PAMPs are upstream of TREM2 during liver injury. (A-C) Drinking 
water with or without antibiotics was administered to WT and Trem2-/- mice for 4 weeks. 
After that mice were injected with CCl4 and 8 hours after were gavaged with 4KDa FITC 
Dextran and sacrificed 4 hours later (12 hours after CCl4 administration) (n=8-9). Serum 
levels of (A) FITC Dextran, (B) ALT and AST were determined. (C) mRNA levels of 
liver Il6 and Il1b were determined. Parametric Student’s t-test was used, data represent 
mean ± SEM and * and ** denote a P value of ˂0.05 and ˂0.01, respectively versus WT 
mice. Abx, antibiotics; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; AU, arbitrary units; CCl4, carbon tetrachloride; FITC, fluorescein 
isothiocyanate; Il, interleukin; IU, international units; n.s. non-significant; 
PAMPs, pathogen-associated molecular patterns; Trem2, triggering receptor expressed 
on myeloid cells 2; WT, wild type. 




R.2 Role of TREM2 in liver regeneration after partial hepatectomy 
R.2.1 TREM2 mRNA expression is upregulated at different time points after PHx in mice.  
After tissue injury or loss of parenchymal mass due to PHx, regenerative mechanisms are 
activated in the liver. The fact that the expression of TREM2 was induced in cirrhotic 
human livers and acute and chronic liver injury models in mice, led us to investigate 
whether its induction in the damaged liver could be part of the regenerative response of 
the liver triggered during acute and chronic liver injury.  
To directly test this hypothesis, we used the well-characterized mouse model of liver 
regeneration after two-thirds PHx. As shown in Figure R.21, Trem2 mRNA expression 
was low in mouse liver in Sham operated mice, and progressively increased after 4, 24 
and 48 hours after PHx, with its expression peaking at 48 hours post-surgery, and 




Figure R.21. TREM2 mRNA expression at different time points after PHx. Trem2 mRNA 
expression was analysed in the remaining mouse liver parenchyma at different time points (2, 4, 
24, 48 and 72 hours) after PHx or sham operation (n=3-4). AU, arbitrary units; PHx, partial 
hepatectomy; Trem2, triggering receptor expressed on myeloid cells 2. 




R.2.2 The initiation of liver regeneration and hepatocyte proliferation following PHx is 
accelerated in Trem2-/- mice 
With the aim of evaluating the significance of Trem2 gene expression during liver 
regeneration after PHx, WT and Trem2-/- mice were used and these were subjected to 
~70% PHx. First, the DNA synthetic response was analysed in WT and Trem2-/- mice at 
different times after PHx, by inmunohystochemical detection of BrdU incorporation into 
DNA, to determine the number of cells in S phase. Of note, 36 hours after surgery Trem2-
/- mice displayed a marked tendency to exhibit increased, albeit not significant, hepatocyte 
proliferation. BrdU incorporation was significantly augmented in Trem2-/- mice 72 hours 
after PHx (Figure R.22A). In line with this observation, a significant elevation of PCNA 
expression in hepatocyte nuclei was observed 72 hours after PHx in Trem2-/- mice, when 
compared to WT mice (Figure R.22B). These results were also confirmed when PCNA 
expression levels were analysed by immunoblotting (Figure R.22C).  
Since the restoration of liver mass is mediated by a network of cytokines, mitogens 
and growth factors in an orchestrated manner, we evaluated the mRNA levels of 
inflammatory and mitogenic genes. As shown in Figure R.23A-B, Trem2-/- mice 
exhibited a differential pro-inflammatory cytokine expression when compared to WT 
mice, as shown by increased levels of Tnf and Il6 mRNAs as early as 1 hour and 6 hours 
after PHx, respectively. Similarly, in Trem2-/- livers augmented levels of Hgf were found 
6 hours after PHx, when compared to WT mice (Figure R.23B).  
Together these data suggest that TREM2 plays a key role modulating the early 
induction of inflammatory cytokine expression after PHx, and in its absence, liver 

















Figure R.22. Liver regeneration after partial hepatectomy is accelerated in Trem2-/- mice. 
(A) Representative immunohistochemical detection of BrdU in liver sections of WT and Trem2-
/- mice at 36 hours after PHx (20X fields) and quantification of positively stained BrdU-labelled 
hepatocytes in liver sections of WT and Trem2-/- mice that were either sham operated or subjected 
to PHx and sacrificed 6, 36, 72 hours after (n=3-6). (B) Representative PCNA stains from WT 
and Trem2-/- mice at 36 hours after PHx (20X fields) and manual counts of positively stained 
PCNA hepatocytes in liver sections of WT and Trem2-/- mice that were either sham operated or 
6, 36, 72 hours and 5 days after PHx (n=3-6). (C) Western blot analysis of PCNA 72 hours after 
PHx, β-actin was used as house-keeping control (n=5). Parametric Student’s T test and non-
parametric Mann-Whitney test were used. Data represent mean ± SEM and *, ** and *** denote 
a P value of <0.05, <0.01 and <0.001, respectively versus WT mice. AU, arbitrary units; BRDU, 
5’-bromo-2’-deoxyuridine; PCNA, proliferating cell nuclear antigen; PHx, partial hepatectomy; 
Trem2, triggering receptor expressed on myeloid cells 2; WT, wild type. 
 






Figure R.23. Early inflammatory cytokine expression after partial hepatectomy is enhanced 
in Trem2-/- mice. (A) mRNA expression of the pro-inflammatory cytokine Tnf 1 hour after PHx 
(n=5-6) and (B) mRNA expression of the pro-inflammatory cytokine Il6 and the growth factor 
Hgf 6 hours following PHx (n=6-11). Parametric Student’s T test was used. Data represent mean 
± SEM and * and *** denote a P value of <0.05 and <0.001 respectively. AU, arbitrary units; 
Hgf, hepatocyte growth factor; Il6, interleukin 6; PHx, partial hepatectomy; Tnf, tumour necrosis 































R.3 Role of TREM2 in HCC 
R.3.1 TREM2 is upregulated in human HCC tissue 
We have previously reported that TREM2 expression is upregulated in human liver 
cirrhosis and experimental mouse models of acute and chronic liver injury (Figure R.1, 
Figure R.2 and Figure R.3). This led us to evaluate whether the expression of TREM2 
was also elevated in the neoplastic liver. We first analysed TREM2 expression data 
retrieved from the TCGA public repository. Interestingly, we observed that TREM2 
expression levels were significantly increased in HCC livers compared to controls in the 
TCGA cohort, consisting in 366 HCC samples and 49 surrounding normal tissue samples 
(Figure R.24A). Moreover, stratifying HCC samples according to tumour stage revealed 
that TREM2 expression was upregulated in advanced T4 stage tumours compared to early 
T1 stage tumours.  
 
Figure R.24. TREM2 expression in human HCC tissues. (A) RNA-seq analysis of TREM2 
expression in surrounding normal tissues and in HCC tissues (n=49 and 366 respectively) and (B) 
stratification of HCC tumors according to tumor stage (T1 n= 179, T2 n= 91, T3 n= 79 and T4 
n= 13) in the TCGA database. Non-parametric Mann-Whitney test and Kruskal-Wallis test 
followed by Dunn’s multiple comparison tests were used. Data represent mean ± SEM and * and 
**** denote a P value of <0.05 and <0.0001 respectively. HCC, hepatocellular carcinoma; TCGA, 
The cancer genome atlas; TREM2, triggering receptor expressed on myeloid cells 2. 




Importantly, we also confirmed these results in an independent cohort of patients (Table 
M.2). TREM2 mRNA expression was also induced in HCC samples compared to healthy 





Figure R.25. TREM2 expression in human HCC tissue. (A) TREM2 mRNA expression in 
normal human livers (controls) and HCC samples (n=21 and 35, respectively) in the San Sebastian 
cohort of patients. Non-parametric Mann-Whitney test was used. Data represent mean ± SEM and 
**** denote a P value of <0.0001. AU, arbitrary units; HCC, hepatocellular carcinoma; TREM2, 
triggering receptor expressed on myeloid cells 2. 
 
 
Next, correlation of fibrotic and inflammatory genes with TREM2 expression was 
analysed in the HCC tissue samples of the San Sebastian cohort of patients and a positive 
correlation between TREM2 expression and the expression levels of the fibrotic marker 
COL1A1 was observed, whereas no correlation was evidenced with the fibrotic marker 
ACTA2 (Figure R.26A). Furthermore, TREM2 mRNA levels positively correlated with 
markers of inflammation, including the pro-inflammatory cytokines IL1B, IL6, IL8 and 
TNF (Figure R.26B).  
We conclude that TREM2 mRNA expression is increased during human HCC and 













Figure R.26. TREM2 mRNA expression in human HCC and its correlation with markers of 
fibrosis and inflammation. Correlation between TREM2 mRNA levels and mRNA levels of the 
fibrosis and inflammation markers in HCC samples in the San Sebastian cohort of patients (n=35). 
(A) Correlation between TREM2 mRNA levels and mRNA levels of the fibrotic markers COL1A1 
and ACTA2. (B) Correlation between mRNA levels of TREM2 and markers of inflammation 
(IL1B, IL6, IL8 and TNF) in HCC samples. Spearman’s correlation test was used. ACTA2, Actin 
alpha 2, smooth muscle; AU, arbitrary units; COL1A1, collagen type I alpha 1 chain; HCC, 
hepatocellular carcinoma; IL, interleukin; TNF, tumour necrosis factor; TREM2, triggering 
receptor expressed on myeloid cells 2.  




R.3.2 Trem2-/- mice have increased levels of hepatocyte damage, inflammation and 
oxidative stress after acute DEN-induced liver injury in adult mice 
In order to clarify the role of TREM2 in the early stages of tumour development, we 
carried out a well-established in vivo approach that provides significant insight into the 
inflammatory mechanisms at play during HCC (163, 227). Thus, 8 week old WT or 
Trem2-/- male mice were injected with 100 mg/kg of DEN and sacrificed 6, 24 or 72 hours 
later.  
Histological analysis of H&E-stained liver sections revealed that the damaged area 
was significantly bigger in the Trem2-/- mice, in comparison to WT mice (Figure R.27A). 
In addition, DNA damage was indirectly measured by phospho-histone H2A.X (γH2AX) 
staining, revealing increased number of damaged hepatocytes in the liver of Trem2-/- 
mice, compared to WT mice (Figure R.27B). In agreement with these data, we found that 
the circulating levels of ALT were significantly elevated in the Trem2-/- mice sera 6 and 
72 hours after DEN injection compared to WT mice (Figure R.27C).  
Importantly, in line with previous observations, we observed an increased 
accumulation of ROS in the liver tissue of Trem2-/- mice 24 hours after DEN challenge, 
when compared with WT mice (Figure R.27D). Next, we analysed the mRNA expression 
of genes implicated in inflammation and oxidative stress. As previously shown in other 
acute and chronic toxic liver injury models, the mRNA levels of Cxcl1 and Mcp1 
chemokines were also found upregulated in the Trem2-/- mice 6 hours post-DEN 
administration (Figure R.28A). In addition, the mRNA expression of the pro-
inflammatory cytokine Tnf, the hepatocyte growth factor Hgf, and the oxidative stress 
marker the inducible enzyme heme oxigenase 1 (Hmox1) were also found increased in 
















Figure R.27. TREM2 protects hepatocytes from DNA damage by attenuating inflammation 
and oxidative stress after acute DEN-induced liver injury. WT and Trem2-/- mice were injected 
with 100 mg/kg of DEN and were sacrificed 6, 24 and 72 hours post injury (n=6-10). (A) 
Representative H&E stains of liver sections post-acute DEN treatment and quantification of the 
damaged area (10X). (B) Representative images of liver sections immunostained for γH2AX and 
manual counts of positively stained hepatocyte nuclei (20X). (C) ALT levels were determined. 
(D) ROS was determined in liver tissue of WT and Trem2-/- mice 24 hours after DEN 
administration. Parametric Student’s T test and non-parametric Mann-Whitney test were used. 
Data represent mean ± SEM and *, **, and **** denote a P value of <0.05, <0.01 and <0.0001, 
respectively versus WT mice. ALT, alanine aminotransferase; DEN, diethylnitrosamine; γH2AX, 
Phospho-Histone H2A.X; IU, international units; ROS, reactive oxygen species; Trem2, 
triggering receptor expressed on myeloid cells 2; WT, wild type. 
 







Figure R.28. mRNA expression analysis of key inflammatory, proliferative and injury 
mediators in WT and Trem2-/- mice after acute DEN administration. WT and Trem2-/- mice 
were injected with 100 mg/kg of DEN and were sacrificed 6 hours post injury (n=7). (A) mRNA 
levels of the pro-inflammatory chemokines Cxcl1 and Mcp1, the cytokine Tnf, (B) the oxidative 
stress enzyme Hmox1 and (C)the growth factor Hgf were determined. Parametric Student’s T test 
and non-parametric Mann-Whitney test were used. Data represent mean ± SEM and * and ** 
denote a P value of <0.05 and <0.01, respectively versus WT mice. Cxcl1, C-X-C motif 
chemokine ligand 1; DEN, diethylnitrosamine; Hgf, hepatocyte growth factor; Hmox1, heme 
oxigenase 1; Mcp1, monocyte chemoattractant protein 1; Tnf, tumor necrosis factor; Trem2, 












Given our previous observations showing that TREM2 modulates the immune cell 
recruitment after acute (Figures R.16 and R.17) and chronic liver injury (Figure R.10), 
we wondered if this receptor could also play a role in inflammatory cell recruitment to 
the liver in the DEN-induced injury model. 
Thus, we evaluated T cell, neutrophil and macrophage content in the liver by 
performing immunohistochemical analysis. As shown in Figure R29, no relevant 
differences were observed in immune cells recruitment to the liver between genotypes.  
In conclusion, these observations further support the concept that TREM2 might be 
protective in early stages after DEN challenge, as it attenuates liver damage, inflammation 
and oxidative stress.  
 
 





Figure R.29. No differences in immune cell recruitment after acute DEN-induced liver 
injury between livers of WT and Trem2-/- mice. Recruitment of immune cells to the liver was 
measured by IHC. Representative images of liver sections immunostained for (A) T cells (anti-T 
cell marker CD3), (B) neutrophils (anti-neutrophil marker NIMP.R14) and (C) macrophages 
(anti-macrophage marker F4/80) (20X). Arrows denote positively stained cells. Manual counts of 
positive cells in livers 24 and 72 hours post-DEN treatment are depicted. Scale bar represent 100 
μm. Data represent mean ± SEM. Parametric Student’s T test and non-parametric Mann-Whitney 
test were used. DEN, diethylnitrosamine; Trem2, triggering receptor expressed on myeloid cells 
2; WT, wild type. 




R.3.3 TREM2 is upregulated in DEN-induced liver carcinogenic mouse model 
To formally investigate the role of TREM2 in hepatocarcinogenesis, we analysed Trem2 
expression in a chemically-induced mouse model of liver cancer. C57BL/6 male mice 
were administered the liver carcinogen DEN (30 mg/kg) 15 days after birth and sacrificed 
30 or 40 weeks after. First, the mRNA expression levels of Trem2 were measured in the 
liver of mice treated with DEN for 30 and 40 weeks. Interestingly, we were able to find 
a significant and progressive upregulation of Trem2 expression in the liver tissue of these 
mice, comparing to saline-injected mice (Figure R.30A). In addition, mRNA levels of 
Trem2 in non-tumour and tumour samples in this animal model were analysed and an 
upregulation of Trem2 mRNA expression in tumours, compared to non-tumour tissue, 
particularly after 40 weeks of DEN administration was observed (Figure R.30B). 
 
 
Figure R.30. Trem2 mRNA expression is upregulated in experimentally induced HCC in 
mice. WT mice were injected with 30 mg/kg DEN and were sacrificed after 30 and 40 weeks 
(n=14-16). (A) qRT-PCR analysis of Trem2 expression in the liver of 30 and 40 week DEN-
injured mice and (B) qRT-PCR analysis of Trem2 expression in non-tumour vs tumour tissue in 
the liver of 30 and 40 week DEN-injured mice (n=4-10). Parametric Student’s T test and non-
parametric Mann-Whitney test were used. Data represent mean ± SEM and *, ** and *** denote 
a P value of <0.05, <0.01 and <0.001, respectively versus saline or non-tumour tissue. AU, 
arbitrary units; DEN, diethylnitrosamine; Trem2, triggering receptor expressed on myeloid cells 
2; WT; wild type. 
 




Next, correlation studies between Trem2 mRNA expression levels and fibrotic or 
inflammatory marker transcript levels were carried out both in the non-tumour tissue 
(Figure R.31) or tumour tissue (Figure R.32). Of note, Trem2 mRNA expression levels 
correlated with markers of fibrosis Col1a1 and Acta2 in the non-tumour liver tissue of 
mice 30 and 40 weeks post-DEN administration (Figure R.31A). Similarly, in DEN-
induced tumour tissue these fibrotic markers also positively correlated with the 
expression of Trem2 (Figure R.32A). In addition, mRNA levels of Trem2 and Mcp1 
positively correlated both in non-tumour tissue and in tumour tissue, whereas no 
correlation was observed between the expression levels of Trem2 and the chemokine 
Cxcl1 (Figure R.31B and Figure R.32B). Interestingly, no correlation was observed 
between the expression levels of Trem2 and the pro-inflammatory cytokines Il1b and Il6 
in the non-tumour tissue, whereas Tnf expression levels correlated with Trem2 expression 
levels (Figure R.31C). In addition, Il6 expression levels correlated with Trem2 
expression levels in DEN-induced tumour tissue (Figure R.32C). 





Figure R.31. Correlation between the expression levels of Trem2 and markers of fibrosis 
and inflammation in the non-tumour liver tissue of DEN-induced mouse carcinogenic 
model. WT mice were injected with 30 mg/kg DEN and were sacrificed after 30 and 40 weeks 
(n=16 and n=14). (A-C) Correlation between the mRNA expression levels of Trem2 and (A) 
markers of fibrosis Col1a1 and Acta2, (B) the chemokines Cxcl1 and Mcp1 and (C) the cytokines 
Il1b, Il6 and Tnf. Non-parametric Spearman’s correlation test was used. Acta2, Actin alpha 2, 
smooth muscle; AU, arbitrary units; Col1a1, collagen type I alpha 1 chain; Il, interleukin; Mcp1, 
monocyte chemoattractant protein 1; Tnf, tumour necrosis factor; Trem2, triggering receptor 
expressed on myeloid cells 2; WT; wild type. 







Figure R.32. Correlation between the expression levels of Trem2 and markers of fibrosis 
and inflammation in the tumour liver tissue of DEN-induced mouse carcinogenic model. 
WT mice were injected with 30 mg/kg DEN and were sacrificed after 30 and 40 weeks (n=4 and 
n=10). (A-C) Correlation between the mRNA expression levels of Trem2 and (A) markers of 
fibrosis Col1a1 and Acta2, (B) the chemokines Cxcl1 and Mcp1 and (C) the cytokine Il6. Non-
parametric Spearman’s correlation test was used. Acta2, Actin alpha 2, smooth muscle; AU, 
arbitrary units; Col1a1, collagen type I alpha 1 chain; Il, interleukin; Mcp1, monocyte 








R.3.4 The number and size of tumours, hepatocyte proliferation and DNA damage in 
Trem2-/- mice is increased in the DEN-induced HCC model 
To investigate the relevance of TREM2 during hepatocarcinogenesis, 15 day old WT and 
Trem2-/- mice were injected with 30 mg/kg of DEN and tumourigenesis was assessed in 
the livers of these mice. Remarkably, Trem2-/- mice developed more tumours after both 
30 and 40 weeks of DEN administration, compared to WT mice (Figure R.33A). We 
have so far demonstrated that lipid peroxidation is enhanced after acute and chronic liver 
injury models and that this was associated with higher levels of ROS in Trem2-/- BMDMs 
(Figure R.18 and Figure R.19). In line with this, we also observed increased ROS levels 
24 hours after acute DEN challenge in Trem2-/- livers. Since exposure to DEN has been 
associated with accumulation of ROS within hepatocytes (90), we decided to perform in 
parallel to the DEN-model an additional experimental mouse model consisting on the 
administration of a normal diet supplemented with the antioxidant compound BHA for 
15 weeks prior to the sacrifice of the animals 30 weeks after DEN administration. 
Remarkably, the administration of BHA in the diet resulted in an almost complete 
abrogation of tumour development in both, WT and Trem2-/- mice, compared to the DEN-
injected mice fed with a normal diet. Importantly, the BHA diet lowered tumour burden 
to the same levels in both genotypes (Figure R.33B), supporting the concept that TREM2 
protects in HCC by attenuating ROS levels. In addition, tumours in the DEN model were 
also analysed according to their size. Trem2-/- mice displayed increased number of small 
(≤ 2mm) and big (≥ 6mm) tumours after 30 weeks of DEN administration, whereas after 
40 weeks of DEN administration Trem2-/- mice exhibited more small and medium size 












Figure R.33. Trem2 null mice develop increased number of tumours after DEN treatment. 
(A) WT and Trem2-/- mice were injected with 30 mg/kg DEN and were sacrificed after 30 and 40 
weeks (n=14-17). Representative pictures of the livers (arrows point to tumours) are depicted and 
total tumour number per mice is shown. (B) WT and Trem2-/- mice were injected with 30 mg/kg 
DEN, treated for 15 weeks with BHA diet and sacrificed after 30 weeks of DEN administration 
(n=7-12). Representative pictures of the livers (arrows point to tumours) are depicted and total 
tumour number per mice is shown. (C) Tumour number classified by size per mice in WT and 
Trem2-/- livers of 30 and 40 week DEN-injured mouse HCC models are shown. Parametric 
Student’s T test and non-parametric Mann-Whitney test were used. Data represent mean ± SEM 
and *, **, *** and **** denote a P value of <0.05, <0.01, <0.001 and <0.0001, respectively 
versus WT mice. BHA, butylated hydroxyanisole; DEN, diethylnitrosamine; Trem2, triggering 
receptor expressed on myeloid cells 2; WT, wild type. 




We further characterized the previously described carcinogenic mouse model by 
performing a microscopic analysis. Histologic analysis of H&E stains confirmed that 
Trem2-/- liver biopsies had increased number of HCC tumours compared to WT livers 
(Figure R.34A). In addition, we measured the expression of the hepatocyte proliferative 
marker PCNA by IHC in non-tumour liver tissue of these mice and we found that Trem2-
/- livers displayed an increased number of PCNA positive nuclei both 30 and 40 weeks 
after DEN administration, compared with the respective WT livers (Figure R.34B). 
Similarly, DNA γH2AX IHC staining was performed in hepatocytes. Of note, Trem2-/- 
liver biopsies presented more positive hepatocyte nuclei compared to WT biopsies, at 
both time-points (Figure R.34C). Importantly, the protective effect of BHA diet shown 
in (Figure R.33B) was accompanied by a reduction of PCNA (Figure R.34B) positive 
and γH2A.X-stained (Figure R.34C) hepatocytes. Of note, the differences observed in 
WT and Trem2-/- mice after 30 weeks of DEN administration were reduced to the same 
level in both genotypes (Figure R.34B-C).  
 
 





Figure R.34. Trem2 null mice display an increased number of proliferative and damaged 
hepatocytes after DEN-induced liver carcinogenesis. Microscopic analysis of WT and Trem2-
/- mice injected with 30 mg/kg DEN sacrificed after 30 and 40 weeks (n=14-17). (A) HCC tumour 
counting and representative H&E stained images after 30 weeks of DEN administration (4X). (B) 
Representative PCNA stained images and manual counts of positively stained hepatocytes (20X). 
(C) Representative γH2AX stained images and manual counts of positively stained hepatocytes 
(20X). Arrows denote positively stained cells. Parametric Student’s T test and non-parametric 
Mann-Whitney test were used. Data represent mean ± SEM and *, ** and *** denote a P value 
of <0.05, <0.01 and <0.001 respectively. AU, arbitrary units; BHA, butylated hydroxyanisole; 
DEN, diethylnitrosamine; γH2AX, Phospho-Histone H2AX; HCC, hepatocellular carcinoma; n.s, 
non-significant; PCNA, proliferating cell nuclear antigen; Trem2, triggering receptor expressed 
on myeloid cells 2; WT; wild type.  




In resemblance with our previous acute DEN-induced liver injury model, no significant 
difference was found in immune cell recruitment to the liver after chronic DEN-induced 
carcinogenic model (Figure R.35A-C).  
 
Figure R.35. No differences in immune cell recruitment after DEN-induced liver 
carcinogenesis between livers of WT and Trem2-/- mice. Recruitment of immune cells to the 
liver was measured by IHC. Representative images of liver sections immunostained for (A) T 
cells (anti-T cell marker CD3), (B) neutrophils (anti-neutrophil marker NIMP.R14) and (C) 
macrophages (anti-macrophage marker F4/80) (20X). Arrows denote positively stained cells. 
Manual counts of positive cells in livers 30 and 40 weeks post-DEN treatment are depicted. Scale 
bar indicates 100 μm. Parametric Student’s T test and non-parametric Mann-Whitney test were 
used. Data represent mean ± SEM ** denote a P value of <0.01 versus WT mice. DEN, 
diethylnitrosamine; Trem2, triggering receptor expressed on myeloid cells 2; WT, wild type. 




We further analyse the mechanisms by which TREM2 inhibits the hepatocarcinogenic 
process performing a proteomic analysis of DEN-induced WT and Trem2-/- mice liver 
tumour tissue. 
Interestingly, 14 proteins were significantly and differentially expressed between 
WT and Trem2-/- liver tumours (Figure R.36)  
 
Figure R.36. Heatmap of differentially expressed proteins in DEN-induce HCC WT and Trem2-
/- tumours (n=5). A1CF, APOBEC1 complementation factor; AACS, acetoacetyl-CoA synthetase; 
ATP5H, ATP synthase subunit d, mitochondrial; CC50A, cell cycle control protein 50A; ENTP5, 
ectonucleoside triphosphate diphosphohydrolase 5; FADS2, fatty acid desaturase 2; GNA1, 
glucosamine 6-phosphate N-acetyltransferase; HSDL2, hydroxysteroid dehydrogenase-like 
protein 2; IRGM1, immunity-related GTPase family M protein 1; NU1M, NADH-ubiquinone 
oxidoreductase chain 1; PROD, proline dehydrogenase 1, mitochondrial; PXMP2, peroxisomal 
membrane protein 2; proteasome subunit beta type-2; SGPL1, sphingosine-1-phosphate lyase 1; 
Trem2, triggering receptor expressed on myeloid cells 2; WT; wild type.  




In accordance to an increased oxidative stress after acute DEN challenge, gene ontology 
analysis showed enriched processes including oxidoreductase activity and lipid 
metabolism (Table R.1). Similarly, Uniprot keywords analysis revealed that these 
processes were also enriched (Table R.1).  
 
 
Table R.1. Gene ontology and Uniprot keywords enriched in the proteins differentially expressed 
in WT and Trem2-/- DEN-induced liver tumours. 
ATP, Adenosine triphosphate; GO, gene ontology. 
 
 
Together, these data suggest that in the absence of Trem2 the generation and development 
of HCC in mice is accelerated and is associated with enhanced hepatocyte damage and 
proliferation. In addition, this process can be inhibited by an antioxidant diet, providing 












GO:0005783~endoplasmic reticulum 42.86 1.12E-03 6.37 
GO:0014070~response to organic cyclic compound 21.43 1.24E-03 52.16 
GO:0006631~fatty acid metabolic process 21.43 4.61E-03 26.75 
GO:0016491~oxidoreductase activity 28.57 7.19E-03 8.89 
GO:0055114~oxidation-reduction process 28.57 8.89E-03 8.23 
GO:0016020~membrane 71.43 1.42E-02 2.01 
GO:0010243~response to organonitrogen compound 14.29 1.52E-02 120.95 
GO:0005739~mitochondrion 35.71 2.20E-02 4.08 
GO:0005743~mitochondrial inner membrane 21.43 2.61E-02 10.89 
GO:0046034~ATP metabolic process 14.29 2.62E-02 69.55 







Oxidoreductase 28.57 5.15E-03 10.14 
Endoplasmic reticulum 28.57 1.74E-02 6.5 
Lipid metabolism 21.43 2.30E-02 11.66 
Acetylation 42.86 2.44E-02 3.11 




R.3.5 HCC cell line spheroid growth is inhibited by TREM2 overexpressing HSC 
supernatant  
With the idea of translating our in vivo results to an in vitro system, we decided to perform 
gain of function experiments. As TREM2 is mainly expressed in non-parenchymal liver 
cells, is significantly induced during HSC activation (Figure R.4) and it is well 
established that activated HSCs infiltrate the tumour stroma, secrete ECM proteins and 
favour HCC tumourigenicity potentially through changes in their secretory phenotype 
(49, 228, 229). We decided to evaluate the impact of HSC expressed TREM2 as a 
potential regulator of HCC growth and translate these findings to the human situation by 
developing a humanized 3D spheroid model. Such models have proved to be invaluable 
for studying the interactions between cancer cells and their surrounding environment 
(230, 231). For that, first we confirmed TREM2 overexpression in LX-2 cells at mRNA 





Figure R.37. TREM2 overexpression in the human LX-2 HSC cell line. Human LX-2 cells 
were transfected with a control or TREM2 overexpressing plasmid and 24 hours post-transfection 
(A) TREM2 mRNA and (B) TREM2 protein levels were determined. Parametric Student’s T test 
was used. Data represent mean ± SEM and, *, **** denote a P value of <0.05 and <0.0001, 
respectively versus control plasmid LX-2 cells. AU, arbitrary units; GAPDH, glyceraldehyde 3-









Next, the role of TREM2 in the crosstalk between HSCs and HCC tumour cells was 
investigated in vitro. For that, we overexpressed TREM2 in the human HSCs cell line LX-
2 and carried out culture hanging droplet liver cancer spheroid growth experiments. 
Strikingly, the supernatant of TREM2 overexpressing LX-2 cells markedly reduced the 
3-dimentional HCC (i.e., Hep3B and PLC/PRF5 HCC cell lines) spheroid growth in vitro 
compared to control conditions (media from LX-2 cells transfected with a control vector) 




Figure R.38. HCC spheroid growth is inhibited in presence of TREM2 overexpressing LX-
2 supernatant. (A) Hep3B or (B) PLC/PRF5 cells were seeded in hanging droplets for 7 days 
forming spheroids. Then, spheroids were treated with LX-2 supernatant (LX-2 overexpressing a 
control plasmid or TREM2 plasmid) and spheroid size was recorded (20X). Non-parametric 
Mann-Whitney test was used. Data represent mean ± SEM and ***, **** denote a P value of 
<0.001 and <0.0001, respectively versus control LX-2 supernatant. AU, arbitrary units; OE, 
overexpression; TREM2, triggering receptor expressed on myeloid cells 2. 
 




In view of these data, we next decided to perform the gene transcription analysis of key 
pro-inflammatory and HCC growth-related mediators in control or TREM2 
overexpressing LX-2 cells. mRNA levels of TNF and MCP1 were downregulated in 
TREM2 overexpressing LX-2 cells compared to controls (Figure R.39A). We also 
verified these data by ELISA in the supernatant of LX-2. (Figure R.39B). In addition, 
the Wnt/β-catenin pathway plays a major role in cancer and particularly in HCC (232, 
233), in this regard, TREM2 has been shown to modulate this pathwayin other cellular 
systems including the bone and brain (234, 235), we next decided to determine the 
potential effects of TREM2 on WNT signaling and HCC growth. Therefore, we checked 
for WNT ligand expression in control or TREM2 overexpressing LX-2 cells and observed 
that the canonical WNT ligands WNT3, WNT7A and WNT8A were downregulated upon 
TREM2 overexpression (Figure R.39C).  
 
Figure R.39. Gene expression analysis in TREM2 overexpressing LX-2 cells. (A) mRNA 
levels of TNF and MCP1 in cell extracts and (B) protein levels of TNF and MCP1 in the cell 
supernatant by ELISA were determined. (C) The mRNA levels of canonical WNT ligands WNT3, 
WNT7A and WNT8A were determined. Parametric Student’s T test and non-parametric Mann-
Whitney test were used. Data represent mean ± SEM and *, **, **** denote a P value of <0.05, 
0.01 and <0.0001, respectively versus control plasmid LX-2 cells. AU, arbitrary units; MCP1, 
monocyte chemoattractant protein 1; OE, overexpression; TNF, tumour necrosis factor; TREM2, 
triggering receptor expressed on myeloid cells 2. 




To mechanistically prove whether TREM2 mediated effects in HCC spheroid growth 
were Wnt/β-catenin pathway dependent, HCC spheroids were treated with the β-catenin 
inhibitor IWR-1. Consistent with the HSC expression of WNT ligands, HCC spheroid 
growth was dependent on Wnt/β-catenin signalling as it was substantially reduced upon 
IWR-1 treatment under control conditions (Figure R.40A). Notably, as these ligands 
were attenuated upon TREM2 overexpression (Figure R.39C), HCC spheroid growth 
attenuation in the presence of TREM2 overexpressing HSC supernatant was abolished 
upon IWR-1 treatment (Figure R.40A). These data suggest that TREM2 expression 
within HSCs attenuates HCC growth through Wnt/β-catenin signalling. To confirm this 
hypothesis we next blocked WNT ligand secretion in both sets of HSCs and could observe 
that blocking WNT ligand secretion abolished the differences associated with TREM2 
overexpression (Figure R.40B). Additionally, to rule out direct autocrine effects of IWP-
2 inhibitor treatment in the HCC spheroid growth, we directly added this inhibitor to 
spheroids. Of note, in presence of IWP-2 inhibitor, spheroid growth was still inhibited by 
TREM2 overexpressing LX-2 media compared to control plasmid overexpressing LX-2 
media (Figure R.40B).  
Thus, we demonstrate that TREM2 reduces HCC spheroid growth in vitro via HSC 
paracrine secretion of WNT ligands. 
 
 






Figure R.40. TREM2 effects in HCC spheroid growth are mediated by LX-2 WNT ligand 
paracrine secretion. (A) Hep3B cells were treated with the Wnt/β-catenin inhibitor IWR-1 and 
(B) LX-2 cells or Hep3B spheroids were treated with the WNT ligand secretion inhibitor IWP-2, 
Hep3B spheroids were incubated in LX-2 conditioned media and spheroid growth was recorded. 
Parametric Student’s T test and non-parametric Mann-Whitney test were used. Data represent 
mean ± SEM and ** and **** denote a P value of <0.01 and <0.0001 respectively. AU, arbitrary 
units; n.s, non-significant; OE, overexpression; TREM2, triggering receptor expressed on myeloid 









































































Unresolved inflammation is a pathogenic feature of liver disease occurring after chronic 
liver injury that contributes to liver damage and fibrosis. During liver injury, alterations 
in the intestinal permeability occur and cause the leakage of pathogens from the gut to 
the liver. In the liver, microbial molecules, also known as PAMPs, are recognized by non-
parenchymal liver cells and recruited cells, among others. In turn, these cells release a 
diverse array of pro-inflammatory mediators, such as cytokines, chemokines and ROS, 
contributing to hepatocyte damage and death.  
In line with this dogma, treatment of mice with antibiotics or probiotics attenuates 
various forms of liver injury including CCl4, BDL and non-alcoholic steatohepatitis 
(NASH) (64, 146). Further, illustrating the importance of innate immunity during liver 
disease, mice deficient in key mediators of LPS signaling such as TLR4, CD14 and 
Myd88 are protected from different types of liver disorders (64, 146, 147, 236, 237) and 
cancer (145, 238). In addition, other members of TLR family such as TLR9 also play an 
important role liver disease, as TLR9 has been shown to promote steatohepatitis and HCC 
(237, 239). 
Here, with the hypothesis that TREM2 could modulate TLR-mediated signaling in 
the liver and be involved in liver disease, we studied the role of this receptor during the 
progression of liver disease, from acute liver injury to chronic liver disease and the 
development of HCC.  
 
 
D.1 Role of TREM2 in liver injury 
In this work, we have shown that TREM2 expression significantly increases during liver 
injury both in humans and mice. Human TREM2 expression was augmented in cirrhotic 
patients compared to healthy controls and mouse Trem2 expression was induced during 
both acute and repetitive CCl4 injury and BDL. We have also demonstrated that hepatic 
mouse Trem2 is expressed on non-parenchymal liver cells, KCs and HSCs. However, 
with our data we cannot exclude that in other species, including humans, TREM2 is not 
expressed in other cell types such us hepatocytes during liver injury. Importantly, 
although TREM2 expression was reported on different resident macrophages, including 
KCs, (151, 184, 192, 209) this is the first time demonstrating that TREM2 is expressed 
on quiescent and activated HSCs, which goes in line with previous studies showing that 
TREM1 is also expressed on HSCs (164). In addition, we show that TREM2 is 




dramatically induced during HSC activation, both in vivo after acute or chronic liver 
injury and during HSC transdifferentiation in vitro. Importantly, the upregulation of 
TREM2 expression during the activation of HSCs in vitro is conserved on different 
species, as shown in mouse, rat and human HSCs.  
However, TREM2 did not impact the activation status of HSCs in vitro, as shown 
by undetectable differences in Acta2 and α1(I)procollagen mRNA levels in WT and 
Trem2-/- HSCs. These data suggest that TREM2 does not directly regulate the production 
of collagen. In agreement with no effects on collagen synthesis, during chronic liver 
injury, WT and trem2-/- mice displayed equal levels of TGF, a key mediator of fibrosis 
and a potent stimulus for collagen production (43, 240). Interestingly, Mmp13 was 
elevated in Trem2-/- mice after chronic liver injury. Of note, this matrix metalloproteinase 
plays a crucial role in fibrosis resolution (241), indicating that upregulation of Mmp13 in 
Trem2-/- mice may serve to attenuate liver fibrosis in these mice. Of note, TREM2 has 
been described as a phagocytic receptor that promotes clearance of bacterial cells and 
apoptotic bodies (63, 242, 243). Even though HSCs are not professional phagocytes, 
phagocytosis of apoptotic bodies by HSCs has been described and associated with HSC 
activation, survival and collagen deposition (187, 188, 190, 192). Therefore, impaired 
bacterial and apoptotic body clearance by Trem2-/- HSCs could also contribute to the 
absence of differences in fibrosis observed between WT and Trem2-/- mice after chronic 
CCl4 injury.  
Importantly, our data suggest that TREM2 inhibits hepatocellular injury primarily 
though the inhibition of inflammation. As it was previously reported in BMDMs (184), 
we have shown that TREM2 dampens TLR4-derived pro-inflammatory cytokine 
regulation in KCs and HSCs. Moreover, consistent with previous studies (185, 188), 
inflammation in Trem2-/- KCs correlates with TLR4-mediated effects on ERK activation 
and an absence of effects in NF-κB pathway. Besides the effects on classic pro-
inflammatory cytokine expression, including Il1b, Il6 and Tnf, we have also demonstrated 
a pivotal role of TREM2 negatively regulating the neutrophil chemoattractant chemokine 
Cxcl1 expression. In agreement with this, during acute CCl4-mediated injury, Trem2
-/- 
mice displayed elevated liver injury and increased expression of Cxcl1 compared to WT 
mice. This correlated with an elevated number of recruited neutrophils in Trem2-/- mice 
compared to WT mice. These observations are in line with other studies showing 
differences in neutrophil recruitment on Trem2-/- mice during pneumococcal infections 
(192). Likewise, after APAP challenge, increased neutrophil influx to the liver was also 




observed in Trem2-/- mice compared to WT mice. However, in this model unlike in acute 
CCl4-mediated injury, liver macrophage content was also elevated on Trem2
-/- mice. 
Therefore, even though the relative contribution of each cell population to the models 
studied remains to be elucidated, we have demonstrated that i) TREM2 dampens liver 
injury in our models ii) gut-derived PAMPs are a driver for acute liver injury of Trem2-/- 
mice iii) After APAP lethal challenge Trem2-/- mice have a worsened survival outcome 
(Figure D.1). 
In terms of mechanistic parallels between chronic CCl4 injury and acute APAP 
challenge, both models are characterized by augmented Mcp1 levels in Trem2-/- mice 
compared to WT mice, which is associated with increased macrophage content. In 
addition, in both models Trem2-/- mice exhibit more liver damage and increased lipid 
peroxidation. As mentioned, resident KCs have their origin in the yolk sac and/or in the 
foetal liver, however, during liver injury, circulating monocytes (Ly6C+) are recruited to 
the liver by the MCP1 chemokine, and can contribute to injury (117-119). Interestingly, 
it has been reported that after APAP challenge, monocyte-derived macrophages are 
recruited to the liver and exert pro-inflammatory functions promoting liver injury. Hence, 
the reduction of monocyte recruitment via MCP1/CCR2 inhibition diminishes APAP-
induced liver injury (244). Taken together, all these data point out that monocyte 
recruitment after hepatotoxic damage perpetuates parenchymal damage. In fact, there are 
studies supporting the concept that KCs are protective in APAP-induced liver injury in 
mice (133). With our data we add new information in this context emphasizing on the key 
role that TREM2 signalling plays suppressing the recruitment of macrophages to the liver 
and consequently reducing APAP-induced liver injury (Figure D.1).  
Importantly, our data indicate that TLR4-dependent MCP1 production is inhibited 
by TREM2 in HSCs, which is associated with decreased macrophage recruitment to the 
liver. Moreover, ROS production is decreased by TREM2 in bone-marrow-derived 
macrophages and this may explain ROS-mediated increased lipid peroxidation and cell 
death in Trem2-/- mice. However, inhibition of ROS production in recruited macrophages 
by TREM2 might not be sufficient to dampen liver injury, as seen in the BM transplant 
experiment, where WT mice reconstituted with Trem2-/- BM cells do not display more 
liver damage compared to WT mice reconstituted with WT BM. Rather, our data points 
towards an important role of TREM2 in HSCs where it regulates the recruitment of 
macrophages to the liver via its effects on MCP1 production in a TLR4-dependent manner 
which is also influenced by ROS and cytokine production from the infiltrating immune 




cells. Accordingly, liver steatosis is able to sensitize CCl4 hepatotoxicity, partly through 
oxidative stress (245). In addition, purified Cd11b+F4/80+Ly6C+ cells from CCl4 treated 
mice can directly activate HSCs, showing more evidences of this cross-talk between 
HSCs and infiltrating cells in liver injury (40). Of note, infiltrating inflammatory Ly6C+ 
macrophages decrease the expression of Ly6C after the uptake of apoptotic hepatocytes 
which is protective in alcohol induced liver injury (246). Even though the nature of the 
infiltrated macrophages in our model needs to be further studied, they seem to play an 
important role for TREM2 limiting the hepatocellular damage after APAP and chronic 
CCl4 injury. Besides, in a context of liver injury, hepatocytes release DAMPS that can 
further enhance cell death, inflammation and macrophage content (224). Such a 
hepatotoxic feed forward loop could happen in the absence of TREM2, explaining the 
enhanced liver damage in Trem2-/- livers after acute APAP and chronic CCl4 injury. Even 
more, other mechanisms such as the effect of TREM2 on liver lipid metabolism may play 
an important role too. In this sense, recent studies have shown that TREM2 is able to 
sense lipids and to alter lipid metabolism and purogenic signalling in the brain (189, 247). 
Importantly, highlighting the role of TREM2 in lipid metabolism, it was reported that 
TREM2 promotes adipogenesis, as mice overexpressing TREM2 fed with a high fat diet 
were more obese and developed more steatosis (248). Even though the authors of this 
study did not extensively address TREM2-mediated liver injury effects in these mice, the 
role of TREM2 in NAFLD-mediated liver injury seems to be complex, involving not only 
effects related to the immune system but also adipogenic and lipid regulatory functions 
(189, 248) (Figure D.1). 
In conclusion, we demonstrated a role of TREM2 attenuating toxic liver injury that 
goes in line with published results in other organs and tissues. As in the colon, where it is 
important for the wound-healing process (203) or in the brain were TREM2 is key in the 
uptake of apoptotic neurons and in limiting microglial inflammation (187, 188).  
In summary, we believe that TREM2 could be an attractive target to promote the 




D.2 Role of TREM2 in liver regeneration after partial hepatectomy 
The regenerative mechanisms are activated in the liver after a liver injury or a hepatic 
parenchymal mass loss. Due to the fact that TREM2 plays an important role in acute and 




chronic liver injury we decided to formally investigate the role of TREM2 in the context 
of liver regeneration after PHx. 
 In the early phases of liver regeneration after PHx, the expression of TNF and IL6 
is increased. These inflammatory mediators are mainly produced by KCs and HSCs (26, 
100). Of note, we show that after PHx, the levels of Il6 and Tnf are upregulated in the 
Trem2-/- mice compared to WT mice during the priming phase, suggesting that 
inflammation after PHx is abnormally high in these mice. This was also accompanied 
with an upregulation of the hepatocyte proliferative factor Hgf 6 hours after PHx. 
Accordingly, hepatocyte proliferation was enhanced 72 hours after PHx in Trem2-/- mice 
(Figure D.1).  
Thus, liver regeneration after PHx is accelerated in Trem2-/- mice, which was 
associated with an enhanced inflammation during the priming phase and augmented 
















D.3 Role of TREM2 in HCC 
HCC often arises in a setting of chronic liver injury caused by different aetiologies. 
Chronic liver injury is characterized by an enhanced inflammation, ROS production, 
DNA damage, hepatocyte death and necrosis. Consequently, compensatory proliferation 
of hepatocytes and liver progenitor cells is triggered, which may finally result in the 
development of HCC (75). Among other factors, gut-liver axis and bacterial translocation 




are known to be involved in the progression of liver disease and HCC development (135). 
However, the molecular mechanisms that fine-tune the innate immune response involved 
in the negative regulation of the inflammatory response in the liver are still unknown and 
need to be studied in order to develop new therapeutic strategies for therapy.  
Even though the role of TREM2 in several human disorders is being uncovered 
(151), there are only few studies that have started to shed light on the impact of TREM2 
in cancer (204, 206, 207, 249). Thus, the role of this receptor in cancer is still largely 
unknown and regarding HCC, it needs to be fully elucidated. Here, we report novel data 
indicating that TREM2 in non-parenchymal cells functions as a natural brake on liver 
inflammation, regulating hepatocyte proliferation and damage, and consequently 
regulating HCC development and growth. 
As aforementioned, TREM2 is induced in cirrhotic patients compared to controls 
and that its expression correlated with markers of inflammation and its absence in murine 
models of liver injury was associated to increased liver damage and inflammation. These 
observations were also observed in HCC, since TREM2 expression is also elevated in 
HCC patients compared to controls, correlating with inflammatory markers. In addition, 
experimental mouse models of hepatocarcinogenesis carried out in WT and Trem2-/- mice 
have demonstrated that Trem2-/- mice present a worsened liver phenotype, in terms of 
presenting higher number of tumours, increased liver damage and inflammation. 
Considering that HCC is a clear example of an inflammation-related cancer, as it usually 
arises and develops in a context of chronic liver inflammation (82) and that TREM2 is 
preferentially expressed in non-parenchymal cells within the liver, where it acts as a 
natural brake on inflammation during acute and chronic hepatotoxic injury, we believe 
that the upregulation of TREM2 in HCC tissue is due to an accumulation of inflammatory 
cells in the liver, such as KCs and HSCs. We therefore postulate that TREM2 is 
upregulated during unresolved inflammation which is present during HCC in an attempt 
to counteract this inflammatory process. 
The administration of the carcinogenic drug DEN inflicts death of hepatocytes 
which in turn results in enhanced proliferation of the intact hepatocytes (250). In this 
regard, TREM2 is able to protect from DEN-induced HCC as its absence enhances 
proliferation and DNA damage in hepatocytes. In other means, when DEN is 
administered 15 days after birth, Trem2-/- mice develop more and bigger liver tumours, 
both 30 and 40 weeks post-DEN injection. Accordingly, upon acute DEN administration, 
Trem2-/- mice exhibit increased number of damaged hepatocytes. Interestingly, this goes 




in line with the results observed with the pro-inflammatory receptor TREM1. This 
receptor has been described to perform opposed functions to TREM2 (151) and is 
detrimental in HCC development, as Trem1-/- mice develop less liver tumours after DEN 
injection (163).  
In addition, we observed increased pro-inflammatory gene (Tnf) and chemokine 
(Mcp1 and Cxcl1) expression in the early phases after acute DEN administration. 
Furthermore, augmented transcript levels of the oxidative stress enzyme Hmox1 and 
increased ROS levels were found in Trem2-/- liver tissues. Therefore, our results suggest 
that Trem2-/- mice display increased inflammation and ROS levels after DEN injury, 
which in turn, may help in the initiation and progression of HCC in these mice (Figure 
D.1). 
Antioxidant intake has been postulated to overcome incipient carcinogenic 
processes. However, there is some controversy regarding the beneficial effects 
antioxidants may produce (251, 252) as they may promote the development of already 
formed tumours (253). Moreover, the balance between ROS and antioxidants needs to be 
optimal and the addition of antioxidants should be considered only in certain patients who 
may show beneficial effects due to high levels of oxidative stress and inflammation (253). 
In this regard, the use of antioxidant diets in mice has been shown to inhibit DEN-
mediated hepatocarcinogenesis by reducing ROS and ROS-mediated DNA damage (90, 
227). Considering that HCC is an inflammation-related cancer we decided to administer 
a diet supplemented with the antioxidant BHA in DEN-injected mice. This way we could 
test if lowering the levels of ROS would also lower the number of tumours in Trem2-/- 
mice to the same levels of WT mice. Indeed, tumour number in both genotypes decreased 
to the same level, indicating that TREM2 might protect from DEN-induced liver 
tumourigenesis by lowering the levels of ROS and inflammation. Of note, this diet was 
administered when the tumours were starting to develop (i.e. 15 weeks after DEN 
administration) and maintained until mice were sacrificed after 30 weeks of DEN 
injection. These results suggest that the activation of TREM2 in a setting of advanced 
chronic liver disease could be beneficial for patients with HCC. 
On the other hand, to study the impact of TREM2 in HCC growth in vitro, we carried 
out sophisticated hanging droplet HCC spheroid growth experiments with the supernatant 
of TREM2 overexpressing HSCs. Of note, the conditioned media of TREM2 
overexpressing HSCs inhibited the growth of HCC spheroids compared to controls and 
this event was associated with a reduction in the expression levels of TNF, MCP1 and 




Wnt ligands. Interestingly, TREM2 reduces HCC tumourigenicity via paracrine 
mechanisms within HSCs that rely on Wnt signalling. Altogether, we believe that TREM2 
inhibits inflammation, proliferative responses as well as HCC development and growth, 
which is indicative of a protective role of this receptor in HCC (Figure D.1).  
In summary, this study provides novel insights into the important role of TREM2 in 
HCC. The tumorigenic drug DEN damages the hepatocytes causing mutations, 
inflammation and ROS. This is exacerbated in the absence of Trem2 leading to hepatocyte 
DNA damage and proliferation, finally leading to increased liver tumourigenesis. In 
addition, liver regeneration is exacerbated in Trem2-/- mice. Taken together, non-
parenchymal TREM2 is able to attenuate hepatocyte damage inhibiting ROS and 
inflammation, protecting the liver from hepatocyte proliferative responses, and the 
development of HCC.  
In conclusion, TREM2 arises as a potential therapeutic target for HCC. Hence, in 
this regard it is important to describe and find TREM2 agonists that might have a 
significant impact on inflammation-driven cancer in humans. Altogether, these results 
provide pivotal findings about the key role of TREM2 in hepatocarcinogenesis, paving 
the way for new clinical strategies for HCC patients. 
 






Figure D.1. Relevance of TREM2 in the liver disease. After liver injury, in the absence of 
Trem2, hepatocyte damage and death are increased. This is associated with increased ROS 
production, augmented cytokine, chemokine, growth factor and WNT ligand expression and DNA 
damage. In addition, immune cell recruitment is enhanced and ROS production in the absence of 
TREM2 in BMDMs is increased which is associatedwith an increased lipid peroxidation. On the 
other hand, during liver regeneration, in the absence of Trem2, increased inflammatory marker 
and growth factor expression is observed, which is in line with enhanced hepatocyte proliferation. 
The pro-inflammatory microenvironment may favour the appearance of mutations in the 
proliferating hepatocytes, promoting their transformation and the development of HCC. BMDMs, 
bone marrow derived macrophages, CXCL1, C-X-C motif ligand 1; DAP-12, DNAX-activation 
protein 12; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; IL, interleukin; LPS, 
lipopolysaccharide; MCP1, monocyte chemoattractant protein 1; ROS, reactive oxygen species; 





































































1. TREM2 expression is upregulated in cirrhotic livers of various aetiologies 
compared to healthy controls in humans. 
2. TREM2 is expressed on non-parenchymal liver cells (KCs and HSCs) and is 
induced during diverse forms of liver injury in mice, including acute and chronic 
CCl4-induced liver injury and BDL-induced cholestatic liver injury models.  
3. Trem2-/- mice exhibit increased liver damage and inflammation during acute and 
chronic CCl4 treatment and APAP intoxication. 
4. Effects of TREM2 in the context of chronic liver injury are dependent on both 
liver resident and infiltrating immune cells. 
5. TREM2 promotes survival during drug-induced liver injury, upon APAP 
challenge. 
6. KCs and HSCs that are deficient for Trem2 display increased pro-inflammatory 
cytokine and chemokine production upon TLR4 stimulation. 
7. TREM2 attenuates hepatic inflammation, liver injury and lipid peroxidation 
during APAP-induced acute and CCl4-induced chronic liver injury. Effects of 
TREM2 on hepatic lipid peroxidation in these mouse models are associated with 
macrophage content and ROS production within infiltrating macrophages. 
8. Liver regeneration following PHx is accelerated in the absence of Trem2 through 
increased pro-inflammatory and growth-factor gene expression during the 
priming phase.  
9. TREM2 expression is induced in human HCC and its expression correlates with 
markers of inflammation. 
10. Trem2 is upregulated in DEN-induced HCC in mice. Trem2-/- mice exhibit 
increased liver tumourigenesis that is mediated by an enhanced hepatocyte DNA 
damage and proliferation.  
11. The role of TREM2 in liver tumorigenesis is associated with protective effects in 
the early phases of HCC development after acute DEN challenge. These effects 
are linked with an attenuation of liver damage, inflammation and oxidative stress. 
12. Enhanced liver carcinogenesis in the absence of Trem2 can be inhibited by an 
antioxidant diet. 




13. The supernatant of TREM2 overexpressing HSCs halts HCC spheroid growth in 
vitro in a Wnt/β-catenin dependent manner. 
 
Therefore, TREM2 arises as a promising therapeutic target to tackle acute liver injury, 













































SUMMARY IN SPANISH 















El hígado es un órgano vital y funcionalmente complejo y tiene un papel fundamental en 
la homeostasis metabólica del organismo. Además de participar en la síntesis, transporte 
y almacenamiento de una gran variedad de sustancias y hormonas, tiene una función muy 
importante en la detoxificación de compuestos que llegan desde el torrente sanguíneo a 
través de la vena porta (2). Por ello, el hígado se encuentra expuesto a diversos agentes 
potencialmente lesivos que participan en la progresión del daño hepático. Entre los 
factores etiológicos se incluyen la infección por los virus de la hepatitis B o C (HBV o 
HCV), el alcohol y otros tóxicos, respuestas inmunes exacerbadas, la esteatohepatitis no 
alcohólica (NASH) y determinadas alteraciones genéticas entre otros (19). 
Al inicio de la lesión hepática la muerte de la célula parenquimal del hígado, el 
hepatocito, desencadena una respuesta inflamatoria con el objetivo de reparar el tejido 
dañado. La inflamación juega un papel esencial tanto en los procesos de regeneración 
como de cicatrización. (26, 28). Tras un daño hepático, uno de los eventos iniciales en 
respuesta al daño es la regeneración hepática. En este sentido, las células de Kupffer 
(KCs) juegan un papel muy importante secretando mediadores inflamatorios y factores 
de crecimiento para promover la proliferación hepatocitaria (25). Además de la 
proliferación hepatocitaria, también es necesario restaurar la estructura hepática, para lo 
cual se precisa de la participación de las células estelares hepáticas (HSCs), que son las 
responsables de remodelar la matriz extracelular (ECM) (39). 
Estos procesos de regeneración hepática y cicatrización son procesos fisiológicos 
que se activan en respuesta al daño para una correcta reparación y cicatrización del hígado 
tras una lesión. Sin embargo, si la lesión hepática persiste en el tiempo y cronifica, se 
desarrolla una hepatitis crónica, en la cual el tejido hepático es progresivamente sustituido 
por tejido fibroso, desarrollándose así la fibrosis hepática (39). Además, si este proceso 
se mantiene en el tiempo, puede desarrollarse la cirrosis hepática, en la cual la estructura 
hepática se pierde y la función hepática se ve comprometida. Cabe destacar que la cirrosis 
hepática es el contexto ideal para el desarrollo de diversas complicaciones, tales como 
fallo renal, ascitis, encefalopatía hepática, fallo hepático agudo y finalmente, el desarrollo 
del carcinoma hepatocelular (HCC) (94). Por lo que la progresión del daño hepático 
sucede por una cronificación de los mecanismos de regeneración y cicatrización hepática. 
 El HCC es el tumor primario más común del hígado, representa el sexto cáncer 
más común y el tercero que más muertes causa a nivel mundial (76). El desarrollo del 




HCC está estrechamente asociado a cirrosis, ya que el 80% de los HCC se desarrollan en 
el contexto de una cirrosis hepática (78). Además, el HCC presenta una elevada 
quimioresistencia, y los tratamientos actuales muestran una eficacia modesta (75), por lo 
que es necesario la búsqueda de nuevas dianas terapéuticas para el desarrollo de nuevas 
terapias para el HCC. 
Recientemente se ha demostrado el papel que juegan la flora bacteriana y los 
receptores tipo Toll (TLRs) en la patogénesis de la fibrosis (52). El sistema inmune innato 
reconoce los microorganismos a través de un número limitado de receptores conocidos 
como receptores de reconocimiento de patrones (PRRs). Estos receptores, concretamente 
los TLRs, parece ser que tienen un papel central en la relación entre el sistema inmune y 
los agentes infecciosos. Los TLRs que están presentes en las células del sistema inmune 
innato pueden ser activados por macromoléculas liberadas por virus o bacterias (PAMPs 
o patrones moleculares asociados a patógenos) y provocar la producción de citoquinas. 
Los pacientes con cirrosis hepática presentan niveles elevados de lipopolisacárido (LPS) 
en la vena porta. La elevación de la presión portal puede dañar la mucosa intestinal y 
comprometer su función de barrera desencadenando la translocación bacteriana. El LPS 
derivado de la flora intestinal es un gran candidato como ligando de TLR4 en las KCs 
durante la fibrosis hepática (148) y un trabajo reciente ha demostrado que en las HSCs 
puede ser incluso más importante (64). Mediante la utilización de aproximaciones 
genéticas y moleculares se ha demostrado que el LPS a través de TLR4 es capaz de 
aumentar la actividad fibrogénica de transforming groth factor β (TGF β) en las HSCs 
(64). Los TLRs funcionan tanto como reguladores clave para el desarrollo de la fibrosis 
hepática como para el desarrollo del HCC puesto que modulan tanto funciones 
inflamatorias como fibrogénicas en las células hepáticas no parenquimales (KCs y HSCs) 
(64, 145). Sin embargo, hasta el momento se desconoce cuáles son los factores que tanto 
de forma positiva como negativa pueden estar regulando la función de estos TLRs. En 
este trabajo se pretenden dilucidar aspectos claves de la regulación de los TLRs.  
En el año 2000, se descubrió la familia de los receptores TREM (triggering receptor 
expressed on myeloid cells), receptores que a través de la interacción ("cross-talk") 
positiva o negativa con los TLRs regulan la respuesta inmune. En términos generales, 
TREM1 se ha definido como un receptor que amplifica la respuesta inmune, mientras que 
TREM2 parece tener un papel en la regulación negativa de la inflamación mediada por 
TLR4 (151). En la actualidad se desconoce cuál puede ser el ligando que pueda activar 
estos receptores. Hasta el momento, existen datos en relación al posible papel que TREM1 




pueda tener como modulador positivo de la hepatocarcinogénesis (163), sin embargo no 
se conoce el papel que el receptor TREM2 pueda desempeñar en la progresión del daño 





























OBJETIVOS E HIPÓTESIS 
 




Debido a que TREM2 juega un papel importante en varios tipos de daño, el interés de 
este estudio está centrado en el análisis del posible papel del receptor TREM2 en el 
hígado. Por lo cual, postulamos la hipótesis de que el receptor TREM2 puede jugar un 
papel importante en la regulación del daño hepático agudo y crónico, en la regeneración 
hepática y en el desarrollo del HCC. Para ello se han planteado los siguientes objetivos: 
 
1. Determinación del papel del receptor TREM2 en el daño hepático. 
1.1. Estudio de la expresión génica del receptor TREM2 en muestras de hígado 
procedentes de pacientes control y pacientes cirróticos, así como en modelos 
experimentales murinos de daño hepático agudo y crónico.  
1.2. Determinación de la expresión y función de TREM2 en los distintos tipos 
celulares del hígado, tales como hepatocitos y células no parenquimales (KCs y 
HSCs). 
1.3. Evaluación de la contribución del receptor TREM2 en el desarrollo del daño 
hepático crónico. 
1.4. Estudio del papel de TREM2 en el daño hepático agudo. 
1.5. Determinación de los mecanismos moleculares por los que TREM2 media sus 
efectos en el daño hepático. 
 
2. Estudio de la contribución del receptor TREM2 en la regeneración hepática. 
2.1. Caracterización del posible papel de TREM2 en el proceso regenerativo hepático 
y en la proliferación del hepatocito. 
 
3. Evaluación del papel del receptor TREM2 en el desarrollo del HCC. 
3.1. Análisis de la expresión génica de TREM2 en muestras de hígado de pacientes 
control y de pacientes con HCC y su correlación con marcadores de inflamación 
y fibrosis. 
3.2. Estudio del papel del receptor TREM2 en el proceso de hepatocarcinogénesis. 
3.3. Determinación de los mecanismos moleculares por los que TREM2 regula el 
proceso hepatocarcinogénico. 
 
MATERIALES Y MÉTODOS 
 




Expresión génica del receptor TREM2 en muestras de tejido hepático de individuos 
control, pacientes con cirrosis y HCCs 
La expresión de TREM2 se analizó tanto a nivel de mRNA como a nivel de proteína en 
muestras de tejido hepático sano, así como en muestras cirróticas y HCCs. Para ello se 
utilizaron muestras de pacientes que fueron obtenidas a través del Biobanco Vasco. Este 
estudio fue aprobado por el Comité de Ética de Investigación Clínica de Euskadi (CEIC-
E) y el CEIC del Hospital Universitario Donostia. Además, la expresión de TREM2 en 
muestras de HCC también se analizó en una segunda cohorte de pacientes del repositorio 
web perteneciente al The Cancer Genome Atlas (TCGA).  
El análisis de la expresión génica a nivel de mRNA se llevó a cabo mediante PCR a 
tiempo real. Asimismo, la expresión de TREM2 a nivel de proteína fue analizada 
mediante mediante inmunohistoquímica (IHC).  
 
Modelos experimentales murinos de daño hepático agudo y crónico, regeneración 
hepática y hepatocarcinogénesis 
Se realizaron varios modelos experimentales en ratones para determinar el papel del 
receptor TREM2 en el daño hepático agudo y crónico, en la regeneración hepática y en 
el desarrollo del HCC. Para ello, utilizamos ratones nulos para Trem2 (Trem2-/-) y los 
correspondientes ratones salvajes. Todos los procedimientos fueron aprobados por los 
comités éticos de experimentación animal (CEEA) del Instituto de Investigación 
Biodonostia y por el comité de uso y cuidado animal de la Medical University of Viena 
y el Ministerio de Ciencia de Austria. 
 
Modelos de daño hepático agudo y crónico inducido por la administración tetracloruro 
de carbono (CCl4) y acetaminofeno (APAP) 
Los modelos de daño hepático agudo y crónico se realizaron en ratones salvajes y ratones 
Trem2-/- de 8 semanas de vida. Para el modelo de daño hepático agudo inducido por la 
administración de CCl4 utilizamos una dosis de 2 μl/g (CCl4:aceite de oliva a una relación 
1:1 [vol:vol]), mientras que para llevar a cabo un modelo de daño hepático crónico 
administramos el CCl4 a una dosis de 2 μl/g (CCl4:aceite de oliva a una relación 1:3 
[vol:vol]), dos veces por semana, durante 8 semanas. Además, se realizó un modelo de 
trasplante de médula ósea en ratones salvajes y Trem2-/-, de esta manera se generaron 




ratones salvajes reconstituidos con médula ósea de ratones salvajes, ratones Trem2-/- 
reconstituidos con médula ósea de ratones Trem2-/- y ratones quiméricos. Además, a estos 
ratones se les indujo un daño crónico mediante la administración de CCl4, tal y como se 
ha descrito previamente. Asimismo, también llevamos a cabo un modelo en el que 
eliminamos la flora bacteriana intestinal de los ratones a través de la administración de 
un cóctel de antibióticos en agua de bebida durante 4 semanas y posterior administración 
aguda de CCl4 a una dosis de 2 μl/g (CCl4:aceite de oliva a una relación 1:1 [vol:vol]). 
Como otro modelo alternativo de daño hepático agudo, administramos APAP a una 
dosis de 300 mg/kg en ratones salvajes y Trem2-/-. Además, también realizamos un 
modelo de fallo hepático agudo. Para ello, administramos una dosis letal de APAP (750 
mg/kg) a ratones salvajes y nulos para Trem2 y monitorizamos la supervivencia de los 
ratones durante 72 horas.  
 
Modelo de regeneración hepática 
Para estudiar la posible participación de TREM2 en los procesos de regeneración 
hepática, se llevó a cabo un modelo de regeneración hepática tras hepatectomía parcial 
(PHx) en ratones salvajes y Trem2-/- en los que se realizó una resección del 70% del 
hígado. 
 
Modelo de carcinogénesis inducida por dietilnitrosamina (DEN)  
Se desarrolló un modelo experimental de tumorigénesis in vivo en ratones salvajes y 
Trem2-/- inducido por la administración del carcinógeno DEN a una dosis de 30 mg/kg. 
El modelo consiste en una única administración del carcinógeno, a los 15 días de vida del 
ratón, y posterior sacrificio a las 30 o 40 semanas tras la administración de DEN. Además, 
se llevó a cabo un modelo de hepatocarcinogénesis en los que previo al sacrificio tras 30 
semanas de la administración de DEN se administró una dieta suplementada con el 
antioxidante hidroxianisol butilado (BHA) durante 15 semanas.  
Para poder dilucidar el papel que TREM2 juega en las fases tempranas del proceso 
carcinogénico se realizó un modelo de daño hepático agudo inducido por la 
administración de una dosis de 100 mg/kg de DEN en ratones salvajes y deficientes para 
Trem2 de 6-8 semanas de edad. Los ratones fueron sacrificados 6, 24, y 72 horas tras la 
administración de DEN. 




Una vez fueron llevados a cabo los modelos in vivo, se procedió al análisis de las 
muestras obtenidas de los ratones. El hígado se dividió en 3 fracciones. Dos de ellas se 
congelaron en nitrógeno líquido para realizar posteriores estudios de expresión génica a 
nivel de mRNA y proteína respectivamente, y la tercera fracción se utilizó para estudios 
histológicos en tejido fijado. Además, se extrajo la sangre de los ratones mediante punción 
cardiaca para analizar los niveles de transaminasas y otros marcadores bioquímicos en el 
suero.  
El análisis de la expresión génica a nivel de mRNA se llevó a cabo tal y como se ha 
descrito previamente (214). 
Las proteínas en estudio fueron detectadas mediante inmunoblot utilizando 
anticuerpos primarios específicos, y posteriormente anticuerpos secundarios conjugados 
con peroxidasa (Sigma-Aldrich). Las bandas de proteína se detectaron utilizando un 
sistema de detección mediante quimioluminiscencia (Amersham, GE Healthcare). 
Para analizar la morfología del parénquima hepático, el daño hepático, así como el 
grado de fibrosis, se realizaron tinciones de Hematoxilina y Eosina (H&E) de Harris 
(Merck), y Rojo Sirio (Sigma-Aldrich) en hígado fijado en formalina y embebido en 
parafina, tal y como hemos descrito previamente (213). Además también se realizaron 
tinciones específicas para marcadores relacionadas con proliferación celular, daño y 
estrés oxidativo mediante IHC tal y como se ha descrito previamente (214). 
Los niveles de especies reactivas del oxígeno (ROS) fueron analizados en lisados de 
tejido hepático de ratones salvajes y Trem2-/-. El lisado fue sonicado e incubado con la 
sonda 2´,7´-diclorodihidrofluorescein diacetato (DCF) (Thermo fisher scientific) durante 
30 min y los niveles de ROS fueron determinados mediante fluorescencia (Fluoroskan 
Ascent®). 
 
Perfusión hepática, aislamiento y tratamiento de células primarias hepáticas 
Las distintas poblaciones celulares del hígado fueron aisladas de ratones salvajes y Trem2-
/-. Los hígados de los ratones fueron perfundidos a través de la vena porta utilizando un 
catéter de 22G-15 mm (BD Insyte). Primeramente, con el objetivo de eliminar las células 
sanguíneas, se perfundió el hígado con una solución salina. A continuación se llevó a 
cabo una digestión secuencial in situ con soluciones que contienen las enzimas pronasa y 
colagenasa (Roche). Finalmente, las distintas poblaciones célulares hepáticas fueron 
aisladas in vitro llevando a cabo una centrifugación en gradiente de densidad con 




Nycodenz (Axis-Shield). Posteriormente, las células fueron tratadas con ligandos que 
activan la señalización mediada por TLRs, como por ejemplo el LPS o bacterias como 
Escherichia coli (E. coli) y también con TNFα e IL1B.  
Asimismo, también se aislaron BMDMs, que fueron obtenidos de las tibias y los 
fémures de los ratones salvajes y Trem2-/-, llevando a cabo un protocolo previamente 
descrito (214). 
En las distintas poblaciones celulares se realizaron estudios de expresión génica 
mediante PCR cuantitativa y proteica mediante inmunoblot o ELISA. Además, también 
se analizó la producción de ROS mediante citometría de flujo. Asimismo, se determinó 
el consumo de oxígeno mediante Seahorse (Seahorse Bioscience). Por último, también se 
realizaron ensayos de viabilidad celular.  
 
Sobreexpresión de TREM2 en HSCs humanas y crecimiento de esferoides in vitro 
La línea de HSCs humana LX-2 fue transfectada con un plásmido de TREM2 (Sino 
Biological Inc, HG11084-UT) o con el respectivo plásmido control (Sino Biological Inc, 
CV011) y se determinó al expresión génica de genes inflamatorios y pro-tumorigénicos 
mediante PCR cuantitativa. Además, la cantidad de proteína de TNF y MCP1 en el medio 
de estas células fue determinada mediante ELISA. Por último, las líneas de HCC humanas 
Hep3B y PLC/PRF5 fueron utilizadas para determinar el papel de TREM2 en el 
crecimiento de esferoides in vitro. Así, las líneas de HCC fueron plaqueadas en gotas en 
suspensión en placas de Petri y fueron incubadas durante 7 días para que se formaran los 
esferoides. Estos esferoides fueron posteriormente tratados con el sobrenadante 
procedente de células LX-2 que sobreexpresaban o no TREM2 y el crecimiento de los 
esferoides fue analizado durante 72 horas. 
 
Análisis estadístico 
Todos los parámetros cuantitativos del estudio fueron incluidos en tablas de MS Excell 
para su posterior análisis estadístico mediante el programa GraphPad Prism 6.00 
(GraphPad Software). Para comparaciones entre dos grupos se utilizaron los tests 
estadísticos T de Student o Mann Whitney en el caso de que las variables de estudio 
cumplieran una distribución paramétrica o no paramétrica, respectivamente. Para 
comparaciones entre dos o más grupos se utilizaron el test paramétrico de análisis de 
varianza unidireccional seguido del test a posteriori de Bonferroni o del test no 




paramétrico Kruskal Wallis seguido del test a posteriori Dunns. Para los análisis de 






























RESULTADOS Y DISCUSIÓN 
 
Papel del receptor TREM2 en el daño hepático 





Expresión de TREM2 durante la lesión hepática crónica y en las distintas poblaciones 
celulares hepáticas 
Con el objetivo de estudiar el potencial papel de TREM2 durante el daño hepático, 
analizamos su expresión en muestras de pacientes cirróticos y sanos, así como en varios 
modelos murinos de daño hepático agudo y crónico. Así, pudimos observar que la 
expresión de TREM2 se encuentra inducida tras la lesión hepática crónica, ya que su 
expresión está aumentada en pacientes cirróticos en comparación con pacientes sanos. 
Asimismo, en modelos de daño hepático agudo y crónicos mediados por la administración 
única o repetitiva de CCl4 o mediante la ligadura del conducto biliar, la expresión de 
Trem2 también se encuentra aumentada en comparación con los respectivos controles. 
Además, se determinó la expresión de TREM2 en las distintas poblaciones de células 
hepáticas pudiéndose demostrar que su expresión estaba prácticamente restringida a las 
células no-parenquimales, tales como KCs y HSCs, mientras que su expresión en 
hepatocitos es prácticamente indetectable. Interesantemente, la expresión de TREM2 
aumenta tras la activación de las HSCs tanto in vitro como in vivo aunque no afecta al 
estado de activación de estas células, ya que los marcadores fibrogénicos no se ven 
alterados. Estos datos sugieren que TREM2 en las células no-parenquimales del hígado 
podría tener un papel importante durante el daño hepático crónico. 
 
Papel del receptor TREM2 y contribución de las células residentes e infiltrantes en el 
daño hepático crónico  
Para estudiar el papel de TREM2 en el daño hepático crónico realizamos un modelo de 
daño hepático crónico mediado por la administración repetitiva de CCl4 durante 8 
semanas en ratones salvajes y deficientes para Trem2. Así, pudimos observar que en 
ausencia de Trem2 los ratones presentaban un mayor daño, necrosis y apoptosis en el 
parénquima hepático. Sin embargo, los ratones Trem2-/- no presentaban mayor fibrosis 
hepática. Además, estos ratones presentaban una elevada expresión hepática de citoquinas 
y quimiocinas inflamatorias y de genes relacionados con estrés oxidativo y apoptosis.  
 Con el objetivo de dilucidar el papel que juegan las células hepáticas residentes y 
las células inmunes infiltrantes y su potencial contribución en el daño hepático que se 
observa en los ratones Trem2-/- se realizó un modelo de trasplantes de médula ósea entre 
ratones salvajes y Trem2-/- seguido de la administración crónica de CCl4 durante 8 
semanas. De este modo pudimos observar que únicamente en situaciones en el que Trem2 




está ausente tanto en las células residentes del hígado como en las inmunitarias infiltradas 
hay diferencias en el daño hepático, reclutamiento de macrófagos y expresión de genes 
pro-inflamatorios. Así, pudimos demostrar por un lado que TREM2 frena el daño hepático 
crónico y que el efecto combinado de las células residentes del hígado y de las células 
inmunes infiltrantes es necesario para que TREM2 pueda frenar la lesión hepática crónica. 
 
Efecto de TREM2 en las células no-parenquimales tras la activación de TLR4 
A continuación se estudió el papel que juega TREM2 en las células no-parenquimales del 
hígado en respuesta a la activación de TLR4. Para ello se aislaron las células no 
parenquimales del hígado de ratones salvajes y deficientes para Trem2 y se trataron con 
el ligando de TLR4, el LPS y E. coli. Así, pudimos observar que los niveles de mediadores 
inflamatorios y quimiocinas se encontraban elevados en los ratones Trem2-/- comparado 
con ratones salvajes, tanto en KCs como en HSCs. Interesantemente, tal y como se ha 
descrito en otros tipos celulares (188, 195), la vía de las MAP quinasas se encontraba 
aumentada en las KCs deficientes en Trem2 mientras que no se observaron alteraciones 
en la vía de señalización NF-κB. Demostrando así que TREM2 frena la inflamación 
mediada por TLR4 en las células no-parenquimales del hígado y que además en KCs lo 
hace a través de la atenuación en la vía de las MAP quinasas. 
 
Papel de TREM2 en modelos de daño hepático agudo 
Posteriormente, decidimos estudiar el papel del receptor TREM2 en modelos de daño 
hepático agudo y daño hepático fulminante para lo cual desarrollamos modelos agudos 
basados en la administración de CCl4 y APAP además de un modelo letal de daño 
hepático fulminante basado en la administración de APAP a una dosis letal. Así, pudimos 
observar que los ratones Trem2-/- presentaban mayor daño hepático, un aumento en la 
expresión de genes inflamatorios y un mayor reclutamiento de células inmunitarias 
comparado con ratones salvajes. Además, interesantemente los ratones deficientes en 
Trem2 presentaron una menor superviviencia en comparación con los ratones salvajes 
tras la administración de una dosis letal de APAP. Concluyendo que TREM2 es 
importante para poder frenar el daño hepático agudo y que además es esencial para 
prevenir el daño hepático fulminante debido a la intoxicación con APAP. 
 




Determinación de los mecanismos moleculares por los que TREM2 media sus efectos en 
la regulación del daño hepático 
Para poder determinar el mecanismo por el cual TREM2 exacerba el daño hepático agudo 
y crónico en el hígado en primer lugar, se analizó la peroxidación lipídica en los tejidos 
los modelos agudos y crónicos estudiados, pudiendo observar una marcada elevación en 
los niveles de peroxidación lipídica en el tejido hepático de los ratones Trem2-/-. Además, 
estos datos correlacionaron con una elevación en la producción de ROS en BMDMs. 
Interesantemente, esta elevación en los niveles de ROS parece ser debida a una mayor 
respiración metabólica, ya que los BMDMs deficientes en Trem2 poseían una respiración 
máxima mitocondrial mayor en comparación con los ratones salvajes. Estos resultados 
demuestran que los efectos que TREM2 media en los macrófagos infiltrados en el hígado 
juegan un papel determinante en el daño hepático, afectando a la producción de ROS y 
peroxidación lipídica en el hígado.  
Por último, analizamos si los efectos que media TREM2 en el hígado podrían estar 
mediados por su potencial papel en la regulación de la inmunidad innata debida a la 
translocación bacteriana. Para ello, se utilizó un modelo agudo de CCl4 en el que previa 
administración del hepatotóxico se administró un coctel de antibióticos durante 4 semanas 
para eliminar la microbiota intestinal. Así, pudimos comprobar que los efectos que se 
observan en el daño hepático en ausencia de Trem2 tras la administración de CCl4 se 
revierten al eliminar la microbiota intestinal, demostrando así que TREM2 es capaz de 








Papel del receptor TREM2 en la regeneración hepática 
 
Efecto del receptor TREM2 en la regeneración hepática tras hepatectomía parcial 
Debido a que los procesos de regeneración y proliferación hepatocitaria son mecanismos 
que se activan en respuesta al daño o debido a la pérdida de la masa hepática y además 




juegan un papel determinante en el desarrollo del HCC (254, 255), decidimos llevar a 
cabo un modelo de regeneración hepática en el que realizamos una resección quirúrgica 
del ~70% del hígado tanto en ratones salvajes como Trem2-/-. Tras PHx, observamos una 
aceleración en la proliferación hepatocitaria en los ratones Trem2-/- en comparación con 
los ratones salvajes. Además, este efecto se vio asociado con una inducción temprana de 
genes clave como Tnf, Il6 y Hgf tras PHx en el hígado de los ratones Trem2-/-. 
Indicándonos que TREM2 es clave durante la regeneración hepática. 
 
Papel del receptor TREM2 en el desarrollo del HCC 
 
Expresión de TREM2 en muestras de pacientes sanos y HCC 
En primer lugar analizamos la expresión del receptor TREM2 en 2 cohortes 
independientes de pacientes con HCC y pacientes sanos observando que su expresión 
estaba inducida en muestras de HCC. Además, pudimos observar que la expresión de 
TREM2 correlaciona con marcadores inflamatorios y fibrogénicos, sugiriendo que 
TREM2 podría también jugar un papel importante en el desarrollo del HCC. 
 
Papel de TREM2 en un modelo de HCC murino y en un modelo agudo mediados por la 
administración de DEN 
Para poder determinar el papel que juega TREM2 en el desarrollo de HCC llevamos a 
cabo un modelo de tumorigénesis hepática basado en la administración de DEN. Así, 
pudimos observar cómo los ratones Trem2-/- desarrollan un mayor número de tumores en 
comparación con los ratones salvajes. Además, estos efectos se asociaron con la presencia 
de mayores niveles de daño en el DNA de los hepatocitos y una mayor proliferación en 
comparación con los ratones salvajes. Para poder dilucidar los mecanismos moleculares 
tempranos durante el desarrollo tumorigénico llevamos a cabo un modelo agudo basado 
en una única administración de DEN en ratones adultos. Así, en concordancia con los 
datos observados, los ratones Trem2-/- presentaban un mayor daño, una elevada expresión 
de marcadores inflamatorios, de factores de crecimiento y de enzimas de estrés oxidativo. 
Además, la producción de ROS también se encontraba elevada en los ratones deficientes 
de Trem2 comparado con los ratones salvajes. Pudimos así demostrar que TREM2 juega 
un importante papel en el desarrollo tumorígenico, frenando el desarrollo de tumores, la 
proliferación y el daño hepatocitario, la inflamación y la producción de ROS. Por último, 




para demostrar si los efectos que observamos en los ratones Trem2-/- están mediados, al 
menos en parte, por la regulación de los niveles de producción de ROS y de un elevado 
estrés oxidativo, desarrollamos un modelo tumorigénico basado en la administración de 
DEN al cual administramos una dieta antioxidante durante 15 semanas. De forma muy 
interesante observamos como el número de tumores y la proliferación hepatocitaria 
descendieron al mismo nivel en ratones salvajes y Trem2-/-. Demostrando así que los 
efectos de TREM2 en el HCC son mediados a través de la regulación de los niveles de 
ROS. 
 
Determinación de los mecanismos moleculares por los que TREM2 inhibe el proceso 
hepatocarcinogénico 
A continuación intentamos trasladar nuestros resultados a un sistema in vitro y para ello 
sobreexpresamos TREM2 en la línea de HSCs humana LX-2, observando que los niveles 
de expresión génica de marcadores inflamatorios y ligandos de la familia de WNT se 
encontraban disminuidos tras la sobreexpresión de TREM2. Además, comprobamos que 
el sobrenadante de estas células contenía una disminución en la concentración de los 
mediadores pro-inflamatorios TNF y MCP1. A continuación desarrollamos un modelo de 
crecimiento de esferoides a partir de células de HCC. Para ello, se formaron los esferoides 
durante 7 días y éstos fueron tratados con el sobrenadante procedente de células LX-2 
que sobreexpresaban TREM2 o un plásmido control. Interesantemente, pudimos observar 
que los esferoides tratados con el medio de cultivo procedente de LX-2 con 
sobreexpresión de TREM2 crecieron menos que los esferoides tratados con el 
sobrenadante de LX-2 transfectadas con un plásmido control. Además, pudimos observar 
que estos efectos eran dependientes de la secreción paracrina de ligandos de WNT de 
HSCs. Estos resultados demuestran que la expresión de TREM2 en las células no 
parenquimales tiene un papel importante en el crecimiento de los esferoides de HCC. 
CONCLUSIONES 
1. La expresión de TREM2 se encuentra inducida en el hígado de pacientes cirróticos 
en comparación con controles sanos. 
2. TREM2 se expresa en las células no-parenquimales hepáticas (KCs y HSCs) y su 
expresión se induce en el hígado durante el daño hepático crónico en modelos 




experimentales en ratón inducidos por la administración de CCl4 o por la ligadura 
del conducto biliar (BDL). 
3. Los ratones Trem2-/- muestran un aumento en el daño hepático e inflamación tras 
los tratamientos agudo y crónico de CCl4 e intoxicación por APAP. 
4. Los efectos de TREM2 observados en el contexto de una lesión hepática crónica 
son dependientes tanto de las células hepáticas residentes como del infiltrado 
inflamatorio. 
5. TREM2 promueve la supervivencia tras la administración letal de APAP. 
6. Las KCs y las HSCs que carecen de Trem2 muestran un aumento en la producción 
de citoquinas pro-inflamatorias y quimioquinas tras la estimulación del receptor 
TLR4. 
7. TREM2 atenúa la inflamación hepática, la lesión hepática y la peroxidación 
lipídica durante la lesión crónica por CCl4. Los efectos de TREM2 en la 
peroxidación lipídica durante la lesión hepática crónica se asocian con el 
contenido de macrófagos y los niveles de ROS en los macrófagos reclutados. 
8. La ausencia de Trem2 acelera la regeneración hepática tras la PHx a través de un 
aumento de la expresión génica de genes pro-inflamatorios y de la proliferación 
de hepatocitos. 
9. La expresión de TREM2 está inducida en muestras de HCC humano y su expresión 
correlaciona con marcadores de inflamación. 
10. La expresión de Trem2 se induce en el hígado en un modelo experimental de HCC 
inducido por la administración de DEN en ratones. La ausencia de Trem2 
promueve el desarrollo y la progresión de HCC, a través de la regulación de 
procesos de daño en el DNA y la proliferación de hepatocitos. 
11. El papel protector de TREM2 en la tumorigénesis hepática están asociados con 
efectos tempranos durante el desarrollo del HCC tras la administración aguda de 
DEN. Estos efectos están relacionados con la atenuación de procesos de daño 
hepático, inflamación y estrés oxidativo. 
12. El proceso de hepatocarcinogénesis que se encuentra potenciado en ausencia de 
Trem2 puede ser inhibido con una dieta antioxidante. 
13. La sobreexpresión de TREM2 en HSCs disminuye la expresión de marcadores 
inflamatorios y ligandos de WNT. Además, el sobrenadante procedente de HSCs 
que sobreexpresan TREM2 frena el crecimiento de esferoides de HCC in vitro. 





Por lo tanto, estos resultados han permitido identificar al receptor TREM2 como una 
nueva diana terapéutica prometedora para abordar la lesión hepática aguda, la progresión 
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